[
    {
        "type": "text",
        "text": "动脉粥样硬化ApoE-/-小鼠模型尿液蛋白质组变化探究",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "华元瑞，孟文书，魏静，刘永涛，高友鹤\\*北京师范大学基因工程药物及生物技术北京市重点实验室，北京100875",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "摘要 ",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "心血管疾病是当今世界第一大致死因素，动脉粥样硬化是其重要病理基础，其早期诊断具有重要意义。尿液更利于积累和反应机体生理状态的变化且不受到稳态机制的调节，是疾病早期生物标志物的良好来源。本文通过高脂饮食诱导 ApoE-/-小鼠5个月构建动脉粥样硬化动物模型，选取七个时间点收集实验组及正常饮食对照组c57BL/6小鼠尿液样品，使用蛋白质组学分析方法，进行自身对照和组间对照。自身对照结果表明高脂饮食1周前后尿液蛋白质组差异显著，同时多种差异蛋白被报道过与动脉粥样硬化相关或可作为其生物标志物。组间对照结果表明差异蛋白GO分析得出的生物学过程能够对应疾病发生发展的进程。两种对照方式得到的差异性化学修饰也多被报道与该疾病进程相关。实验证明了尿液蛋白质组学有敏锐监测机体变化的潜力，为寻找动脉粥样硬化早期生物标志物提供了可能。",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "关键词：动脉粥样硬化；尿液蛋白质组；蛋白质化学修饰；早期生物标志物",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "Urine proteome changes in ApoE-/- mouse model of ",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "atherosclerosis ",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "Hua Yuanrui，Meng Wenshu，Wei Jing，Liu Yongtao，Gao Youhe\\* Gene Engineering Drug and Biotechnology Bei jing Key Laboratory,Bei jing Normal University，Beijing 100875，China ",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "Abstract: ",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "Cardiovascular disease is the leading cause of death in the world today. Atherosclerosis is an important pathological basis of cardiovascular disease, and its early diagnosis is of great significance. Urine is more conducive in the accumulation and response of changes in body physiological state and is not regulated by homeostasis mechanism, so it is a good source of biomarkers in the early stage of disease. In this study， ApoE-/- mice induced by high fat diet for 5 months were used to construct an animal model of atherosclerosis. Urine samples of experimental group and control group which are c57BL /6 mice with normal diet were collected at seven time points. Proteomic analysis method was used for selfcontrol and intergroup control. Self control results showed significant difference in urine proteome before and after 1 week high-fat diet，and several differential proteins have been reported to be associated with atherosclerosis or can be used as biomarkers. The results of inter-group control indicated that the biological process enriched by the GO analysis of the differential protein could correspond to the development of the disease. Differences in chemical modifications of the two comparisons have also been reported to be associated with the disease progression. This study demonstrates that urine proteomics has the potential to monitor the changes in the body sensitively and provides the possibility to search for early biomarkers of atherosclerosis. ",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "Keywords:Atherosclerosis;Urine proteome;Chemical modification of protein;Early biomarker ",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1引言",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "动脉粥样硬化（AS）是心血管疾病的主要病理基础(CVD)，心血管疾病是当今世界第一大致死因素2。2015年有1700 多万人死于心血管疾病，占全球所有死亡人数的 $3 1 \\% ^ { [ 3 ] }$ 。动脉粥样硬化的影响在晚期会更为显著并诱发心肌梗塞和中风等一系列致命后果，因此，在其早期阶段进行诊断有着重要的意义。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "尿液是早期生物标志物的理想来源，由于生物标志物是与稳态机制调节下的生物学过程相关的可测量的变化，而尿液可以积累这些早期变化4。这一结论已被许多相关研究所证实。例如，在通过向大鼠脑部注射肿瘤细胞构建的胶质母细胞瘤动物模型中，在磁共振成像反映出肿瘤所带来的的变化之前，尿液蛋白质组就已经发生了变化。同样有研究证实即便在大鼠皮下接种约10个细胞，尿液蛋白质组也能够发生显著变化。此外，尿液也更易获取且无创。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "使用动物模型可以避免遗传、环境等因素对尿液蛋白质组的影响，更便于判断动脉粥样硬化的早期阶段从而寻找其生物标志物。载脂蛋白E (ApoE)通过运输血液中的脂肪 (脂类)，在维持血清中胆固醇和甘油三酯的正常水平方面起着重要作用8。ApoE 功能缺失的小鼠会出现高胆固醇血症，极低密度脂蛋白（VLDL）升高，高密度脂蛋白（HDL）降低，表现为自发形成斑块，且高脂饮食可大大加速斑块/病变的形成。所以载脂蛋白E敲除（ApoE-/-）的小鼠是动脉粥样硬化的良好生物模型。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "本实验通过ApoE-/-小鼠高脂饮食5个月构建动脉粥样硬化模型，并分别于实验进程的第0周、第1周、第1月、第2月、第3月、第4月、第5月（WO/W1/M1/M2/M3/M4/M5）收集尿液并进行质谱分析，进行自身对照及与正常饮食 c57BL/6小鼠进行对照，探究疾病进展过程中尿液蛋白质组及其化学修饰的变化，为寻找生物标志物提供借鉴。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "2 材料与方法",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "2.1实验动物及模型构建 ",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "6只4周龄雄性 $\\mathrm { { A p o E ^ { - } } / - }$ 小鼠购自北京大学医学部实验动物科学部，饲喂高脂饮食（ $2 1 \\%$ 脂肪和 $0 . 1 5 \\%$ 胆固醇，北京科澳协力饲料有限公司）5个月，期间给予12小时正常光暗循环、温度为 $( 2 2 ^ { \\circ } \\mathrm { C } \\pm 1 ^ { \\circ } \\mathrm { C } )$ 、湿度为 $( 6 5 \\% - 7 0 \\% )$ 的标准条件。所有实验操作符合动物伦理审查标准。动物许可证为SCXK(北京)2016-0010。所有实验均经北京协和医学院基础医学研究所机构动物护理使用与福利委员会批准（动物福利保障编号：ACUC-A02-2014-007）。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "2.2组织病理学",
        "text_level": 1,
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "将实验组的6只6月龄ApoE-/-小鼠与购入的4只6月龄正常饮食c57BL/6小鼠（购自北京维通利华实验动物中心）一并处死后，取主动脉进油红0整体染色[°，即先将主动脉在 $4 \\%$ 多聚甲醛固定后异丙醇脱水，纵向切开后油红0染液（biotopped）染色20分钟，异丙醇漂洗三次后固定。使用数码相机（canon，Japan）拍摄主动脉图像并用imageJ软件（1.52a，NIH,USA）进行分析。",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "2.3尿液收集及样品处理",
        "text_level": 1,
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "（1）尿液蛋白的提取和酶切",
        "text_level": 1,
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "为鉴别高脂饮食短期内对动物的影响，收集了实验过程中WO和W1的实验组小鼠尿液样品，为监测整个病程中的尿液蛋白质组变化，收集实验M1/M2/M3/M4/M5的实验组小鼠尿液样品。分别收集4只年龄对应的正常饮食c57BL/6小鼠（均购自北京维通利华实验动物中心）的尿液作为对照组（非同一批)。每只小鼠在代谢笼过夜收集尿液10小时，期间不提供食物和饮水。收集后的尿液样品立即置于 $- 8 0 ^ { \\circ } \\mathrm { C }$ 条件下保存。实验流程见图1。",
        "page_idx": 2
    },
    {
        "type": "image",
        "img_path": "images/3eeeb5d68568547c713cb2d132ee4a33fa8d7a5157d6b1d80ad5b9223c844fb3.jpg",
        "img_caption": [
            "图1实验流程",
            "Fig.1 Experimental flow graph "
        ],
        "img_footnote": [],
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "尿液收集后用 $1 2 0 0 0 \\mathrm { g }$ 离心40分钟，取上清用3倍体积的乙醇沉淀过夜，然后 $1 2 0 0 0 \\mathrm { g }$ 离心30 分钟。将蛋白沉淀重悬于裂解液(8mol/L 尿素，2 mol/L硫脲， $2 5 \\mathrm { m m o l / L }$ 二硫苏糖醇和 50 mmol/L Tris)。用Bradford 法测量蛋白浓度。使用滤器辅助样品制备（FASP）方法进行尿蛋白酶解[1]。将尿蛋白加载到10kDa 超滤管(PALL 公司)的滤膜上，用 UA (8mol/L 尿素,0.1mol/L Tris-HCl,pH 8.5)和 25mmol/LNH4HC03 溶液洗涤两次；加入 20 mmol/L 二硫苏糖醇(Sigma 公司)在 $3 7 ^ { \\circ } \\mathrm { C }$ 中变性1 小时，再与 50 mmol/L 碘乙酰胺(Sigma 公司)在黑暗中烷基化30 分钟,用UA 和 NH4HCO3 溶液洗涤两次，以1：50 比例加入胰酶(Promega 公司)在 $3 7 ^ { \\circ } \\mathrm { C }$ 水浴中消化 14 小时。将多肽通过HLB 柱(Waters公司)除盐后用真空干燥仪进行抽干。",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "（2）高pH反相色谱预分离",
        "text_level": 1,
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "酶切后的样品用 $0 . 1 \\%$ 甲酸水重溶，并稀释到 $0 . 5 \\mu \\mathrm { g / u L }$ ，取每个样品制备混合多肽样，使用高 pH 反相肽段分离试剂盒(Thermo Fisher Scientific)进行分离。将混合多肽样品加于色谱柱上，用乙腈浓度梯度递增的溶液进行洗脱，通过离心收集十份流出液，使用真空干燥仪抽干后用 $0 . 1 \\%$ 甲酸水复溶。本次研究使用iRT合成多肽（Biognosis 公司)，以10：1的体积比例加入到十个组分和每个样品中。",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "（3）高效液相串联质谱数据采集",
        "text_level": 1,
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "使用 EASY-nLC 1200 色谱系统(Thermo Fisher Scientific)和 OrbitrapFusion Lumos Tribrid 质谱仪(Thermo Fisher Scientific)进行质谱采集和分析。将肽段样品加载到预柱（75 ${ \\mu \\mathrm { ~ m } } { \\times } 2$ cm,C18, $2 \\mu \\mathrm { { m } }$ ，Thermo Fisher）和反相分析柱（50 $\\mu \\mathrm { m } \\times 1 5$ cm，C18, $2 \\mu \\mathrm { { m } }$ ，Thermo Fisher），以 400nL/min 流速进行洗脱，洗脱时间为120分钟，洗脱用梯度为 $4 \\% - 3 5 \\%$ 的流动相 ( $8 0 \\%$ 乙腈$+ 0 . 1 \\%$ 甲酸 $+ 2 0 \\%$ 水)。参数设置如下：喷雾电压 $2 . 4 \\mathrm { k V } .$ ，一级全扫描范围为 $3 5 0 -$ $1 5 5 0 \\mathrm { m / z }$ ，分辨率60000；二级扫描范围为 $2 0 0 { - } 2 0 0 0 \\mathrm { m / z }$ ，分辨率30000，循环时间3s，最高速度模式， $3 0 \\%$ HCD 碰撞能量。分别对反相色谱柱分离得到的10个组分和酶解得到的所有样品采取DDA 模式采集质谱数据。",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "（4）质谱数据分析",
        "text_level": 1,
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "把上述10 个组分的DDA 采集结果导入 ProteomeDiscoverer 软件（版本2.1）搜库，参数：小鼠数据库（2019年发布，含17038条序列）附加iRT多肽序列，胰酶酶切，最多允许两个漏切位点，母离子质量容差10ppm，碎片离子质量容差0.02Da,甲硫氨酸氧化为可变修饰，固定化修饰为半胱氨酸的氨酰甲基化修饰，蛋白FDR设置为 $1 \\%$ 。PD搜库结果用于建立DIA采集方法，根据 $\\mathrm { m / z }$ 分布密度计算窗口宽度和数量。将单个多肽样品进行DIA 模式采集质谱数据。",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "使用 Spectronaut X 软件对质谱数据进行处理和分析¹2。根据 DDA 搜库结果 pdResult 文件与 10 个 DDA raw 文件建立谱图库，导入每个样品 DIA采集的raw文件进行搜库。高度可信蛋白标准为肽段qvalue<0.01，采用二级肽段所有碎片离子峰面积进行蛋白定量。",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "（5）蛋白质化学修饰数据库检索",
        "text_level": 1,
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "使用pFindStudio软件（3.1.6版，中国科学院计算技术研究所）对酶解样品的DDA采集结果进行无标记的定量分析[13]。目标检索数据库来自Uniprot 下载的Musmusculus 数据库（更新至2020 年9月），检索时，仪器类型为 HCD-FTMS，酶全特异性，为胰蛋白酶，最多有2个漏切位点。选择“开放式搜索（open-search）”。筛选条件为在肽水平上的FDR小于 $1 \\%$ 。数据同时使用正向和反向数据库检索策略来分析数据。初步筛选后，采用限制性搜索的方式加以验证。",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "（6）统计学分析",
        "text_level": 1,
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "对质谱鉴定结果进行缺失值填充（KNN方法）[4]和CV值筛选（ $\\mathrm { ( C V } { \\langle 0 . 3 \\rangle }$ [15]，每两组数据之间的比较采用独立样本t检验。实验组各时间点自身对照、实验组和对照组相同时间点的样品对照筛选差异蛋白，筛选标准为：两组之间变化倍数 $\\mathrm { F C } \\geqslant 1 . 5$ 或 $\\mathrm { F C } \\leqslant 0 . 6 7$ ,P<0.05。同时每两组进行对比的样品都进行了随机组合，按照与正常筛选相同的条件计算所有排列组合的平均差异蛋白数目（见附表1)，确保了差异蛋白是由组间差异产生而非随机产生。",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "计算不同类型的化学修饰位点占全部修饰位点的比例，每两组数据之间的比较采用独立样本t检验，筛选标准为：两组之间变化倍数 $\\mathrm { F C } \\geqslant 1 . 5$ 或FC≤0.67,P<0.05。",
        "page_idx": 4
    },
    {
        "type": "text",
        "text": "（7）差异蛋白功能注释",
        "text_level": 1,
        "page_idx": 4
    },
    {
        "type": "text",
        "text": "将筛选到的差异蛋白用 DAVID 数据库（https://david.ncifcrf.gov/）[16]和IPA 软件(Ingenuity Systems，Mountain View，CA，USA)进行功能富集分析。均采用 $\\mathrm { ~ P ~ } \\langle \\ 0 . 0 5$ 的显著性阈值。",
        "page_idx": 4
    },
    {
        "type": "text",
        "text": "3实验结果和讨论",
        "text_level": 1,
        "page_idx": 4
    },
    {
        "type": "text",
        "text": "3.1组织病理学",
        "text_level": 1,
        "page_idx": 4
    },
    {
        "type": "text",
        "text": "为评估动脉粥样硬化模型构建效果，比较经过5个月高脂饮食饲喂后的6月龄 ApoE-/-小鼠与正常饮食的6 月龄小鼠的主动脉整体油红0 染色面积占比，实验组平均着色区域面积占比为 $1 7 . 7 8 \\pm 2 . 1 4 \\%$ （ $\\mathrm { n } { = } 6$ )，对照组平均比例为$0 . 8 8 \\pm 0 . 3 4 \\%$ ( $\\mathrm { \\Delta } \\cdot \\mathrm { n } { = } 4$ ， $\\mathrm { p { = } 0 . 0 0 0 4 }$ （见图2）。",
        "page_idx": 4
    },
    {
        "type": "image",
        "img_path": "images/e8fa4e852ab483eef5fb8da4cf5ab76b4780db00b4959f841d10d928baf51018.jpg",
        "img_caption": [],
        "img_footnote": [],
        "page_idx": 4
    },
    {
        "type": "image",
        "img_path": "images/801a780a596bdbd873640a091ba3710db60609aa6fa6bc352f3e9f3781337a21.jpg",
        "img_caption": [
            "图2主动脉整体油红0染色结果及定量分析。"
        ],
        "img_footnote": [],
        "page_idx": 5
    },
    {
        "type": "text",
        "text": "C ",
        "page_idx": 5
    },
    {
        "type": "text",
        "text": "A 对照组油红O染色结果；B实验组油红0染色结果；C着色区域占比对比。",
        "page_idx": 5
    },
    {
        "type": "text",
        "text": "Fig.2 Results and quantitative analysis of oil red O staining of whole aorta. A Results of oil red O staining in control group;B Results of oil red O staining in experimental group;C The comparison of staining area ratio. ",
        "page_idx": 5
    },
    {
        "type": "text",
        "text": "3.2差异蛋白筛选及功能注释",
        "text_level": 1,
        "page_idx": 5
    },
    {
        "type": "text",
        "text": "实验组和对照组共有来自七个时间点（WO/W1/M1/M2/M3/M4/M5）的69个样品用于非标记LC-MS/MS 定量（实验组W0 的一个样品遗失)。共有 592 种蛋白至少鉴定到2个独特肽段且 $\\mathrm { F D R } { \\langle 1 \\% }$ ，平均每个样品鉴定到360 种尿蛋白。",
        "page_idx": 5
    },
    {
        "type": "text",
        "text": "（1）实验组自身对照筛选结果及功能注释",
        "text_level": 1,
        "page_idx": 5
    },
    {
        "type": "text",
        "text": "$\\textcircled{1}$ 高脂饮食短期的影响",
        "text_level": 1,
        "page_idx": 5
    },
    {
        "type": "text",
        "text": "为鉴别高脂饮食带来的影响，在ApoE-/-小鼠进行高脂饮食一周后，将WO 和W1收集到的尿液样品进行比较分析，共有27种蛋白质发生显著变化（见表1)。",
        "page_idx": 5
    },
    {
        "type": "text",
        "text": "共有12 种蛋白质在W1显著上调。包括主要尿蛋白1、主要尿蛋白5、主要尿蛋白17、主要尿蛋白18和主要尿蛋白20，主要尿蛋白(MUPs)是脂钙蛋白家族的成员，它可以隔离和运输血液和其他亲水体液中的各种亲脂分子[7]。半乳糖凝集素3结合蛋白同样在W1上调，有文献报道半乳糖凝集素3浓度的局部升高可能会增强单核细胞和巨噬细胞募集到动脉壁8，加剧动脉粥样硬化病变的促炎状态[。有文献表明妊娠区蛋白可以结合组织型纤溶酶原激活剂并通过低密度脂蛋白受体相关蛋白促进其清除20。内皮蛋白C也被文献报道称在血栓形成过程中扮演重要角色2。谷胱甘肽过氧化物酶的上升已经在动物试验中被证实对氧化压力和动脉粥样硬化具有保护作用22。组织蛋白酶L则被报道在人动脉粥样硬化中，与细胞凋亡和斑块失稳显著相关[23]。细胞间粘附分子1则被报道称与动脉粥样硬化的早期发展有重要影响[24，在高脂饮食喂养的大鼠血管内皮细胞中含量也增加[25]。此外，分泌球蛋白家族 2B成员 20也发生了上调。",
        "page_idx": 5
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 6
    },
    {
        "type": "text",
        "text": "15 种蛋白质在W1显著下调。中性粒细胞在动脉粥样硬化中发挥作用，而其通过主要组织相容性复合体I呈递抗原[2]。桥粒胶蛋白1和2在氧化低密度脂蛋白的影响下，在人脐静脉内皮细胞中含量减少[27]，并有文献称这桥粒胶蛋白2及其介导的细胞黏附可以被半乳糖凝集素3调节[28]。神经节苷脂GM2 激活蛋白也被报道称可以结合、溶解和运输广谱的脂质分子，可能作为一种普通的细胞内和细胞间的脂质运输蛋白[2]。慢性肾病患者较低的血清胰淀粉酶水平可能是营养不良-炎症-动脉粥样硬化综合征的组成部分[3°。有文献报道称，在组织蛋白酶E基因敲除的小鼠中，白色脂肪组织和棕色脂肪组织发育不良3。在人动脉粥样硬化中，组织蛋白酶L与细胞凋亡和斑块失稳显著相关23。血管紧张素原在脂肪细胞代谢和炎症发展中发挥关键作用[32。定期监测维生素 B12状态可能有助于预防动脉粥样硬化相关疾病，而反钴胺素2可以运载维生素 $\\mathrm { B 1 2 ^ { [ 3 3 ] } }$ 。I型胶原蛋白是动脉粥样硬化的早期生物标志物34。再生胰岛衍生的蛋白质3β作为一种炎症标记物，对巨噬细胞的招募和组织修复有重要意义[35]。气味结合蛋白同样是一种载脂蛋白[36]。此外，类酪氨酸蛋白10、分泌球蛋白家族 2B 成员2、巢蛋白2、Costars 家族蛋白ABRACL也发生了下调。",
        "page_idx": 6
    },
    {
        "type": "text",
        "text": "对这27种蛋白质用DAVID进行GO分析，所获得的生物学过程绝大多数都与脂质代谢和糖代谢相关（见图3)。同时对照组W1和W0的差异蛋白（见附表2）并未富集到任何显著变化生物学过程，表明小鼠的生理状态在W1并未发生巨大改变，表明即使一周的高脂饮食也会给动物尿蛋白质组带来巨大变化，这也进一步证明了尿液蛋白质组具有灵敏反映机体变化的能力。",
        "page_idx": 6
    },
    {
        "type": "image",
        "img_path": "images/2a8a27bd270455ccb18bea7da0eb88455ca964a53295337ffd48976c3545b3b7.jpg",
        "img_caption": [
            "图3实验组W1与W0 样品差异蛋白所富集的生物学过程（ $\\mathrm { p } { < } 0 . \\ 0 5 \\$ )"
        ],
        "img_footnote": [],
        "page_idx": 7
    },
    {
        "type": "text",
        "text": "Fig.3 Biological processes enriched by differential proteins between week 1 and week 0 samples of experimental group ( $\\cdot \\mathrm { p } { < } 0 . 0 5$ ）： ",
        "page_idx": 7
    },
    {
        "type": "text",
        "text": "$\\textcircled{2}$ 疾病进程中自身对照尿液蛋白质组学的改变",
        "text_level": 1,
        "page_idx": 7
    },
    {
        "type": "text",
        "text": "与实验组W0相比，实验组在M1/M2/M3/M4/M5时间点分别有51/69/86/65/88个蛋白显著变化。韦恩图（图4）显示共有17种蛋白质在五个时间点都显著变化，DIA定量结果显示这17种蛋白质在五个时间点变化趋势都相同。另有18 种蛋白质在后四个时间点都显著变化且在每个时间点变化趋势相同（见表2)。这其中有 26 种蛋白质及其家族成员曾被其他研究报道与脂质代谢和动脉粥样硬化进展有关。",
        "page_idx": 7
    },
    {
        "type": "text",
        "text": "除主要尿蛋白外，小鼠三叶因子2的敲除能保护其在高脂饮食条件下免于肥胖[37]。血管紧张素原在脂肪细胞代谢和炎症发展中发挥关键作用[32]。α1-抗胰蛋白酶已经被报道是动脉粥样硬化的生物标志物[34。有报道称，CCN4通过与 $\\mathrm { ~ a ~ } 5 \\beta \\mathrm { ~ 1 ~ }$ （204号整合素相互作用，促进血管平滑肌细胞的迁移和增殖3，其在在动脉粥样硬化的发生发展中起着至关重要的作用。定期监测维生素B12状态可能有助于预防动脉粥样硬化相关疾病，而反钴胺素2可以运载维生素 $\\mathrm { B 1 2 ^ { [ 3 3 ] } }$ 。再生胰岛衍生的蛋白质3β作为一种炎症标记物，对巨噬细胞的招募和组织修复有重要意义[35]。α-2-HS-糖蛋白水平与动脉粥样硬化替代参数正相关,如内膜-中膜厚度(IMT)和动脉硬化等[39]。文献表明凝溶胶蛋白通过与细丝末端的结合来稳定肌动蛋白细丝，从而阻止单体交换，其下调表明人类冠状动脉粥样硬化介质内血管平滑肌细胞的细胞骨架被解除调控4。文献报道称 SCUBE2可能通过 Hh 信号转导在动脉粥样硬化斑块进展中发挥重要作用4。I型胶原蛋白是动脉粥样硬化的早期生物标志物[34]。淋巴细胞抗原6C2、Costars 家族蛋白 ABRACL 和巢蛋白2没有直接文献报道与动脉粥样硬化相关。",
        "page_idx": 7
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 8
    },
    {
        "type": "text",
        "text": "Igκ 链V-III区PC 7043、Igκ 链V-II区26-10 和免疫球蛋白κ 都参与获得性免疫反应。结合珠蛋白多态性与包括动脉粥样硬化在内的许多炎症疾病的流行和临床演变有关[42]。MHCII抗原呈递在动脉粥样硬化中具有重要的保护功能[43]。白介素-18 在动脉粥样硬化中发挥关键作用，也在在食欲控制和肥胖的发展中发挥了作用[44]。有文献称，与健康对照组相比，冠心病患者外周血白细胞中LAMP-2 基因表达及蛋白水平明显升高[45]。T-钙黏着蛋白对新内膜和动脉粥样硬化斑块病变中脂联素的积累至关重要46。肾脏雄激素调节蛋白也被报道在高脂饮食的ApoE-/-小鼠尿液中出现34。纤维连接蛋白是动脉粥样硬化过程中结缔组织形成的指示物[47]。外周动脉闭塞病(PAOD)是全身性动脉粥样硬化的主要表现之一，甲状腺素运载蛋白和补体因子B是监测血浆PAOD 疾病的潜在标记物48。转铁蛋白在动脉粥样硬化中发挥重要作用[49]。而丝氨酸蛋白酶抑制剂A3 在血管中的差异表达与人类动脉粥样硬化明显相关[50]。催乳素在血管平滑肌细胞增生中发挥作用，而血管平滑肌细胞增生是高血压、动脉粥样硬化等心血管疾病的发病特征[51]。尚无研究表明泛酰巯基乙胺酶、二-N-乙酰壳聚糖酶和蛋白质LEG1同源物与动脉粥样硬化有直接关系。",
        "page_idx": 8
    },
    {
        "type": "image",
        "img_path": "images/735eddfb147a0d3dcedd3d234202956a0500aba1ed56d7efdb18976d773545b8.jpg",
        "img_caption": [
            "图4实验组各时间点样品（M1/M2/M3/M4/M5）与W0对照差异蛋白韦恩图。",
            "Fig.4 Venn diagram of differential proteins between other time points (M1/M2/M3/M4/M5) and week O samples of experimental group. "
        ],
        "img_footnote": [],
        "page_idx": 8
    },
    {
        "type": "text",
        "text": "将上述在疾病进程中持续变化的差异蛋白用DAVID进行GO分析（图5），所富集到的生物学过程如图所示。",
        "page_idx": 8
    },
    {
        "type": "text",
        "text": "主要尿蛋白引起的脂质代谢和糖代谢相关生物学过程变化显著；急性期反应被文献报道与动脉粥样硬化相关2；成纤维细胞增殖的正调控也显著变化，据称血管损伤和血管周围脂肪组织的功能障碍促进血管扩张、成纤维细胞的激活和肌成纤维细胞的分化[53]；伤口愈合同样与动脉粥样硬化相关[54；细胞外基质赋予动脉粥样硬化病变区域抗拉强度、粘弹性和可压缩性；同样有文献表明骨质疏松与动脉粥样硬化间存在关联 5；ERK1/ERK2 通路在胰岛素(INS)和凝血酶诱导的血管平滑肌细胞增殖中起着重要作用57；细胞粘附在动脉粥样硬化中发挥重要作用[58]。以上生物学过程在整个疾病进程中发挥重要作用。",
        "page_idx": 8
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 9
    },
    {
        "type": "image",
        "img_path": "images/a567055614aa576da7bcdf77927fd777e7ce7036e96f81bdb7eabe223eae2414.jpg",
        "img_caption": [
            "图5实验组自身对照持续变化差异蛋白富集生物学过程（ $\\mathrm { : p < 0 . 0 5 \\AA }$ ）"
        ],
        "img_footnote": [],
        "page_idx": 9
    },
    {
        "type": "text",
        "text": "Fig.5 Biological processes enriched by continuous changing proteins in the self control of experimental group （ $\\mathrm { \\Phi _ { p } } < 0 . \\ 0 5$ ）： ",
        "page_idx": 9
    },
    {
        "type": "text",
        "text": "将实验组不同时间点与WO对比得出的差异蛋白做IPA分析，结果如下。",
        "page_idx": 9
    },
    {
        "type": "text",
        "text": "急性期反应被文献报道与动脉粥样硬化相关[59。LXR/RXR 和FXR/RXR 激活都与脂质代谢和葡萄糖代谢密切相关[60]。补体系统是动脉粥样硬化的重要参与者[61]。Apelin信号通路被认为是血管生成的重要贡献者62。凝集系统也被报道与动脉粥样硬化相关3。文献同样表明 $\\mathrm { A p o E } \\left( - / - \\right)$ 小鼠饲喂高脂饮食可以诱发肝纤维化。乳糖可与半乳糖素结合，后者在炎症中发挥作用]。Y-谷酰基循环与谷胱甘肽形成密切相关6，谷胱甘肽调节细胞活性氧的水平，并参与细胞氧化应激反应，其失衡与动脉粥样硬化有关[67]。IL-12参与动脉粥样硬化的发生[8]。吞噬细胞的吞噬作用在脂质代谢和泡沫细胞形成过程中发挥重要作用。硫酸软骨素和硫酸皮肤素结构的改变可能与动脉粥样硬化有关7°。成熟的树突细胞也参与内皮细胞炎症和动脉粥样硬化的发生[7]。低密度脂蛋白与受体结合后在肝脏内降解需要依赖网格蛋白介导的内吞作用[72]。有文献称由于细胞内高铁水平诱导促炎、促动脉粥样硬化的M1巨噬细胞表型，降低细胞内铁含量的因素可能促进M1巨噬细胞表型向M2巨噬细胞表型的转变，从而防止动脉粥样硬化的发生[73]。以上通路都在至少三个时间点出现。",
        "page_idx": 9
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 10
    },
    {
        "type": "text",
        "text": "从M1独有的信号通路来看，NADH和糖酵解等能量代谢过程密切相关4，文献称干扰素 $\\gamma$ 信号通路由JAK等介导，在动脉粥样硬化中高表达，诱导调节脂质摄取的基因表达，对内皮细胞有着重要作用，促进粘附分子的表达[75]。",
        "page_idx": 10
    },
    {
        "type": "text",
        "text": "从 M3独有的信号通路来看，ApoE可促进CD1d对外源性脂质抗原的摄取和呈递[76]。血栓形成是动脉粥样硬化急性并发症的主要机制，凝血酶原扮演重要角色[7]。p70S6K 通路对增强血管平滑肌细胞的增殖和迁移至关重要，后者是动脉粥样硬化的重要病理事件[78]。整合素通过ILK信号等通路调节细胞功能，其异常可能会导致动脉粥样硬化等心血管疾病9。文献也表明动脉粥样硬化/心血管疾病和骨丢失/骨密度可能是相关的\"°。文献称低密度脂蛋白可促进T 细胞分化为Th1 细胞8，Th1细胞能够促进促动脉粥样硬化炎症介质的生成82。自然杀伤细胞和树突细胞的相互串扰能够促进先天和适应性免疫反应的协调刺激[83]。内皮-间充质转化在动脉粥样硬化斑块的进展和不稳定中起着重要作用，其作用机制分别是成纤维细胞浸润和基质金属蛋白酶分泌的增加84。细胞迁移在动脉粥样硬化中发挥作用，而肌动蛋白骨架在迁移中扮演重要角色[85]。",
        "page_idx": 10
    },
    {
        "type": "text",
        "text": "从 M4独有的信号通路来看，氧化损伤是心血管疾病的重要诱因8，去乙酰化酶家族作为应激适配体和表观遗传酶参与控制心血管疾病相关的细胞事件[87，IL-6 是一种上游炎症细胞因子，在动脉粥样硬化的下游炎症反应中发挥核心作用[52]。",
        "page_idx": 10
    },
    {
        "type": "text",
        "text": "从M5 独有的信号通路来看，Wnt/β-连环蛋白信号通路可以调控血管平滑肌细胞的迁移和增殖，甲状腺功能减退被认为与动脉粥样硬化和缺血性心脏病有关48，糖尿病显然与动脉粥样硬化有着重要关系[89，RhoGDI在血管重建中发挥重要作用[9]，神经酰胺是非酒精性脂肪肝及动脉粥样硬化之间的中介[91]。",
        "page_idx": 10
    },
    {
        "type": "image",
        "img_path": "images/5851319d325dc26e0bbee5f1a2a36072c8d7c1ab7c31d6523812a46fa66cf6a7.jpg",
        "img_caption": [
            "图6实验组自身对照通路变化（ $\\mathrm { p } { < } 0 . 0 5 \\dot { } \\dot { }$ ）"
        ],
        "img_footnote": [],
        "page_idx": 11
    },
    {
        "type": "text",
        "text": "Fig.6 Changes of pathway in the self control of experimental group （ $_ { \\cdot \\mathrm { p } < 0 . 0 5 ) }$ ： ",
        "page_idx": 11
    },
    {
        "type": "text",
        "text": "$\\textcircled{3}$ 实验组前后对照筛选结果",
        "text_level": 1,
        "page_idx": 11
    },
    {
        "type": "text",
        "text": "为进一步探究疾病进程的不同时间点尿液蛋白质组新出现的变化，将实验组M2 样品鉴定结果与M1样品结果进行对比、M3与M2进行对比、M4与M3进行对比以及M5与M4 进行对比，分别筛选出 $1 3 / 9 / 1 5 / 3 3$ 个差异蛋白（见附表3)，分别富集到的生物学过程见表3。实验组前后相邻时间点自身对照，差异蛋白及其能富集到的生物学过程相对较少，说明各相邻时间点间的状态较为接近，直接与WO 进行自身对照是较好的方式。",
        "page_idx": 11
    },
    {
        "type": "text",
        "text": "表3实验组前后对照差异蛋白富集生物学过程变化。",
        "page_idx": 11
    },
    {
        "type": "text",
        "text": "Tab.3 Biological processes enriched by differential proteins between adjacent time points of experimental group. ",
        "page_idx": 11
    },
    {
        "type": "table",
        "img_path": "images/2918457837629ef6d8fb05845c765b3d9113bbbda319af9d180cdb439dea7695.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td>Group</td><td>Biological Process</td><td>P-value</td></tr><tr><td>EM2-EM1</td><td>immune system process cell adhesion</td><td>0.0220 0.0340</td></tr><tr><td>EM3-EM2</td><td></td><td></td></tr><tr><td>EM4-EM3</td><td>negative regulation of inflammatory response regulation of cell growth</td><td>0.0017 0.0410 0.0460</td></tr><tr><td>EM5-EM4 immunoglobulin mediated immune response retina homeostasis</td><td>wound healing copper ion transport regulation of neuron death response to reactive oxygen species</td><td>0.0240 0.0250</td></tr></table></body></html>",
        "page_idx": 12
    },
    {
        "type": "text",
        "text": "（2）实验组与对照组对照筛选结果",
        "text_level": 1,
        "page_idx": 12
    },
    {
        "type": "text",
        "text": "将实验组与对照组相同时间点的鉴定结果进行对比分析，在$\\mathbb { W } 0 / \\mathbb { W } 1 / \\mathbb { M } 1 / \\mathbb { M } 2 / \\mathbb { M } 3 / \\mathbb { M } 4 / \\mathbb { M } 5$ 分别得到 $4 4 / 1 6 / 5 4 / 2 3 / 4 8 / 5 7 / 4 6$ 个差异蛋白（表4、附图1)。",
        "page_idx": 12
    },
    {
        "type": "text",
        "text": "在 WO，再生胰岛衍生的蛋白质 $3 \\beta$ 作为一种炎症标记物，对巨噬细胞的招募和组织修复有重要意义[35。文献表明凝溶胶蛋白通过与细丝末端的结合来稳定肌动蛋白细丝，从而阻止单体交换，其下调表明人类冠状动脉粥样硬化介质内血管平滑肌细胞的细胞骨架被解除调控[40]。嗜酸性粒细胞阳离子蛋白是冠心病诊断的生物标志物[92]。α $^ { - 2 }$ -HS-糖蛋白水平与动脉粥样硬化替代参数正相关,如内膜-中膜厚度(IMT)和动脉硬化等[39]。α 1-抗胰蛋白酶已经被报道是动脉粥样硬化的生物标志物[34。外周动脉闭塞病(PAOD)是全身性动脉粥样硬化的主要表现之一，甲状腺素运载蛋白和补体因子B 是监测血浆PAOD 疾病的潜在标记物[93]。脱氧核糖核酸酶1治疗可降低斑块净含量和巨噬细胞炎症，促进降脂后动脉粥样硬化的解决[94]。 $\\mathrm { I g } \\gamma - 2 \\mathrm { A }$ 链C区分泌形式和 $\\mathrm { I g } \\mathrm { ~ \\AA ~ }$ 链V-III区PC 7043参与获得性免疫。考虑到炎症和内皮细胞破坏反应在动脉粥样硬化发病和进展中的作用，凝血酶可能是一个重要的因素95。肾脏雄激素调节蛋白也被报道在高脂饮食的 ApoE-/-小鼠尿液中出现[34。白介素-18在动脉粥样硬化中发挥关键作用，也在在食欲控制和肥胖的发展中发挥了作用[44]。肝补体因子D 是免疫补体通路激活的标志[96]。CD44 也被报道与动脉粥样硬化有关。MHCII抗原呈递在动脉粥样硬化中具有重要的保护功能4。多种肿瘤坏死因子存在于人类动脉粥样硬化斑块中，并在动脉粥样硬化中显示出强大的免疫调节功能，在动脉粥样硬化小鼠模型中导致动脉粥样硬化的发生或保护作用98。酪氨酸蛋白激酶受体UFO被报道在止血和炎症中发挥重要作用[99]。α-1酸性糖蛋白可作为动脉粥样硬化血栓的生物标志物[100]。血管紧张素转换酶2被报道对心脏和血管有保护作用[101]。谷胱甘肽过氧化物酶的上升已经在动物试验中被证实对氧化压力和动脉粥样硬化具有保护作用2。小鼠三叶因子2的敲除能保护其在高脂饮食条件下免于肥胖[37。也有报道称可逆蛋白组氨酸磷酸化的改变可作为心血管疾病的细胞内信号[102]。VDAC1在 ala－ sdt 诱导 THP-1巨噬细胞凋亡中起着至关重要的作用，靶向VDAC1可能是调控巨噬细胞凋亡的潜在途径[103]。主要尿蛋白(MUPs)是脂钙蛋白家族的成员，它可以隔离和运输血液和其他亲水体液中的各种亲脂分子4，而在W0 实验组小鼠的主要尿蛋白1/2/3/5/17/18/20含量均低于对照组。有文献称，与健康对照组相比，冠心病患者外周血白细胞中LAMP-2基因表达及蛋白水平明显升高[45。内皮蛋白C也被文献报道称在血栓形成过程中扮演重要角色2。文献报道称抗菌肽LL-37在动脉粥样硬化病变中产生，它可能通过激活黏附分子和趋化因子表达，作为免疫调节剂发挥作用，从而增强动脉粥样硬化的固有免疫[104]。结合珠蛋白多态性与包括动脉粥样硬化在内的许多炎症疾病的流行和临床演变有关[42]。",
        "page_idx": 12
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 13
    },
    {
        "type": "text",
        "text": "巢蛋白2、天冬氨酸蛋白酶A、SH3结构域结合的富谷氨酸样蛋白3、角质蛋白A、淋巴细胞抗原、CMRF35样分子3和桥粒斑蛋白尚无文献报道与动脉粥样硬化直接相关。",
        "page_idx": 13
    },
    {
        "type": "text",
        "text": "在经过一周的高脂饮食饲喂后，实验组小鼠有16 种蛋白质发生显著变化。文献称抑制表皮生长因子受体可通过减少炎症和氧化应激而减轻动脉粥样硬化[105]。组织蛋白酶 B 能够降解动脉内膜内的细胞外基质，从而增加了斑块的脆弱性[106]。颈动脉粥样硬化中芳基硫酸酯酶B的上调与大脑栓塞有关[107]。有文献报道称，在组织蛋白酶E基因敲除的小鼠中，白色脂肪组织和棕色脂肪组织发育不良[。钙蛋白是一种参与凝血和动脉钙化的调节蛋白，也具有与动脉粥样硬化相关的细胞外功能[108]。抵抗素样分子被报道称是治疗动脉粥样硬化的潜在靶点[109]。",
        "page_idx": 13
    },
    {
        "type": "text",
        "text": "除先前提到过的蛋白外，尚未有文献报道分泌球蛋白家族2B成员20、N-乙酰半乳糖胺-6 硫酸酯酶、类酪氨酸蛋白10 和β-半乳糖苷酶与动脉粥样硬化直接相关。",
        "page_idx": 13
    },
    {
        "type": "text",
        "text": "在实验的M1时间点，实验组与对照组间有54个差异蛋白。",
        "page_idx": 13
    },
    {
        "type": "text",
        "text": "除先前提到过的蛋白外，波形蛋白在小鼠巨噬细胞中的缺乏可以增加氧化压力和血管炎症，但是会加剧动脉粥样硬化[10]。纤维蛋白原水平升高表明止血系统激活增加，是血栓性疾病的主要危险因素[]。细胞核中甘油醛 3磷酸脱氢酶的积累可导致内皮细胞的死亡，而这是动脉粥样硬化之前的步骤[2]。T-钙黏着蛋白对新内膜和动脉粥样硬化斑块病变中脂联素的积累至关重要[46]。细胞外超氧化物歧化酶的酶促特性可能对含脂巨噬细胞的功能和动脉粥样硬化过程有重要意义[1]。纤维连接蛋白是动脉粥样硬化过程中结缔组织形成的指示物[]。NPC细胞内胆固醇转运体2与NPC1协同作用，而 NPC1已被证明在动脉粥样硬化中发挥关键作用[114]。富亮氨酸重复序列蛋白19 在免疫应答中发挥作用[15]。有文献称维生素D 具有潜在的抗动脉粥样硬化作用[116。铜蓝蛋白(CP)是一种急性期的反应物和动脉粥样硬化血栓形成风险的潜在生物标志物7]。有文献表明前胶原c-肽内酶增强蛋白2具有抗动脉粥样硬化作用，是胆固醇逆向转运HDL系统的重要组成部分[18]。I型干扰素也被确认为动脉粥样硬化前细胞因子，干扰素β的处理会增加斑块的形成和巨噬细胞的积累[9]。血管紧张素原在脂肪细胞代谢和炎症发展中发挥关键作用29。中性粒细胞在动脉粥样硬化中发挥作用，而其通过主要组织相容性复合体I呈递抗原[23]。定期监测维生素B12状态可能有助于预防动脉粥样硬化相关疾病，而反钴胺素2可以运载维生素 $\\mathrm { B 1 2 ^ { [ 3 3 ] } }$ 。谷胱甘肽调节细胞活性氧的水平，并参与细胞氧化应激反应，其失衡与动脉粥样硬化有关， $\\gamma$ -谷酰基循环与谷胱甘肽形成密切相关。补体因子I和 $\\mathrm { I g } \\gamma - \\mathrm { 2 A }$ 链C区参与免疫反应。桥粒胶蛋白1和2在氧化低密度脂蛋白的影响下，在人脐静脉内皮细胞中含量减少[24]，并有文献称这桥粒胶蛋白2及其介导的细胞黏附可以被半乳糖凝集素3调节[25]。文献报道称 SCUBE2可能通过 Hh 信号转导在动脉粥样硬化斑块进展中发挥重要作用[41]。心房利钠肽(ANP)被脑啡肽酶(NEP)快速降解，可减少损伤诱导的内皮细胞渗漏[120]。内皮细胞选择性粘附分子失活可通过抑制斑块新生血管形成和巨噬细胞浸润动脉粥样硬化易感性降低[121]。槲皮素/巯基氧化酶1（QS0X1）可以促进血管平滑肌细胞迁移和增殖[122]。T-钙黏着蛋白对新内膜和动脉粥样硬化斑块病变中脂联素的积累至关重要[39。催乳素在血管平滑肌细胞增生中发挥作用，而血管平滑肌细胞增生是高血压、动脉粥样硬化等心血管疾病的发病特征[48]。气味结合蛋白同样是一种载脂蛋白3。慢性肾病患者较低的血清胰淀粉酶水平可能是营养不良-炎症-动脉粥样硬化综合征的组成部分[27]。",
        "page_idx": 13
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 14
    },
    {
        "type": "text",
        "text": "尚未有文献报道 EFEMP1、溶酶体保护蛋白、羧酸酯酶1C、核糖核酸酶 T2-A、激活素受体1B型、淋巴抗原6D、SPINK1、Costars家族蛋白ABRACL、Afamin、WFDC2、糖蛋白整合膜蛋白1、蛋白质YIPF3、β己糖胺酶β亚基、分泌球蛋白家族 2B成员2和蛋白质LEG1同源物与动脉粥样硬化直接相关，可能有潜力作为新的生物标志物。",
        "page_idx": 14
    },
    {
        "type": "text",
        "text": "在M2，实验组和对照组有23个差异蛋白。",
        "page_idx": 14
    },
    {
        "type": "text",
        "text": "除先前提到过的蛋白外，β-防御素1是一种炎症调控的多肽，而β-防御素3可以通过对肿瘤坏死因子α的响应抑制NF－κB和MAPK信号，在内皮细胞发挥抗炎症和抗氧化作用[123]。硫氧还蛋白80在体外和体内小鼠研究中都发挥了强大的血管生成作用，ApoE-/-小鼠巨噬细胞中特异性过表达人硫氧还蛋白80的转基因小鼠主动脉粥样硬化病变显著增加[124]。异柠檬酸脱氢酶可能通过参与7-KC- mir -144-idh2 通路促进动脉粥样硬化的进展[125]。载脂蛋白A-I通过调节反向胆固醇的运输等方式在动脉粥样硬化中起到保护作用[126]。通过泛素-蛋白酶体系统管理蛋白质稳态对动脉粥样硬化的发展至关重要[127]。激肽-1 (KLK1)和血管紧张素转换酶(ACE)分别是激肽-激肽系统和肾素-血管紧张素系统的两个关键分子，负责维持血管平衡和稳定，在动脉粥样硬化中发挥重要作用[128]。CD59a的敲除与动脉粥样硬化斑块中膜攻击复合物(MAC)沉积增加和斑块早期平滑肌细胞增殖增加有关[129]。转铁蛋白在动脉粥样硬化中发挥重要作用[46]。神经节苷脂GM2 激活蛋白也被报道称可以结合、溶解和运输广谱的脂质分子，可能作为一种普通的细胞内和细胞间的脂质运输蛋白[26]。文献称缺失功能黏附分子A可导致血小板功能激活阈值降低，炎症活性增加，在疾病早期阶段导致了斑块形成的增加[130]。动脉粥样硬化与高C 反应蛋白和低血清白蛋白的相关性很强，独立于其他动脉粥样硬化危险因素[131]。",
        "page_idx": 14
    },
    {
        "type": "text",
        "text": "在M3，实验组和对照组有48个差异蛋白。",
        "page_idx": 14
    },
    {
        "type": "text",
        "text": "除先前提到过的蛋白外，小脯氨酸丰富蛋白3被鉴定为一种新型的动脉粥样硬化保护因子[132]，小脯氨酸丰富蛋白2b (Sprr2b)是在心脏病期间CFs 中上调最多的基因之一[13]。硫氧还蛋白-1/过氧还蛋白-1 是动脉粥样硬化 NADPH氧化酶活性介导的氧化应激的传感器[134]。尽管碳酸酐酶6 和15无相关文献报道，但是碳酸酐酶1表达及其介导的钙化与动脉粥样硬化进展显著相关[135]。I型胶原蛋白是动脉粥样硬化的早期生物标志物34。Ig kappa 链V-II 区 26-10、免疫球蛋白kappa 和Iglambda-1链C区参与获得性免疫。延长因子1α1与疾病的关系无直接报道，但有文献称削弱延长因子2激酶的活性可以减少动脉粥样硬化斑块的形成[136。内皮功能障碍被认为是动脉粥样硬化的早期指标，其特征是粘附分子的过度表达，包括细胞间粘附分子-1（ICAM-1）和血管细胞粘附分子-1（VCAM-1）[137]。有报道称，CCN4通过与α5β1整合素相互作用，促进血管平滑肌细胞的迁移和增殖5]，其在在动脉粥样硬化的发生发展中起着至关重要的作用。血管生成素 2 通过调控血管生成和炎症影响主动脉瘤和动脉粥样硬化[138]。文献报道半乳糖凝集素3浓度的局部升高可能会增强单核细胞和巨噬细胞募集到动脉壁8，加剧动脉粥样硬化病变的促炎状态[19]。鞘脂是一类生物活性脂质，可以调节炎症等生理过程，与动脉粥样硬化相关39。有文献表明妊娠区蛋白可以结合组织型纤溶酶原激活剂并通过低密度脂蛋白受体相关蛋白促进其清除[20]。",
        "page_idx": 14
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 15
    },
    {
        "type": "text",
        "text": "角质蛋白B、SPARC 样蛋白1、真核翻译起始因子6和基质重塑相关蛋白8无文献报道直接与动脉粥样硬化相关，有成为新生物标志物的潜力。",
        "page_idx": 15
    },
    {
        "type": "text",
        "text": "在M4，实验组和对照组有57个差异蛋白。",
        "page_idx": 15
    },
    {
        "type": "text",
        "text": "除先前提到过的蛋白外，铜转运蛋白Atox1通过促进损伤血管平滑肌细胞迁移和炎症细胞募集参与血管损伤后新生内膜的形成[140]。Ig κ 链V-III区 50S10.1参与获得性免疫。文献称抑制表皮生长因子受体可通过减少炎症和氧化应激而减轻动脉粥样硬化[105]。血清尿调节素是一种新的肾功能和肾小管完整性的生物标志物，已被证实与心血管高危患者的心血管事件和总死亡率有关[141]。溶酶体α-葡糖苷酶可能参与了冠心病的发展[142。文献报道称黏连蛋白可由afadin与肌动蛋白细胞骨架结合并在血管生成中发挥作用[143]。有文献报道称，在组织蛋白酶E基因敲除的小鼠中，白色脂肪组织和棕色脂肪组织发育不良[31]。在人动脉粥样硬化中，组织蛋白酶L与细胞凋亡和斑块失稳显著相关[23]。文献报道称纤溶酶原介导巨噬细胞表达的尿激酶的致动脉粥样硬化作用，并加速 ApoE 敲除小鼠的动脉粥样硬化[14]。而丝氨酸蛋白酶抑制剂A3在血管中的差异表达与人类动脉粥样硬化明显相关[50]。补体C3在动脉粥样硬化中发挥重要作用[145]。中性粒细胞明胶酶相关载脂蛋白(NGAL)调节基质金属蛋白酶(MMP）9的活性，它是动脉粥样硬化中血管重塑和斑块不稳定的重要介质[146]。",
        "page_idx": 15
    },
    {
        "type": "text",
        "text": "前列腺干细胞抗原、前表皮生长因子、ATP 结合盒亚家族A成员13、二-N-乙酰壳聚糖酶、泛酰巯基乙胺酶和附睾特异的α-甘露糖苷酶尚无文献报道与动脉粥样硬化直接相关，有成为新生物标志物的潜力。",
        "page_idx": 15
    },
    {
        "type": "text",
        "text": "在M5，实验组和对照组有46个差异蛋白。",
        "page_idx": 15
    },
    {
        "type": "text",
        "text": "除先前提到过的蛋白外，文献报道称在无症状颈动脉粥样硬化患者中，β-2-微球蛋白与不良心血管事件独立且显著相关[147]。小鼠前列腺素D2 合酶的敲除会促进动脉粥样硬化[148]。包含组织蛋白酶 Z 在内的半胱氨酸蛋白酶在动脉粥样硬化中发挥重要作用[49。膜突蛋白能够控制PDGF诱导的血管平滑肌细胞的迁移，PDGF 是一种参与血管生成或动脉粥样硬化等病理生理过程的生长因子[150]。Ig K链V-III区PC3741／TEPC111和Ig重链V区AC38205.12参与获得性免疫。谷胱甘肽调节细胞活性氧的水平，并参与细胞氧化应激反应，其失衡与动脉粥样硬化有关[]。文献报道称整体蛋白多糖 4 (Prg4)的缺乏增加载脂蛋白 E敲除和低密度脂蛋白受体敲除小鼠的动脉粥样硬化易感性[151]",
        "page_idx": 15
    },
    {
        "type": "text",
        "text": "淋巴管内皮透明质酸受体1、聚合免疫球蛋白受体、磷酸肌醇-3-激酶相互作用蛋白1、核转运因子2和分泌和跨膜蛋白1A尚无文献直接报道与动脉粥样硬化有关，有成为新生物标志物的潜力。",
        "page_idx": 15
    },
    {
        "type": "text",
        "text": "对差异蛋白用DAVID进行GO分析，不同时间点显著变化的生物学过程如图7所示。实验组脂肪代谢和糖代谢相关生物学过程从WO开始就与对照组存在显著差异，在WO 和M4两个时间点，免疫相关过程差异显著。M1差异蛋白主要富集到细胞粘附相关过程，M2差异蛋白主要富集到氧化还原反应相关过程，M3差异过程开始出现伤口愈合，也存在较多粘附相关过程，M4 除大量免疫相关过程差异显著外，还出现纤维原细胞增殖正调控和血管生成的负调控过程，M5 吞噬",
        "page_idx": 15
    },
    {
        "type": "text",
        "text": "作用和蛋白质水解相关过程开始出现。",
        "page_idx": 16
    },
    {
        "type": "text",
        "text": "文献表明，在动脉粥样硬化开始的早期阶段，低密度脂蛋白(LDL)颗粒在动脉内膜中积聚，从而免受血浆抗氧化剂的影响，接受氧化和其他修饰，具有促炎和免疫原性。典型的单核细胞在血液中循环，表现出抗炎症的功能，并能与激活的内皮细胞表达的黏附分子结合从而进入内膜。一旦进入内膜，单核细胞就可以成熟为巨噬细胞，这些细胞表达能与脂蛋白颗粒结合的清道夫受体，成为泡沫细胞，形成动脉粥样硬化斑块的核心。T淋巴细胞也可以进入内膜，调节天然免疫细胞、内皮细胞和平滑肌细胞的功能。中膜中的平滑肌细胞可以在白细胞的介质作用下迁移到内膜中，分泌细胞外基质，形成纤维帽[152]。而在本实验的探究中，在第一周实验组与对照组的差异蛋白富集到了上皮细胞分化，M1富集到细胞粘附，可能与单核细胞粘附相关；在M2实验组和对照组的差异蛋白可富集到与氧化还原相关的生物学过程，可能与LDL颗粒的氧化还原相关；M3细胞粘附同样发生变化，可能涉及到吞噬细胞等的招募；M4免疫相关生物学过程大量变化，可能与T细胞等免疫细胞的参与有关，成纤维细胞增殖的调控可能与纤维帽形成有关；M5蛋白质水解等变化显著，据报道激活的巨噬细胞会分泌蛋白水解酶，可能会降解基质成分。基质成分的丢失可能随后导致斑块的不稳定，增加斑块破裂和血栓形成的风险[153]，纤维蛋白的溶解在动脉粥样硬化发生发展中发挥重要作用[154]。各不同时间点差异蛋白富集到的生物学过程能够一定程度上与已知疾病发生发展进程相对应，表明尿液蛋白质组具有监测疾病进程的潜力。",
        "page_idx": 16
    },
    {
        "type": "text",
        "text": "除此之外，在W0，与脂质和糖代谢相关的生物学过程就存在显著性差异，表明ApoE基因敲除使得实验组小鼠脂质运输受到较大影响，在相当早的时期就能够有所体现。急性期反应、免疫应答、细胞因子和蛋白质水解也都与动脉粥样硬化密切相关[50.15-157]。实验组小鼠经过一周高脂饮食后，蛋白激酶B信号通路在巨噬细胞的存活、增殖和迁移中发挥重要作用，可能影响动脉粥样硬化的发展[158]经过一个月高脂饮食后，多个生物学过程发生显著变化。研究表明尿钠排泄量是颈动脉内膜-中膜厚度的决定性因素，而后者是动脉粥样硬化的指标[159；补体激活经典途径也与动脉粥样硬化相关[145；铜与同型半胱氨酸相互作用产生自由基，从而氧化LDL，这已在动脉粥样硬化斑块中被发现 6。在M2，雌激素被报道具有多种抗动脉粥样硬化的特性，包括影响血浆脂蛋白水平，刺激前列环素和一氧化氮的产生[161]。在M3，伤口愈合同样与动脉粥样硬化相关[54]。在M4，ERK1/ERK2 通路在胰岛素(INS)和凝血酶诱导的血管平滑肌细胞增殖中起着重要作用[57]；有文献称由于细胞内高铁水平诱导促炎、促动脉粥样硬化的M1巨噬细胞表型，降低细胞内铁含量的因素可能促进M1巨噬细胞表型向M2巨噬细胞表型的转变，从而防止动脉粥样硬化的发生[73]；补体激活替代途径和主要组织相容性复合体家族II 等曾被报道与动脉粥样硬化相关[73,162]。在 M5 差异蛋白的富集结果中，伴侣介导的自噬(CMA)在肝细胞的脂质代谢和脂质代谢中起着重要的上游调节作用[163]。",
        "page_idx": 16
    },
    {
        "type": "image",
        "img_path": "images/410c833c77d0bc0ee54fa5ee94678eb7d9c800046b8f2cf3a26a9e2ed4415427.jpg",
        "img_caption": [
            "图7实验组与对照组各时间点差异蛋白功能注释（ $\\mathrm { \\cdot _ { p } } { < } 0 . 0 5$ ）"
        ],
        "img_footnote": [],
        "page_idx": 17
    },
    {
        "type": "text",
        "text": "Fig.7 Functional annotation of differential proteins in different time points between experimental group and control group ( $\\cdot \\mathrm { p } { < } 0 . \\ 0 5 )$ ： ",
        "page_idx": 17
    },
    {
        "type": "text",
        "text": "3.3蛋白质化学修饰分析",
        "text_level": 1,
        "page_idx": 17
    },
    {
        "type": "text",
        "text": "为进一步探究高脂饮食诱导的动脉粥样硬化对尿液蛋白质化学修饰的影响，选取 EW0/EM5/CM5 三个时间点共15 个样品，在基于 open-pFind 软件检索数据（.raw）之后，在pBuild中导出分析结果。",
        "page_idx": 17
    },
    {
        "type": "text",
        "text": "在15个样本中共鉴定到923种不同化学修饰类型，其中EW0 组共鉴定出 468种化学修饰类型，EM5组共鉴定到748种化学修饰类型，CM5组共鉴定到611种化学修饰类型。",
        "page_idx": 17
    },
    {
        "type": "image",
        "img_path": "images/b73cf74012bdbc688dffb5ec3bf4b840a41dd485ef7a62cd1093374a01c948ba.jpg",
        "img_caption": [
            "图8三组样品修饰类型韦恩图。",
            "Fig.8 Venn diagram of modification types in three groups. "
        ],
        "img_footnote": [],
        "page_idx": 18
    },
    {
        "type": "text",
        "text": "对所有修饰进行非监督聚类分析，发现CM5组与其他两组能够很好区分（图9)。",
        "page_idx": 18
    },
    {
        "type": "text",
        "text": "对EWO组与EM5组的不同修饰类型的位点占比进行统计，分析自身对照前后发生的修饰变化。其中，有1种修饰类型为EW0 组独有且在4个以上样品中存在（总样品数为5)，有23种修饰类型为EM5 组独有且在5个以上样品中存在（总样品数为6)，有68种修饰类型为两组共有且存在显著差异 $\\langle \\operatorname { F C } \\geqslant 1 . 5$ 或 $\\leqslant 0 . 6 7$ ，$\\mathrm { p } { < } 0 . \\ 0 5 )$ 。同时对CM5 组和 EM5 组的不同类型修饰的位点占比进行统计，分析实验组和对照组之间的不同。其中，有8种修饰类型为CM5 组独有且在3个以上样品中存在（总样品数为4)，有19种修饰类型为EM5 组独有且在5个以上样品中存在（总样品数为6)，有72种修饰类型为两组共有且存在显著差异（ $\\mathrm { F C } \\geqslant 1 . 5$ 或 $\\leqslant 0 . 6 7$ ， $\\mathrm { p } { < } 0 . 0 5$ ）（详见附表4）。",
        "page_idx": 18
    },
    {
        "type": "image",
        "img_path": "images/d66a7c7ff1e96a87bc5b113c2fbbc567d3fb392b6ddc51c90be7803cd7469332.jpg",
        "img_caption": [
            "图9三组样品全修饰类型非监督聚类结果。"
        ],
        "img_footnote": [],
        "page_idx": 19
    },
    {
        "type": "text",
        "text": "Fig.9 Unsupervised clustering of all the modification types in three groups. ",
        "page_idx": 19
    },
    {
        "type": "image",
        "img_path": "images/027d55ce0cd9fa0a3455efa966e943c1c77054b2de6dc605d57c228bac90ec6c.jpg",
        "img_caption": [
            "图10自身对照与组间对照差异修饰类型韦恩图。"
        ],
        "img_footnote": [],
        "page_idx": 19
    },
    {
        "type": "text",
        "text": "Fig.10 Venn diagram of differential modification types in self control and group control. ",
        "page_idx": 19
    },
    {
        "type": "text",
        "text": "为排除开放式检索模式带来的假阴性影响，采用限制性搜索的方式进行验证。固定开放式检索修饰位点占比前五的修饰类型，并选定在一组中独有且在各个样品中都存在的修饰类型、有文献报道过与动脉粥样硬化相关的修饰类型及可能与其相关的修饰类型进行检索。在EM5-EW0组中选定20 种修饰，在EW5-CM5组中选定25种修饰，计算修饰位点在总位点数中所占比例（见表5），筛选标准为 $\\mathrm { F C } \\geqslant 1 . 5$ 或 $\\leqslant 0 . 6 7$ ， $\\mathrm { p } { < } 0 . 0 5$ 。最终在实验组自身对照中（EM5-EW0)，N末端氨基甲酰化修饰（Carbamyl[AnyN-term]）、天冬氨酸的CHDH修饰（CHDH[D]）、色氨酸被犬尿氨酸取代（Trp->Kynurenin[W]）、脯氨酸的氧化修饰（Oxidation[P]）、半胱氨酸的半胱氨酰化修饰（Cysteinyl[C]）、半胱氨酸的二氧化硫修饰（SulfurDioxide［C]）、半胱氨酸的NO_SMX_SIMD修饰(NO_SMX_SIMD[C」）和赖氨酸的Delta_H(2)C(3)修饰（Delta_H(2)C(3)[K」)显著变化。在实验组和对照组比较中（EM5-CM5)，赖氨酸的胍基化修饰（Guanidinyl[K]）、酪氨酸的磷酸尿苷化修饰（PhosphoUridine[Y]）、N末端氨基甲酰化修饰（Carbamyl[AnyN-term]）、N末端的Delta_H(2)C(2)修饰(Delta_H(2)C(2)[AnyN-term]）和精氨酸的二羟基咪唑烷修饰（Dihvdroxvimidazolidine「Rl）显著变化。",
        "page_idx": 20
    },
    {
        "type": "text",
        "text": "在实验组自身对照观察到的变化中，许多研究表明氨甲酰化蛋白参与疾病的发生，特别是动脉粥样硬化和慢性肾功能衰竭[164]。犬尿氨酸通路是色氨酸代谢的主要途径，在早期动脉粥样硬化中发挥着重要作用[165]。脯氨酸的氧化可以形成谷氨酸半醛，而谷氨酸半醛与脂质过氧化密切相关[166]。血浆同型半胱氨酸升高也被广泛研究为动脉粥样硬化的独立危险因素[167]。二氧化硫/天冬氨酸氨基转移酶途径受阻与许多心血管疾病的发病机理有关同样已为人知[168]。赖氨酸的Delta_H(2)C(3)修饰也指丙烯醛的38 位加成，而丙烯醛等α、β 不饱和醛类物质，被认为是炎症和血管功能障碍的介质[169]。天冬氨酸的CHDH修饰和半胱氨酸的 NO_SMX_SIMD 修饰暂无文献报道与动脉粥样硬化相关，可能是潜在的修饰位点。",
        "page_idx": 20
    },
    {
        "type": "text",
        "text": "虽未在限制性搜索中得到验证，也有文献称，亲电试剂介导的细胞信号的中断与动脉粥样硬化和癌症的发生有关，HNE和ONE及其衍生物都是活跃的脂质亲电试剂，能够在一定程度上抑制促炎因子的释放[170]。Nε-羧甲基-赖氨酸(CML)被报道在糖尿病和动脉粥样硬化的组织中大量积累，而葡糖酮醛与其形成相关[171]异硫氰酸苄酯盐据报道在高脂饮食饲喂的肥胖小鼠中可以抑制脂生成和脂肪肝的形成[72]。文献报道称噻唑烷的衍生物在治疗LDLR $( - / - )$ 动脉粥样硬化小鼠中有着积极作用[173]。此外，赖氨酸的羧乙基化也发生变化，有文献指出在糖尿病小鼠血浆中赖氨酸的羧甲基化和羧乙基化程度明显提高[174]。岩藻糖基化低聚糖表达的改变在动脉粥样硬化等病理过程中被观察到[175]。此外，酪氨酸的磷酸尿苷化修饰与酯的形成有关，同样可能参与脂质代谢及疾病的发生发展。",
        "page_idx": 20
    },
    {
        "type": "text",
        "text": "而在实验组和对照组的差异修饰中，部分显著变化的修饰在实验组自身对照同样发生变化，除此之外，氨基酸N端的Delta_H(2)C(2)修饰也指乙醛的 26 位加成，乙醛以一种notch依赖的方式刺激血管平滑肌细胞的生长，从而促进动脉粥样硬化的发生[176。晚期蛋白糖基化是包括动脉粥样硬化在内的糖尿病晚期并发症发生的重要机制，甲基乙二醛衍生的氢咪唑酮-1 是人血浆中最丰富的晚期糖基化终末产物[177]。此外，赖氨酸的胍基化修饰也可能与动脉粥样硬化有关。",
        "page_idx": 20
    },
    {
        "type": "text",
        "text": "虽未在限制性搜索中得到验证，越来越多的研究表明，短链脂肪酸及其同源酰化参与心血管疾病，2-羟基异丁酰化、丙二酰化和丁烯酰化在实验组中所占比例都显著升高[178]。Nε-羧甲基-赖氨酸(CML)被报道在糖尿病和动脉粥样硬化的组织中大量积累，其诱导的PI3K/Akt信号抑制促进了泡沫细胞的凋亡和动脉粥样硬化的进展[179]，而与其形成密切相关的葡糖醛酮在实验组中也显著升高。酪氨酸氧化可产生二羟基苯丙氨酸（DOPA)，组织中的蛋白结合DOPA在许多年龄相关的病理疾病中升高，如动脉粥样硬化和白内障形成[180]。",
        "page_idx": 20
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 21
    },
    {
        "type": "text",
        "text": "然而，主要尿蛋白家族成员对实验结果影响较大，尤其是在雄性小鼠尿液中主要尿蛋白含量较高且可能在雄性性行为和竞争交流中很重要[181]，后续应当考虑采取雌性小鼠模型或其他种类动物模型。动物只数也有待增加，如能获取到每个取尿时间点的生理病理学变化结果将更有说服力。对照组如能采用同一批小鼠也会是较好的优化方案。此外，人类尿液中并不存在主要尿蛋白，限制了该结果向人体的进一步应用，应当收集类似病因（如高脂血症）引发的动脉粥样硬化的临床尿液样本进行实验。在关于蛋白质化学修饰的分析中，开放性检索和限制性检索方式均存在不足之处，期待能够得到进一步的改进。",
        "page_idx": 21
    },
    {
        "type": "text",
        "text": "4结论",
        "text_level": 1,
        "page_idx": 21
    },
    {
        "type": "text",
        "text": "本研究探究了高脂饮食 ApoE-/-动脉粥样硬化小鼠的尿液蛋白质组学变化。自身对照结果表明即使仅进行一周高脂饮食，对照组尿液蛋白质组未发生明显变化时，实验组尿液蛋白质组已发生显著变化，所富集到的生物学通路大多与脂质代谢和糖代谢相关，表明尿液蛋白质组具有早期敏锐监测生物体变化的潜力；在疾病进展过程中持续变化且变化趋势相同的蛋白质及其家族成员大多数被报道过与动脉粥样硬化相关或可作为其生物标志物。组间对照结果表明各不同时间点差异蛋白富集到的生物学过程能够一定程度上与疾病发生发展进程相对应，尿液蛋白质组具有监测疾病进程的潜力。实验组自身对照和实验组与对照组对比得出的差异性修饰也有多种被报道过与动脉粥样硬化相关，可作为寻找新型生物标志物的参考。",
        "page_idx": 21
    },
    {
        "type": "text",
        "text": "表1实验组W1与W0对照显著变化的蛋白质信息。",
        "text_level": 1,
        "page_idx": 22
    },
    {
        "type": "table",
        "img_path": "images/914044625e9fb46e1bc5a183ff69b9d785def6991616e9b93bc00c935df7e0ea.jpg",
        "table_caption": [
            "Tab.1 Details of differential proteins between week 1 and week O samples in experimental group. "
        ],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td>Uniprot</td><td>Human Uniprot</td><td>Protein Name</td><td>P-value</td><td>Fold Change</td><td>Mechanism or Biomarker</td></tr><tr><td>B5X0G2</td><td>No</td><td> Major urinary protein 17</td><td>0.0008</td><td>7.92</td><td>[14]</td></tr><tr><td>P11588</td><td>No</td><td> Major urinary protein 1</td><td>0.0007</td><td>7.84</td><td>[14]</td></tr><tr><td>A2BIM8</td><td>No</td><td>Major urinary protein 18</td><td>0.0014</td><td>3.19</td><td>[14]</td></tr><tr><td>Q9JI02</td><td>No</td><td>Secretoglobin family 2B member 20</td><td>0. 0488</td><td>2.75</td><td>1</td></tr><tr><td>Q5FW60</td><td>No</td><td>Major urinary protein 20</td><td>0. 0121</td><td>2.65</td><td>[14]</td></tr><tr><td>Q07797</td><td>Q08380</td><td>Galectin-3-binding protein</td><td>0. 0077</td><td>2.59</td><td>[15][16]</td></tr><tr><td>Q61838</td><td>No</td><td>Pregnancy zone protein</td><td>0.0411</td><td>2.46</td><td>[17]</td></tr><tr><td>P11591</td><td>No</td><td>Major urinary protein 5</td><td>0.0136</td><td>2.40</td><td>[14]</td></tr><tr><td>Q64695</td><td>Q9UNN8</td><td>Endothelial protein C receptor</td><td>0.0150</td><td>2.23</td><td>[18]</td></tr><tr><td>Q91WR8</td><td>P59796</td><td>Glutathione peroxidase 6</td><td>0. 0469</td><td>1.99</td><td>[19]</td></tr><tr><td>P06797</td><td>P07711</td><td>Cathepsin L1</td><td>0. 0146</td><td>1.84</td><td>[20]</td></tr><tr><td>P13597</td><td>P05362</td><td>Intercellular adhesion molecule 1</td><td>0. 0432</td><td>1. 66</td><td>[21][22]</td></tr><tr><td>Q9JK39</td><td>A8MVZ5</td><td>Butyrophilin-like protein 10</td><td>0. 0446</td><td>0.60</td><td>1</td></tr><tr><td>P01898</td><td>P01891</td><td>H-2 class I histocompatibility antigen， Q10</td><td>0.0429</td><td>0.59</td><td>[23]</td></tr><tr><td>P55292</td><td>Q02487</td><td>alpha chain Desmocollin-2</td><td>0.0160</td><td>0.57</td><td>[24][25]</td></tr><tr><td>P23780</td><td>P16278</td><td>Beta-galactosidase</td><td>0.0384</td><td>0.56</td><td>1</td></tr><tr><td>Q60648</td><td>P17900</td><td>Ganglioside GM2 activator</td><td>0.0382</td><td>0.56</td><td>[26]</td></tr><tr><td>P00688</td><td>P04746</td><td>Pancreatic alpha-amylase</td><td>0.0311</td><td>0.55</td><td>[27]</td></tr><tr><td>P70269</td><td>P14091</td><td>Cathepsin E</td><td>0.0299</td><td>0.54</td><td>[28]</td></tr><tr><td>P11859</td><td>P01019</td><td>Angiotensinogen</td><td>0.0338</td><td>0.51</td><td>[29]</td></tr><tr><td>Q6UGQ3</td><td>No</td><td>Secretoglobin family 2B member 2</td><td>0.0270</td><td>0.49</td><td></td></tr><tr><td>088322</td><td>Q14112</td><td>Nidogen-2</td><td>0.0004</td><td>0.43</td><td>1 二</td></tr></table></body></html>",
        "page_idx": 22
    },
    {
        "type": "table",
        "img_path": "images/4b179708aa5bdb4a61308c43d0878fa8195ce3cfc33d7582b253e1e620c9572a.jpg",
        "table_caption": [
            "表2实验组自身对照持续变化的差异蛋白信息。"
        ],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>088968</td><td>P20062</td><td>Transcobalamin-2</td><td>0.0155</td><td>0.39</td><td>[30]</td></tr><tr><td>P11087</td><td>P02452</td><td>Collagen alpha-1(I）chain</td><td>0.0080</td><td>0.34</td><td>[31]</td></tr><tr><td>Q4KML4</td><td>Q9P1F3</td><td>Costars family protein ABRACL</td><td>0.0181</td><td>0.28</td><td></td></tr><tr><td>P35230</td><td>Q06141</td><td>Regenerating islet-derived protein 3-beta</td><td>0.0012</td><td>0.24</td><td>[32]</td></tr><tr><td>A2AEP0</td><td>No</td><td>Odorant-binding protein 1b</td><td>0.0213</td><td>0.20</td><td>[33]</td></tr></table></body></html>",
        "page_idx": 23
    },
    {
        "type": "text",
        "text": "Tab.2 Details of continuous changing differential proteins in self control of experimental group. ",
        "page_idx": 23
    },
    {
        "type": "table",
        "img_path": "images/3d2844b33199f7292e9e802980c429f3d1b2fdc51c8834846021ea763bae70c7.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td rowspan=\"2\">Uniprot</td><td rowspan=\"2\">Human Uniprot</td><td rowspan=\"2\">Protein Name</td><td colspan=\"6\">Fold Change</td><td rowspan=\"2\">Mechanism or Biomarker</td></tr><tr><td>EW0</td><td>EM1</td><td>EM2</td><td>EM3</td><td>EM4</td><td>EM5</td></tr><tr><td>B5X0G2</td><td>No</td><td> Major urinary protein 17</td><td>1</td><td>11.94</td><td>27.92</td><td>27.91</td><td>20.90</td><td>11. 18</td><td>[14]</td></tr><tr><td>P11588</td><td>No</td><td>Major urinary protein 1</td><td>1</td><td>9.59</td><td>18.11</td><td>17.19</td><td>21.96</td><td>9.24</td><td>[14]</td></tr><tr><td>P01665</td><td>No</td><td>Ig kappa chain V-III region PC 7043</td><td>1</td><td>一</td><td>11.01</td><td>8.41</td><td>18.15</td><td>9.95</td><td>1</td></tr><tr><td>Q61646</td><td>P00738</td><td>Haptoglobin</td><td>1</td><td>一</td><td>7. 68</td><td>8.66</td><td>5.76</td><td>11.25</td><td>[39]</td></tr><tr><td>P04441</td><td>P04233</td><td>H-2 class II histocompatibility antigen gamma chain</td><td>1</td><td>1</td><td>4.99</td><td>5.50</td><td>10.95</td><td>4.80</td><td>[40]</td></tr><tr><td>Q5FW60</td><td>No</td><td>Major urinary protein 20</td><td>1</td><td>4.24</td><td>6.10</td><td>5.57</td><td>7.53</td><td>4.28</td><td>[14]</td></tr><tr><td>P11591</td><td>No</td><td> Major urinary protein 5</td><td>1</td><td>3.94</td><td>5.26</td><td>4.40</td><td>6.76</td><td>3.95</td><td>[14]</td></tr><tr><td>P0CW03</td><td>No</td><td>Lymphocyte antigen 6C2</td><td>1</td><td>2.91</td><td>4.45</td><td>2.95</td><td>6.45</td><td>2.59</td><td>1</td></tr><tr><td>Q03404</td><td>Q03403</td><td>Trefoil factor 2</td><td>1</td><td>1. 76</td><td>3.04</td><td>2.16</td><td>5.91</td><td>2.41</td><td>[34]</td></tr><tr><td>Q9Z0M9</td><td>095998</td><td>Interleukin-18-binding protein</td><td>1</td><td>1</td><td>3.01</td><td>2.08</td><td>3.93</td><td>3.08</td><td>[41]</td></tr><tr><td>P11589</td><td>No</td><td>Major urinary protein 2</td><td>1</td><td>一</td><td>2.52</td><td>2.56</td><td>4.30</td><td>2.43</td><td>[14]</td></tr><tr><td>P17047</td><td>P13473</td><td>Lysosome-associated membrane glycoprotein 2</td><td>1</td><td>一</td><td>2.10</td><td>3.13</td><td>3.20</td><td>2.64</td><td>[42]</td></tr></table></body></html>",
        "page_idx": 23
    },
    {
        "type": "table",
        "img_path": "images/99c04981606ba9f6da5d322b33b9e97bbcafffc4d8a99a7288e38572cf4c0ead.jpg",
        "table_caption": [
            "表4实验组和对照组各时间点差异蛋白信息"
        ],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td>Q9Z0K8</td><td>095497</td><td></td><td>Pantetheinase</td><td>1</td><td></td><td>1.73</td><td>1.79</td><td>1.75</td><td>5.22</td><td>一</td></tr><tr><td></td><td>P09803</td><td>P12830</td><td>Cadherin-1</td><td>1</td><td></td><td>2.20</td><td>2.88</td><td>2.28</td><td>2.13</td><td>[43]</td></tr><tr><td></td><td>P61110</td><td>P61109</td><td>Kidney androgen-regulated protein</td><td>1</td><td></td><td>1.84</td><td>1.92</td><td>3.54</td><td>1. 63</td><td>[31]</td></tr><tr><td></td><td>P01837</td><td>P01834</td><td>Immunoglobulin kappa constant</td><td>1</td><td></td><td>1. 94</td><td>2.78</td><td>2.35</td><td>1. 61</td><td></td></tr><tr><td></td><td>P01631</td><td>No</td><td>Ig kappa chain V-II region 26-10</td><td>1</td><td></td><td>1.74</td><td>1.78</td><td>2.77</td><td>1.85</td><td></td></tr><tr><td></td><td>Q8R242</td><td>Q01459</td><td>Di-N-acetylchitobiase</td><td>1</td><td></td><td>1. 65</td><td>2.16</td><td>1.99</td><td>2.08</td><td>1</td></tr><tr><td></td><td>P11276</td><td>P02751</td><td>Fibronectin</td><td>1</td><td></td><td>0.63</td><td>0.48</td><td>0.59</td><td>0.40</td><td>[44]</td></tr><tr><td></td><td>P07309</td><td>P02766</td><td>Transthyretin</td><td>1</td><td></td><td>0.51</td><td>0.53</td><td>0.56</td><td>0.49</td><td>[45]</td></tr><tr><td></td><td>Q921I1</td><td>P02787</td><td>Serotransferrin</td><td>1</td><td></td><td>0.46</td><td>0.45</td><td>0.37</td><td>0.45</td><td>[46]</td></tr><tr><td>P11859</td><td></td><td>P01019</td><td>Angiotensinogen</td><td>1</td><td>0. 44</td><td>0.47</td><td>0.46</td><td>0.37</td><td>0.35</td><td>[29]</td></tr><tr><td>P07759</td><td></td><td>P01011</td><td>Serine protease inhibitor A3K</td><td>1</td><td>1</td><td>0.38</td><td>0.38</td><td>0.35</td><td>0.37</td><td>[47]</td></tr><tr><td>P07758</td><td></td><td>P01009</td><td>Alpha-1-antitrypsin 1-1</td><td>1</td><td>0.51</td><td>0.29</td><td>0.29</td><td>0.30</td><td>0.41</td><td>[31]</td></tr><tr><td>054775</td><td></td><td>095388</td><td>CCN family member 4</td><td>1</td><td>0.24</td><td>0.30</td><td>0.40</td><td>0.42</td><td>0.20</td><td>[35]</td></tr><tr><td>088968</td><td></td><td>P20062</td><td>Transcobalamin-2</td><td>1</td><td>0.36</td><td>0.37</td><td>0.27</td><td>0.31</td><td>0.19</td><td>[30]</td></tr><tr><td>Q4KML4</td><td></td><td>Q9P1F3</td><td>Costars family protein ABRACL</td><td>1</td><td>0.32</td><td>0.29</td><td>0.37</td><td>0.26</td><td>0.25</td><td>1</td></tr><tr><td>P35230</td><td></td><td>Q06141</td><td>Regenerating islet-derived protein 3-beta</td><td>1</td><td>0.18</td><td>0.27</td><td>0.25</td><td>0.37</td><td>0.32</td><td>[32]</td></tr><tr><td>P02816</td><td></td><td>P12273</td><td>Prolactin-inducible protein homolog</td><td>1</td><td></td><td>0.30</td><td>0.24</td><td>0.21</td><td>0.35</td><td>[48]</td></tr><tr><td>P29699</td><td></td><td>P02765</td><td>Alpha-2-HS-glycoprotein</td><td>1</td><td>1 0.39</td><td>0.27</td><td>0.16</td><td>0.32</td><td>0.11</td><td>[36]</td></tr><tr><td>P13020</td><td></td><td>P06396</td><td>Gelsolin</td><td>1</td><td>0.39</td><td>0.27</td><td>0.18</td><td>0.24</td><td>0.15</td><td>[37]</td></tr><tr><td>Q9JJS0</td><td></td><td>Q9NQ36</td><td>Signal peptide, CUB and EGF-like domain-containing protein 2</td><td>1</td><td>0.23</td><td>0.24</td><td>0.17</td><td>0.23</td><td>0.09</td><td>[38]</td></tr><tr><td>088322</td><td></td><td>Q14112</td><td>Nidogen-2</td><td>1</td><td>0.24</td><td>0.20</td><td>0.14</td><td>0.29</td><td>0.08</td><td>一</td></tr><tr><td>Q8C6C9</td><td></td><td>Q6P5S2</td><td>Protein LEG1 homolog</td><td>1</td><td></td><td>0.16</td><td>0.11</td><td>0.08</td><td>0.11</td><td>1</td></tr><tr><td>P11087</td><td></td><td>P02452</td><td>Collagen alpha-1(I） chain</td><td>1</td><td>1 0.07</td><td>0.11</td><td>0.10</td><td>0.14</td><td>0.06</td><td>[31]</td></tr></table></body></html>",
        "page_idx": 24
    },
    {
        "type": "text",
        "text": "Tab.4 Details of differential proteins between experimental group and control group indifferent time points. ",
        "page_idx": 25
    },
    {
        "type": "table",
        "img_path": "images/f66f6763c31317105f761e941d2333af19b81eacbebc0e1deb863bf0a85501db.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td rowspan=\"2\">Uniprot</td><td rowspan=\"2\">Human Uniprot</td><td rowspan=\"2\">Protein Name</td><td colspan=\"7\">Fold Change</td><td rowspan=\"2\">Mechanism or</td></tr><tr><td>EW0-</td><td>EW1-</td><td>EM1-</td><td>EM2-</td><td>EM3-</td><td>EM4-</td><td>EM5-</td></tr><tr><td></td><td></td><td></td><td>CW0</td><td>CW1</td><td>CM1</td><td>CM2</td><td>CM3</td><td>CM4</td><td>CM5</td><td>Biomarker</td></tr><tr><td>P35230</td><td>Q06141</td><td>Regenerating islet-derived protein 3-beta</td><td>5.22</td><td>1</td><td>1</td><td>1</td><td>1</td><td></td><td>1</td><td>[32]</td></tr><tr><td>P13020</td><td>P06396</td><td>Gelsolin</td><td>2.83</td><td></td><td>一</td><td>一</td><td>一</td><td>一</td><td></td><td>[37]</td></tr><tr><td>P97426</td><td>P12724</td><td>Eosinophil cationic protein 1</td><td>2.57</td><td>1</td><td>一</td><td>1</td><td>1.77</td><td>7.57</td><td>一</td><td>[89]</td></tr><tr><td>088322</td><td>Q14112</td><td>Nidogen-2</td><td>2.32</td><td>1.96</td><td>1</td><td>一</td><td>1</td><td>/</td><td>0.39</td><td>1</td></tr><tr><td>P29699</td><td>P02765</td><td> Alpha-2-HS-glycoprotein</td><td>2.27</td><td></td><td></td><td></td><td>一</td><td>1</td><td></td><td>[36]</td></tr><tr><td>P07758</td><td>P01009</td><td>Alpha-1-antitrypsin 1-1</td><td>2.11</td><td></td><td>一</td><td></td><td>0.58</td><td>0.25</td><td></td><td>[31]</td></tr><tr><td>P07309</td><td>P02766</td><td>Transthyretin</td><td>2.06</td><td></td><td>1</td><td></td><td>一</td><td>一</td><td>1</td><td>[90]</td></tr><tr><td>P49183</td><td>P24855</td><td>Deoxyribonuclease-1</td><td>1.79</td><td></td><td>0.47</td><td>一</td><td></td><td></td><td></td><td>[91]</td></tr><tr><td>P01864</td><td>No</td><td>Ig gamma-2A chain C region secreted form</td><td>1.55</td><td></td><td>0.30</td><td>1</td><td></td><td></td><td>1</td><td>1</td></tr><tr><td>P19221</td><td>P00734</td><td>Prothrombin</td><td>0.63</td><td></td><td></td><td></td><td></td><td>1</td><td>0.54</td><td>[92]</td></tr><tr><td>P61110</td><td>P61109</td><td> Kidney androgen-regulated protein</td><td>0.62</td><td></td><td></td><td></td><td>一</td><td>6.55</td><td>1</td><td>[31]</td></tr><tr><td>Q9Z0M9</td><td>095998</td><td>Interleukin-18-binding protein</td><td>0.60</td><td></td><td>一</td><td></td><td>2.11</td><td>1</td><td>1</td><td>[41]</td></tr><tr><td>P05533</td><td>No 096009</td><td>Lymphocyte antigen 6A-2/6E-1</td><td>0.60</td><td></td><td>1</td><td></td><td>1</td><td>一</td><td>一</td><td>一</td></tr><tr><td>009043</td><td></td><td>Napsin-A</td><td>0.59</td><td></td><td></td><td></td><td>0.42</td><td>1</td><td></td><td>1</td></tr><tr><td>P03953</td><td>P00746</td><td>Complement factor D</td><td>0.59</td><td>一</td><td>一</td><td>1</td><td>一</td><td>2.60</td><td>一</td><td>[93]</td></tr><tr><td>Q91VW3</td><td>Q9H299</td><td> SH3 domain-binding glutamic acid-rich-like protein 3</td><td>0.58</td><td>1</td><td>1</td><td>2.22</td><td>一</td><td>1</td><td></td><td>1</td></tr><tr><td>P15379</td><td>P16070</td><td>CD44 antigen</td><td>0.58</td><td>/</td><td>0.25</td><td>1</td><td>1</td><td>3.43</td><td>1</td><td>[94]</td></tr><tr><td>P04441</td><td>P04233</td><td>H-2 class II histocompatibility antigen gamma chain</td><td>0.54</td><td></td><td>一</td><td>／</td><td>4.59</td><td>13.02</td><td>一</td><td>[40]</td></tr><tr><td>P25119</td><td>P20333</td><td> Tumor necrosis factor receptor superfamily member 1B</td><td>0.54</td><td>一</td><td>一</td><td>一</td><td>1.74</td><td>一</td><td></td><td>[95]</td></tr></table></body></html>",
        "page_idx": 25
    },
    {
        "type": "table",
        "img_path": "images/ad8f79d0928a5c4a61fa4560151abb13d039a5e0e17067148da1c38fb0a75261.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td>Q00993</td><td>P30530</td><td>Tyrosine-protein kinase receptor UFO</td><td>0.53</td><td></td><td></td><td>0.51</td><td>2.16</td><td>3.62</td><td></td><td>[96]</td></tr><tr><td>P07361</td><td>P02763</td><td>Alpha-1-acid glycoprotein 2</td><td>0.52</td><td>一</td><td></td><td></td><td>1</td><td>0.13</td><td>一</td><td>[97]</td></tr><tr><td>P09470</td><td>P12821</td><td>Angiotensin-converting enzyme</td><td>0.51</td><td>1</td><td>/</td><td>一</td><td></td><td>1</td><td>一</td><td>[98]</td></tr><tr><td></td><td>P59796</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>一</td><td>[19]</td></tr><tr><td>Q91WR8</td><td>Q07654</td><td>Glutathione peroxidase 6</td><td>0.47</td><td>一</td><td>1</td><td>1</td><td>一</td><td>3.34</td><td></td><td>[34]</td></tr><tr><td>Q62395</td><td>Q9NRX4</td><td>Trefoil factor 3</td><td>0.46</td><td>一</td><td>一</td><td>1</td><td>一</td><td>/</td><td>1</td><td></td></tr><tr><td>Q9DAK9</td><td>095711</td><td>14 kDa phosphohistidine phosphatase Lymphocyte antigen 86</td><td>0.46 0.45</td><td>/</td><td>一</td><td></td><td></td><td></td><td>2.02</td><td>[99]</td></tr><tr><td>088188 Q60932</td><td>P21796</td><td>Voltage-dependent anion-selective channel protein 1</td><td>0.44</td><td>0.45</td><td>1</td><td>一 3.68</td><td>/</td><td>一</td><td>1</td><td>1 [100]</td></tr><tr><td>P11589</td><td>No</td><td> Major urinary protein 2</td><td>0.44</td><td></td><td>3.82</td><td></td><td>一</td><td>1</td><td>一</td><td></td></tr><tr><td>Q62266</td><td>No</td><td>Cornifin-A</td><td>0.43</td><td>1</td><td></td><td>一</td><td>1.98</td><td>6.19</td><td>3.16</td><td>[14]</td></tr><tr><td>P17047</td><td>P13473</td><td>Lysosome-associated membrane glycoprotein 2</td><td>0.42</td><td>0.49</td><td>1</td><td></td><td>1</td><td>1</td><td>1 2.44</td><td>1 [42]</td></tr><tr><td>POCW03</td><td>No</td><td>Lymphocyte antigen 6C2</td><td>0.41</td><td>1</td><td></td><td></td><td>2.19</td><td>3.45</td><td></td><td>1</td></tr><tr><td>Q60590</td><td>P02763</td><td>Alpha-1-acid glycoprotein 1</td><td>0.41</td><td>一</td><td></td><td></td><td></td><td>1</td><td></td><td>[97]</td></tr><tr><td>P01665</td><td>No</td><td>Ig kappa chain V-III region PC 7043</td><td>0.41</td><td>一</td><td></td><td></td><td></td><td>0.08</td><td>1 2.38</td><td></td></tr><tr><td>P04939</td><td>No</td><td>Major urinary protein 3</td><td>0.39</td><td>一</td><td></td><td></td><td>一</td><td>7.91</td><td></td><td>1 [14]</td></tr><tr><td>Q6SJQ5</td><td>Q6UXZ3</td><td>CMRF35-like molecule 3</td><td>0.35</td><td></td><td></td><td></td><td>一</td><td>1</td><td>1</td><td>1</td></tr><tr><td>Q64695</td><td>Q9UNN8</td><td>Endothelial protein C receptor</td><td>0.31</td><td></td><td></td><td></td><td></td><td></td><td>0.56</td><td>[18]</td></tr><tr><td>E9Q557</td><td>P15924</td><td>Desmoplakin</td><td>0.29</td><td></td><td></td><td></td><td>1</td><td></td><td></td><td>1</td></tr><tr><td>P11591</td><td>No</td><td>Major urinary protein 5</td><td>0.27</td><td></td><td>一</td><td></td><td>3.82</td><td>一</td><td>一 2.30</td><td>[14]</td></tr><tr><td>P51437</td><td>P49913</td><td>Cathelicidin antimicrobial peptide</td><td>0.24</td><td>一</td><td>一</td><td></td><td>一</td><td>4.49</td><td></td><td>[101]</td></tr><tr><td>Q5FW60</td><td>No</td><td></td><td></td><td></td><td></td><td></td><td></td><td>1</td><td>1</td><td>[14]</td></tr><tr><td>A2BIM8</td><td>No</td><td>Major urinary protein 20</td><td>0.23</td><td></td><td>一 6.10</td><td>1</td><td>一</td><td></td><td>2.14 一</td><td>[14]</td></tr><tr><td></td><td>P00738</td><td> Major urinary protein 18</td><td>0.20</td><td>0.50</td><td></td><td></td><td>2.10</td><td>丨</td><td></td><td>[39]</td></tr><tr><td>Q61646 P11588</td><td>No</td><td>Haptoglobin</td><td>0.14</td><td>1</td><td>1</td><td></td><td>1</td><td>0.09</td><td></td><td>[14]</td></tr><tr><td></td><td></td><td> Major urinary protein 1</td><td>0.07</td><td>0.45</td><td>1</td><td>1</td><td>2.17</td><td>1</td><td></td><td></td></tr><tr><td>B5X0G2 Q9JI02</td><td>No No</td><td>Major urinary protein 17</td><td>0.06</td><td>0.34 2.83</td><td>28.79 一</td><td>1</td><td>1</td><td>一</td><td>4.06 一</td><td>[14]</td></tr></table></body></html>",
        "page_idx": 26
    },
    {
        "type": "table",
        "img_path": "images/c37284bf92fd5c9e8eaa4bbd078f93ab5941640611972b13bcb7cf6155c380bb.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td></td><td>P00533</td><td></td><td></td><td></td><td>/</td><td>一</td><td>一</td><td>一</td><td>/</td><td></td><td>[102]</td></tr><tr><td>Q01279</td><td></td><td>Epidermal growth factor receptor</td><td>一</td><td>1.52</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P10605</td><td>P07858</td><td>Cathepsin B</td><td></td><td>0.63</td><td>0.44</td><td></td><td></td><td></td><td></td><td></td><td>[103]</td></tr><tr><td>P50429</td><td>P15848</td><td>Arylsulfatase B</td><td></td><td>0.56</td><td>1</td><td></td><td></td><td></td><td>1</td><td></td><td>[104]</td></tr><tr><td>Q571E4</td><td>P34059</td><td>N-acetylgalactosamine-6-sulfatase</td><td></td><td>0.52</td><td>一</td><td></td><td></td><td></td><td>3.57</td><td>1</td><td>1</td></tr><tr><td>Q9JK39</td><td>A8MVZ5</td><td>Butyrophilin-like protein 10</td><td></td><td>0.50</td><td>1</td><td></td><td></td><td>1</td><td>一</td><td>一</td><td>1</td></tr><tr><td>P23780</td><td>P16278</td><td>Beta-galactosidase</td><td></td><td>0.48</td><td>0.15</td><td>1</td><td></td><td>0.28</td><td>1</td><td>一</td><td></td></tr><tr><td>P70269</td><td>P14091</td><td>Cathepsin E</td><td></td><td>0.42</td><td>／</td><td></td><td>1</td><td></td><td>2.14</td><td>/</td><td>[28]</td></tr><tr><td>035887</td><td>043852</td><td>Calumenin</td><td></td><td>0.40</td><td>一</td><td></td><td></td><td>2.88</td><td>4.38</td><td>1.88</td><td>[105]</td></tr><tr><td>Q9EP95</td><td>Q9BQ08 P08670</td><td>Resistin-like alpha</td><td></td><td>0.27</td><td>1</td><td></td><td></td><td></td><td>1</td><td>0.20</td><td>[106]</td></tr><tr><td>P20152</td><td>P02675</td><td>Vimentin</td><td></td><td>1</td><td>16.24</td><td>一</td><td></td><td></td><td></td><td>1</td><td>[107]</td></tr><tr><td>Q8K0E8 P16858</td><td>P04406</td><td>Fibrinogen beta chain</td><td>1</td><td></td><td>8.28</td><td></td><td></td><td></td><td></td><td></td><td>[108]</td></tr><tr><td></td><td>P55290</td><td>Glyceraldehyde-3-phosphate dehydrogenase</td><td></td><td></td><td>4.72</td><td>1</td><td></td><td>1</td><td>／</td><td>一</td><td>[109]</td></tr><tr><td>Q9WTR5</td><td>P01009</td><td>Cadherin-13</td><td>一</td><td></td><td>2.78</td><td></td><td></td><td></td><td></td><td>1</td><td>[43]</td></tr><tr><td>Q00897 009164</td><td>P08294</td><td>Alpha-1-antitrypsin 1-4 Extracellular superoxide dismutase [Cu-Zn]</td><td>一</td><td></td><td>2.57</td><td></td><td></td><td>1</td><td>1</td><td>3.27</td><td>[31]</td></tr><tr><td>P11276</td><td>P02751</td><td></td><td></td><td></td><td>2.11</td><td>1.56</td><td></td><td>一</td><td>3.37</td><td>1</td><td>[110]</td></tr><tr><td>Q9Z0J0</td><td>P61916</td><td>Fibronectin NPC intracellular cholesterol transporter 2</td><td></td><td></td><td>0.58</td><td></td><td></td><td></td><td>2.15</td><td></td><td>[44]</td></tr><tr><td>Q8BPB5</td><td>Q12805</td><td>EGF-containing fibulin-like extracellular matrix protein 1</td><td></td><td></td><td>0.57 0.53</td><td>1</td><td>一</td><td></td><td>1</td><td>一</td><td>[111]</td></tr><tr><td>Q8BZT5</td><td>Q9H756</td><td>Leucine-rich repeat-containing protein 19</td><td>一</td><td></td><td>0.52</td><td>0.46 0.50</td><td>0.55</td><td></td><td>/</td><td>1</td><td>1</td></tr><tr><td>P21614</td><td>P02774</td><td></td><td>1</td><td></td><td></td><td></td><td></td><td></td><td>1</td><td>1</td><td>[112]</td></tr><tr><td></td><td>P10619</td><td>Vitamin D-binding protein</td><td></td><td></td><td>0.50</td><td>1</td><td>1</td><td></td><td>一</td><td>0.49</td><td>[113]</td></tr><tr><td>P16675</td><td>P00450</td><td>Lysosomal protective protein</td><td>1</td><td></td><td>0.49</td><td></td><td></td><td></td><td>一</td><td>2.51</td><td>1</td></tr><tr><td>Q61147</td><td>No</td><td>Ceruloplasmin</td><td></td><td></td><td>0.49</td><td>1</td><td></td><td></td><td>0.35</td><td>一</td><td>[114]</td></tr><tr><td>P23953</td><td>Q15113</td><td>Carboxylesterase 1C</td><td>一</td><td></td><td>0.48</td><td>一</td><td></td><td></td><td>1</td><td></td><td>1 [115]</td></tr><tr><td>Q61398</td><td>P48551</td><td> Procollagen C-endopeptidase enhancer 1</td><td>1 1</td><td></td><td>0.48</td><td>1</td><td>一</td><td></td><td>一</td><td>一</td><td>[116]</td></tr><tr><td>035664</td><td></td><td>Interferon alpha/beta receptor 2</td><td></td><td></td><td>0.47</td><td>一</td><td></td><td></td><td></td><td>一</td><td></td></tr><tr><td>P11859</td><td>P01019</td><td>Angiotensinogen</td><td></td><td></td><td>0.45</td><td></td><td></td><td></td><td>0.15</td><td></td><td>[29]</td></tr></table></body></html>",
        "page_idx": 27
    },
    {
        "type": "table",
        "img_path": "images/81cc6b987ab18ecbca32424458020e379c125fd5223c53ee6239125b6d023ab8.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td>P01898</td><td>P01891</td><td>H-2 class I histocompatibility antigen，Qi0 alpha chain</td><td></td><td></td><td>0.45</td><td>1</td><td></td><td></td><td>2.03</td><td>[23]</td></tr><tr><td>COHKG5</td><td>No</td><td>Ribonuclease T2-A</td><td></td><td></td><td>0.42</td><td>0.60</td><td></td><td></td><td></td><td></td></tr><tr><td>Q61271</td><td>P36896</td><td>Activin receptor type-1B</td><td></td><td></td><td>0.42</td><td></td><td></td><td>3. 64</td><td></td><td>一</td></tr><tr><td>088968</td><td>P20062</td><td>Transcobalamin-2</td><td></td><td>一</td><td>0.40</td><td></td><td></td><td></td><td>一</td><td>[30]</td></tr><tr><td>Q9Z0L8</td><td>Q92820</td><td>Gamma-glutamyl hydrolase</td><td></td><td></td><td>0.39</td><td></td><td></td><td></td><td></td><td>[63][64]</td></tr><tr><td>P35459</td><td>Q14210</td><td>Lymphocyte antigen 6D</td><td></td><td></td><td>0.39</td><td>0.57</td><td></td><td></td><td></td><td></td></tr><tr><td>Q61129</td><td>P05156</td><td>Complement factor I</td><td></td><td></td><td>0.38</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P01878</td><td>No</td><td>Ig alpha chain C region</td><td></td><td></td><td>0.38</td><td></td><td>5.03</td><td></td><td></td><td>1</td></tr><tr><td>P55292</td><td>Q02487</td><td>Desmocollin-2</td><td></td><td></td><td>0.38</td><td></td><td>3.72</td><td></td><td></td><td>[24][25]</td></tr><tr><td>Q9JJS0</td><td>Q9NQ36</td><td>Signal peptide,CUB and EGF-like domain-containing protein</td><td></td><td></td><td>0.35</td><td></td><td>1</td><td></td><td></td><td>[38]</td></tr><tr><td>Q9Z319</td><td>Q9Y5Q5</td><td>2 Atrial natriuretic peptide-converting enzyme</td><td></td><td></td><td>0.35</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P09036</td><td>P00995</td><td> Serine protease inhibitor Kazal-type 1</td><td></td><td></td><td>0.34</td><td></td><td></td><td></td><td></td><td>[117]</td></tr><tr><td>Q4KML4</td><td>Q9P1F3</td><td>Costars family protein ABRACL</td><td></td><td></td><td>0.33</td><td>/</td><td></td><td></td><td></td><td>1</td></tr><tr><td>Q925F2</td><td>Q96AP7</td><td>Endothelial cell-selective adhesion molecule</td><td></td><td></td><td></td><td></td><td>2.18</td><td></td><td>一</td><td>一</td></tr><tr><td>089020</td><td>P43652</td><td></td><td></td><td></td><td>0.32</td><td>1</td><td></td><td>/</td><td>0.48</td><td>[118]</td></tr><tr><td>Q9DAU7</td><td>Q14508</td><td>Afamin WAP four-disulfide core domain protein 2</td><td></td><td></td><td>0.31</td><td>0.50</td><td></td><td></td><td></td><td>[119]</td></tr><tr><td></td><td>000391</td><td>Sulfhydryl oxidase 1</td><td></td><td></td><td>0.31</td><td>1</td><td></td><td></td><td></td><td></td></tr><tr><td>Q8BND5</td><td>P12830</td><td>Cadherin-1</td><td></td><td></td><td>0.30</td><td>0.40</td><td>一</td><td></td><td>0.61</td><td></td></tr><tr><td>P09803</td><td>P12273</td><td></td><td></td><td></td><td>0.29</td><td>1</td><td>2.78</td><td>2.34</td><td>一</td><td>[39]</td></tr><tr><td>P02816</td><td>Q9NU53</td><td>Prolactin-inducible protein homolog</td><td></td><td></td><td>0.27</td><td>1</td><td>0.45</td><td>1</td><td>/</td><td>[48]</td></tr><tr><td>Q91WR6</td><td>Q9GZM5</td><td>Glycoprotein integral membrane protein 1</td><td></td><td></td><td>0.26</td><td>0.59</td><td>一</td><td></td><td>0.45</td><td>1</td></tr><tr><td>Q3UDR8</td><td></td><td>Protein YIPF3</td><td></td><td></td><td>0.26</td><td>一</td><td></td><td>一</td><td>1</td><td>一</td></tr><tr><td>Q6UGQ3</td><td>No</td><td>Secretoglobin family 2B member 2</td><td></td><td></td><td>0.25</td><td></td><td>1</td><td>一</td><td>2. 03</td><td>1</td></tr><tr><td>Q9D3H2</td><td>No</td><td>Odorant-binding protein la</td><td>1</td><td>一</td><td>0.25</td><td></td><td>1.75</td><td>一</td><td>1</td><td>[33]</td></tr><tr><td>P20060</td><td>P07686</td><td>Beta-hexosaminidase subunit beta</td><td>一</td><td></td><td>0.23</td><td>一</td><td>0.35</td><td></td><td>一</td><td>1</td></tr><tr><td>Q8K1H9</td><td>Q9NY56</td><td>Odorant-binding protein 2a</td><td></td><td></td><td>0.21</td><td></td><td>0.31</td><td>0.21</td><td>一</td><td>[33]</td></tr></table></body></html>",
        "page_idx": 28
    },
    {
        "type": "table",
        "img_path": "images/579dc790356aabb61faa4d93f57bac28e058cb67bc05ad028cd22063a223b093.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td>A2AEP0</td><td>No</td><td>Odorant-binding protein 1b</td><td></td><td></td><td>0.20</td><td></td><td></td><td></td><td></td><td>[33]</td></tr><tr><td>Q8C6C9</td><td>Q6P5S2</td><td>Protein LEG1 homolog</td><td></td><td></td><td>0.15</td><td></td><td>0.44</td><td>一</td><td>一</td><td>1</td></tr><tr><td></td><td>P04746</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P00688</td><td></td><td>Pancreatic alpha-amylase</td><td>一</td><td></td><td>0.14</td><td></td><td>1</td><td>0.32</td><td>一</td><td>[27]</td></tr><tr><td>P10287</td><td>P22223</td><td>Cadherin-3</td><td></td><td></td><td>0.13</td><td>1</td><td>3.19</td><td>5.62</td><td>、</td><td>[39]</td></tr><tr><td>P56386</td><td>P60022</td><td>Beta-defensin 1</td><td></td><td></td><td></td><td>3.94</td><td></td><td>5.25</td><td>1.90</td><td>[120]</td></tr><tr><td>P10639</td><td>P10599</td><td>Thioredoxin</td><td></td><td></td><td></td><td>3.63</td><td></td><td>1</td><td></td><td>[121]</td></tr><tr><td>088844</td><td>075874 P02647</td><td>Isocitrate dehydrogenase [NADP] cytoplasmic</td><td></td><td></td><td></td><td>2.71</td><td></td><td></td><td>一</td><td>[122]</td></tr><tr><td>Q00623</td><td>P0CG47</td><td>Apolipoprotein A-I Polyubiquitin-B</td><td></td><td></td><td></td><td>2.07</td><td></td><td>1</td><td>0.36</td><td>[123]</td></tr><tr><td>P0CG49</td><td>Q03403</td><td>Trefoil factor 2</td><td></td><td></td><td></td><td>1.98</td><td>1</td><td>1</td><td>1</td><td>[124]</td></tr><tr><td>Q03404</td><td>P06870</td><td>Kallikrein-1</td><td></td><td></td><td></td><td>1. 69</td><td>2.11</td><td>8.94</td><td>一</td><td>[34]</td></tr><tr><td>P15947 055186</td><td>P13987</td><td>CD59A glycoprotein</td><td></td><td></td><td></td><td>0.66 0.61</td><td>一</td><td>1.74</td><td></td><td>[125] [126]</td></tr><tr><td>Q921I1</td><td>P02787</td><td>Serotransferrin</td><td></td><td></td><td></td><td></td><td>一</td><td>2.53</td><td>1</td><td></td></tr><tr><td>Q60648</td><td>P17900</td><td>Ganglioside GM2 activator</td><td></td><td></td><td></td><td>0.57</td><td>0.43</td><td>0.09</td><td>0.21</td><td>[46]</td></tr><tr><td>088792</td><td>Q9Y624</td><td> Junctional adhesion molecule A</td><td></td><td></td><td></td><td>0.51</td><td>1</td><td>1</td><td>2.27</td><td>[27]</td></tr><tr><td>P07724</td><td>P02768</td><td>Albumin</td><td></td><td></td><td></td><td>0.49</td><td>一</td><td>1</td><td>1</td><td>[127]</td></tr><tr><td>070554</td><td>No</td><td>Small proline-rich protein 2B</td><td></td><td></td><td></td><td>0.38</td><td></td><td>0.38</td><td>0.43</td><td>[128]</td></tr><tr><td>Q62267</td><td>No</td><td>Cornifin-B</td><td></td><td></td><td></td><td></td><td>7.98</td><td>1</td><td>3.26</td><td>[129][130]</td></tr><tr><td>P35700</td><td>Q06830</td><td>Peroxiredoxin-1</td><td></td><td></td><td></td><td></td><td>5.69</td><td>一</td><td>一</td><td>一</td></tr><tr><td>P18761</td><td>P23280</td><td>Carbonic anhydrase 6</td><td></td><td></td><td></td><td></td><td>3.75</td><td></td><td>一</td><td>[131]</td></tr><tr><td>P01631</td><td>No</td><td>Ig kappa chain V-II region 26-10</td><td></td><td></td><td></td><td></td><td>3.37</td><td>1</td><td>1</td><td>[132]</td></tr><tr><td>P11087</td><td>P02452</td><td>Collagen alpha-1(I） chain</td><td></td><td></td><td></td><td></td><td>3.29</td><td>3.00</td><td></td><td>1</td></tr><tr><td></td><td>P01834</td><td></td><td></td><td></td><td></td><td></td><td>3.21</td><td></td><td></td><td>[31]</td></tr><tr><td>P01837</td><td>No</td><td>Immunoglobulin kappa constant</td><td></td><td></td><td></td><td></td><td>3.19</td><td></td><td></td><td>1</td></tr><tr><td>Q99N23</td><td>P68104</td><td>Carbonic anhydrase 15</td><td>1</td><td>一</td><td>1</td><td>一</td><td>2.91</td><td>1</td><td>一</td><td>[132]</td></tr><tr><td>P10126 P70663</td><td>Q14515</td><td>Elongation factor l-alpha 1 SPARC-like protein 1</td><td></td><td></td><td></td><td></td><td>2.90 2.74</td><td>一</td><td></td><td>[133] 一</td></tr></table></body></html>",
        "page_idx": 29
    },
    {
        "type": "table",
        "img_path": "images/0d453fb0d31278f21188a0f9e07f8d98c445bc60d6edd7133f4d938e0d0f3fa8.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td>Q60847</td><td>Q99715</td><td>Collagen alpha-1(XII） chain</td><td></td><td></td><td></td><td>2.68</td><td></td><td>一</td><td></td><td>[31]</td></tr><tr><td></td><td>P19320</td><td>Vascular cell adhesion protein 1</td><td></td><td></td><td></td><td>2.62</td><td>2.12</td><td></td><td></td><td>[134]</td></tr><tr><td>P29533</td><td>P56537</td><td>Eukaryotic translation initiation factor 6</td><td></td><td></td><td></td><td></td><td>2.55</td><td>/</td><td>一</td><td>一</td></tr><tr><td>055135</td><td>095388</td><td>CCN family member 4</td><td>一</td><td>一</td><td></td><td></td><td>2.47</td><td></td><td>0.47</td><td>[35]</td></tr><tr><td>054775 P01843</td><td>No</td><td>Ig lambda-1 chain C region</td><td></td><td></td><td></td><td></td><td>2.45</td><td></td><td>1</td><td>一</td></tr><tr><td>Q9DBV4</td><td>Q9BRK3</td><td>Matrix remodeling-associated protein 8</td><td></td><td></td><td></td><td>1.70</td><td></td><td></td><td>1.80</td><td></td></tr><tr><td>035608</td><td>015123</td><td>Angiopoietin-2</td><td></td><td></td><td></td><td></td><td>1. 61</td><td></td><td></td><td>[135]</td></tr><tr><td>Q07797</td><td>Q08380</td><td>Galectin-3-binding protein</td><td></td><td></td><td></td><td></td><td>1.59</td><td></td><td>一</td><td>[15]</td></tr><tr><td>Q04519</td><td>P17405</td><td>Sphingomyelin phosphodiesterase</td><td></td><td></td><td></td><td></td><td>0.57</td><td></td><td>1.89</td><td>[136]</td></tr><tr><td>Q61838</td><td>No</td><td>Pregnancy zone protein</td><td>一</td><td>一</td><td></td><td></td><td>0.52</td><td></td><td></td><td>[17]</td></tr><tr><td>Q08423</td><td>P04155</td><td>Trefoil factor 1</td><td></td><td></td><td></td><td></td><td></td><td>1 12.79</td><td>1</td><td>[34]</td></tr><tr><td>008997</td><td>000244</td><td>Copper transport protein ATOX1</td><td></td><td></td><td></td><td></td><td></td><td>8.07</td><td></td><td>[137]</td></tr><tr><td>P03977</td><td>No</td><td>Ig kappa chain V-III region 50S10.1</td><td></td><td></td><td></td><td></td><td></td><td>4.79</td><td></td><td>1</td></tr><tr><td>P42567</td><td>P42566</td><td>Epidermal growth factor receptor substrate 15</td><td></td><td></td><td></td><td></td><td></td><td>4.53</td><td></td><td>[102]</td></tr><tr><td>Q91X17</td><td>P07911</td><td>Uromodulin</td><td></td><td>一</td><td></td><td></td><td></td><td>4.22</td><td></td><td>[138]</td></tr><tr><td>P57096</td><td>043653</td><td>Prostate stem cell antigen</td><td></td><td></td><td></td><td></td><td></td><td>3.53</td><td></td><td></td></tr><tr><td>P70699</td><td>P10253</td><td> Lysosomal alpha-glucosidase</td><td></td><td></td><td></td><td></td><td></td><td>3.37</td><td></td><td>1</td></tr><tr><td>P01132</td><td>P01133</td><td>Pro-epidermal growth factor</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>[139]</td></tr><tr><td>P32507</td><td>Q92692</td><td>Nectin-2</td><td></td><td></td><td></td><td></td><td></td><td>3.13</td><td></td><td>1</td></tr><tr><td>Q5SSE9</td><td>Q86UQ4</td><td>ATP-binding cassette sub-family A member 13</td><td></td><td></td><td></td><td></td><td></td><td>3.03</td><td></td><td>[140]</td></tr><tr><td>P06797</td><td>060911</td><td></td><td></td><td></td><td></td><td></td><td></td><td>2.92</td><td></td><td>1</td></tr><tr><td>Q8R242</td><td>Q01459</td><td>Cathepsin L1 Di-N-acetylchitobiase</td><td></td><td></td><td></td><td></td><td></td><td>2.63</td><td></td><td>[20][28]</td></tr><tr><td></td><td>095497</td><td></td><td></td><td></td><td></td><td></td><td></td><td>2.47</td><td></td><td>一</td></tr><tr><td>Q9Z0K8</td><td>Q9Y2E5</td><td>Pantetheinase</td><td>1</td><td></td><td></td><td></td><td></td><td>2.32</td><td>3. 65</td><td></td></tr><tr><td>054782</td><td></td><td>Epididymis-specific alpha-mannosidase</td><td>1</td><td>1 1</td><td></td><td>一</td><td></td><td>1. 99</td><td></td><td></td></tr><tr><td>P22599 P13634</td><td>P01009 P00915</td><td>Alpha-1-antitrypsin 1-2 Carbonic anhydrase 1</td><td>一</td><td>一</td><td>一</td><td></td><td></td><td>0.50 0.39</td><td>1 3.37</td><td>[31] [132]</td></tr></table></body></html>",
        "page_idx": 30
    },
    {
        "type": "table",
        "img_path": "images/19d38c08df7f7d23c196f3bfc60b8eb596d642337a0ce38083631073062183c7.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td>P20918</td><td>P00747</td><td>Plasminogen</td><td>一</td><td></td><td></td><td></td><td>一</td><td>0.32</td><td>0.63</td><td>[141]</td></tr><tr><td>P07759</td><td>P01011</td><td>Serine protease inhibitor A3K</td><td></td><td></td><td></td><td></td><td></td><td>0.26</td><td>一</td><td>[47]</td></tr><tr><td>P02088</td><td>P68871</td><td>Hemoglobin subunit beta-1</td><td></td><td></td><td></td><td></td><td></td><td>0.24</td><td></td><td>1</td></tr><tr><td>P01027</td><td>P01024</td><td>Complement C3</td><td></td><td></td><td></td><td></td><td></td><td>0.20</td><td></td><td>[142]</td></tr><tr><td>Q00898</td><td>P01009</td><td>Alpha-1-antitrypsin 1-5</td><td></td><td></td><td></td><td></td><td></td><td>0.18</td><td></td><td>[31]</td></tr><tr><td>P11672</td><td>P80188</td><td> Neutrophil gelatinase-associated lipocalin</td><td></td><td></td><td></td><td></td><td></td><td>0.04</td><td></td><td>[143]</td></tr><tr><td>P01887</td><td>P61769</td><td>Beta-2-microglobulin</td><td></td><td></td><td></td><td></td><td></td><td>1</td><td>3.07</td><td>[144]</td></tr><tr><td>009114</td><td>P41222</td><td>Prostaglandin-H2 D-isomerase</td><td></td><td></td><td></td><td></td><td></td><td></td><td>2.41</td><td>[145]</td></tr><tr><td>Q9WUU7</td><td>Q9UBR2</td><td>Cathepsin Z</td><td></td><td></td><td></td><td></td><td></td><td></td><td>2.32</td><td>[146]</td></tr><tr><td>Q8BHC0</td><td>Q9Y5Y7</td><td>Lymphatic vessel endothelial hyaluronic acid receptor 1</td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.61</td><td></td></tr><tr><td>070570</td><td>P01833</td><td>Polymeric immunoglobulin receptor</td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.55</td><td>一</td></tr><tr><td>P26041</td><td>P26038</td><td>Moesin</td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.53</td><td>[147]</td></tr><tr><td>Q7TMJ8</td><td>Q96FE7</td><td> Phosphoinositide-3-kinase-interacting protein 1</td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.52</td><td>[148]</td></tr><tr><td>P01660</td><td>No</td><td>Ig kappa chain V-III region PC 3741/TEPC 111</td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.43</td><td>1</td></tr><tr><td>Q60928</td><td>P19440</td><td>Glutathione hydrolase 1 proenzyme</td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.39</td><td>[64]</td></tr><tr><td>P61971</td><td>P61970</td><td>Nuclear transport factor 2</td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.36</td><td>一</td></tr><tr><td>P06330</td><td>No</td><td>Ig heavy chain V region AC38 205.12</td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.36</td><td></td></tr><tr><td>Q921W8</td><td>Q8WVN6</td><td>Secreted and transmembrane protein 1A</td><td>一</td><td></td><td></td><td></td><td>一</td><td>一</td><td>0.35</td><td></td></tr><tr><td>Q8BX43</td><td>Q969Z4</td><td> Tumor necrosis factor receptor superfamily member 19L</td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.33</td><td>[95]</td></tr><tr><td>Q9JM99</td><td>Q92954</td><td>Proteoglycan 4</td><td>一</td><td></td><td></td><td></td><td></td><td>一</td><td>0.26</td><td>[148]</td></tr></table></body></html>",
        "page_idx": 31
    },
    {
        "type": "text",
        "text": "表5蛋白质化学修饰限制性搜索结果。",
        "text_level": 1,
        "page_idx": 32
    },
    {
        "type": "table",
        "img_path": "images/7f42d07075b9a4290a3aa0381f846ea8b727dd6be9773bda303714295b35d51e.jpg",
        "table_caption": [
            "Tab.5 Results of limited search of modifications. ",
            "Crr1001-413111:0111114 "
        ],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td rowspan=\"2\">Group</td><td rowspan=\"2\">Modification Name</td><td rowspan=\"2\">Modification Type</td><td rowspan=\"2\">P-value</td><td>Fold</td><td>References</td></tr><tr><td>Change</td><td></td></tr><tr><td rowspan=\"20\">EM5 1 EW0</td><td>Carbamyl[AnyN-term]</td><td>Multiple</td><td>0.0000</td><td>4.65</td><td>[164]</td></tr><tr><td>CHDH[D]</td><td>Post-translational</td><td>0.0005</td><td>2.31</td><td>1</td></tr><tr><td>Trp->Kynurenin[W]</td><td>Chemical derivative</td><td>0.0375</td><td>2.04</td><td>[165]</td></tr><tr><td>NHS-LC-Biotin[AnyN-term]</td><td>Chemical derivative</td><td>0.1206</td><td>1.92</td><td>1</td></tr><tr><td>HNE+Delta_H(2)[K]</td><td>Chemical derivative</td><td>0.2029</td><td>1. 69</td><td>[170]</td></tr><tr><td>Thiazolidine[W]</td><td>Chemical derivative</td><td>0.9862</td><td>1.00</td><td>[173]</td></tr><tr><td>Carboxyethyl[K]</td><td>Post-translational</td><td>0. 7766</td><td>0.91</td><td>[174]</td></tr><tr><td>PhosphoUridine[Y]</td><td> Post-translational</td><td>0. 7787</td><td>0.90</td><td>1</td></tr><tr><td>glucosone[R]</td><td>Other</td><td>0. 6874</td><td>0.86</td><td>[171]</td></tr><tr><td>Hep[T]</td><td>O-linked glycosylation</td><td>0.5316</td><td>0.83</td><td>1</td></tr><tr><td>Ethyl+Deamidated[N]</td><td>Chemical derivative</td><td>0.1841</td><td>0.83</td><td>1</td></tr><tr><td>dHex [N]</td><td>N-linked glycosylation</td><td>0.3045</td><td>0.74</td><td>[175]</td></tr><tr><td>AccQTag[AnyN-term]</td><td>Chemical derivative</td><td>0.0364</td><td>0.70</td><td>1</td></tr><tr><td>4-ONE[H]</td><td>Chemical derivative</td><td>0.2781</td><td>0.52</td><td>[170]</td></tr><tr><td>Oxidation[P]</td><td>Post-translational</td><td>0.0000</td><td>0.47</td><td>[166]</td></tr><tr><td>Cysteinyl[C]</td><td>Multiple</td><td>0.0234</td><td>0.43</td><td>[167]</td></tr><tr><td>BITC[AnyN-term]</td><td>Chemical derivative</td><td>0.1039</td><td>0.39</td><td>[172]</td></tr><tr><td>SulfurDioxide[C]</td><td>Post-translational</td><td>0.0050</td><td>0.33</td><td>[168]</td></tr><tr><td>NO_SMX_SIMD[C]</td><td>Chemical derivative</td><td>0.0003</td><td>0.31</td><td>1</td></tr><tr><td>Delta_H(2)C(3)[K]</td><td>Other</td><td>0.0045</td><td>0.29</td><td>[169]</td></tr><tr><td rowspan=\"16\">EM5</td><td>Guanidinyl[K]</td><td>Chemical derivative</td><td>0.0093</td><td>2.72</td><td>1</td></tr><tr><td>Carboxymethyl[K]</td><td>Chemical derivative</td><td>0.1476</td><td>2.46</td><td>[179]</td></tr><tr><td>PhosphoUridine[Y]</td><td>Post-translational</td><td>0.0204</td><td>1.88</td><td>1</td></tr><tr><td>Carbamyl[AnyN-term]</td><td>Multiple</td><td>0.0061</td><td>1.76</td><td>[164]</td></tr><tr><td>DeStreak[C]</td><td>Chemical derivative</td><td>0.2293</td><td>1. 33</td><td>1</td></tr><tr><td>glucosone[R]</td><td>Other</td><td>0.5228</td><td>1.32</td><td>[171]</td></tr><tr><td>Crotonaldehyde[C]</td><td>Other</td><td>0.4124</td><td>1.30</td><td>[178]</td></tr><tr><td>BITC[K]</td><td>Chemical derivative</td><td>0. 5487</td><td>1.22</td><td>[172]</td></tr><tr><td>Arg->Trp[R]</td><td>AA substitution</td><td>0. 4018</td><td>1. 21</td><td>1</td></tr><tr><td>2-hydroxyisobutyrylation[K]</td><td>Post-translational</td><td>0.6458</td><td>1.15</td><td>[178]</td></tr><tr><td>1 Cysteinyl[C] CM5</td><td>Multiple</td><td>0.8368</td><td>1.09</td><td>[167]</td></tr><tr><td>4-ONE[H]</td><td>Chemical derivative</td><td>0.8445</td><td>1.06</td><td>[170]</td></tr><tr><td>dHex[N]</td><td>N-linked glycosylation</td><td>0.8163</td><td>1.05</td><td>[175]</td></tr><tr><td>phenylsulfonylethyl[C]</td><td>Chemical derivative</td><td>0.9917</td><td>1. 00</td><td>1</td></tr><tr><td>Delta_H(2)C(3)[K]</td><td>Other</td><td>0.5922</td><td>0.93</td><td>[169]</td></tr><tr><td>Oxidation[Y]</td><td>Post-translational</td><td>0.2648</td><td>0.86</td><td>[180]</td></tr><tr><td>SulfurDioxide[C]</td><td>Post-translational</td><td>0.3743</td><td>0.80</td><td>[168]</td></tr><tr><td>Malony1[C]</td><td>Chemical derivative</td><td>0.3600</td><td>0.77</td><td>[178]</td></tr><tr><td>HNE+Delta_H(2)[K]</td><td></td><td>0.5489</td><td>0.76</td><td></td></tr><tr><td>MG-H1[R](Delta_H(2)C(3)0(1)[R])</td><td>Chemical derivative Other</td><td>0.2428</td><td>0.72</td><td>[170] [177]</td></tr></table></body></html>",
        "page_idx": 32
    },
    {
        "type": "table",
        "img_path": "images/244e3d0f4ffe73d1674bd857fc463aa86aaaaeb5531c44a0dd0d9df49c78f9a1.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td rowspan=\"7\"></td><td>His->Ser[H]</td><td>AA substitution</td><td>0.1070</td><td>0.60</td><td>一</td></tr><tr><td>Carboxyethyl[K]</td><td>Post-translational</td><td></td><td></td><td>[174]</td></tr><tr><td></td><td></td><td>0.2808</td><td>0.53</td><td></td></tr><tr><td>Oxidation[P]</td><td>Post-translational</td><td>0.1375</td><td>0.47</td><td>[166]</td></tr><tr><td>Delta_H(2)C(2)[AnyN-term]</td><td>Other</td><td>0.0260</td><td>0.39</td><td>[176]</td></tr><tr><td>Dihydroxyimidazolidine[R]</td><td>Multiple</td><td>0.0147</td><td>0.31</td><td>1</td></tr></table></body></html>",
        "page_idx": 33
    },
    {
        "type": "text",
        "text": "参考文献",
        "text_level": 1,
        "page_idx": 34
    },
    {
        "type": "text",
        "text": "1. Rahman，M.S.and K. Woollard，Atherosclerosis.Adv Exp Med Biol，2017．1003:p.121- 144.   \n2. Tabas，I.，G. Garcia-Cardena,and G.K. Owens,Recent insights into the cellular biology of atherosclerosis. J Cell Biol，2015. 209(1): p. 13-22.   \n3. World Health Organization. Cardiovascular diseases (CvDs) Fact Sheet. 2017.   \n4. Gao,Y.， Urine-an untapped goldmine for biomarker discovery? Sci China Life Sci， 2013. 56(12):p. 1145-6.   \n5. Ni,Y.，et al.，Early candidate biomarkers found from urine of glioblastoma multiforme rat before changes in MRI. Sci China Life Sci，2018. 61(8): p. 982-987.   \n6. Wei，J.，W. Meng，and Y. Gao， Urine proteome changes in rats subcutaneously inoculated with approximately ten tumor cells. PeerJ，2019. 7: p. e7717.   \n7. Zhao， M.， et al.， Dynamic changes of urinary proteins in a focal segmental glomerulosclerosis rat model. Proteome Sci， 2014. 12: p. 42.   \n8. Hatters， D.M.，C.A. Peters-Libeu, and K.H. Weisgraber， Apolipoprotein E structure: insights into function. Trends Biochem Sci，2006. 31(8):p. 445-54.   \n9. Rosenfeld, M.E.，et al.，Advanced atherosclerotic lesions in the innominate artery of the ApoE knockout mouse. Arterioscler Thromb Vasc Biol，2000. 20(12):p. 2587-92.   \n10. Qu,G.，et al.，The promotion effect of novel magnetic nanoparticles on atherosclerotic plaque vulnerability in apolipoprotein $E ( - / - )$ mice.Toxicology，2019. 419:p. 24-31.   \n11. Wisniewski， J.R.，et al.， Universal sample preparation method for proteome analysis. Nat Methods，2009.6(5):p.359-62.   \n12. Bruderer，R.，et al.， Extending the limits of quantitative proteome profiling with data-independentacquisition and application to acetaminophen-treated threedimensional liver microtissues. Mol Cell Proteomics，2015.14(5):p. 1400-10.   \n13. Chi,H.，et al.，Comprehensive identification of peptides in tandem mass spectra using an efficient open search engine. Nat Biotechnol，2018.   \n14. Armitage，E.G.，et al.， Missing value imputation strategies for metabolomics data. Electrophoresis，2015. 36(24): p. 3050-60.   \n15. Wang， S.，et al.， NAguideR: performing and prioritizing missing value imputations for consistent bottom-up proteomic analyses. Nucleic Acids Res，2020. 48(14): p. e83.   \n16. Huang da,W.，B.T. Sherman，and R.A. Lempicki， Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc， 2009. 4(1): p. 44- 57.   \n17. Kwak，J.，et al.， Are MUPs a Toxic Waste Disposal System? PLoS One，2016. 11(3): p. e0151474.   \n18. Sano， H.， et al.， Human galectin-3 is a novel chemoattractant for monocytes and macrophages.J Immunol，2000．165(4)：p.2156-64.   \n19. Papaspyridonos， M.， et al.， Galectin-3is an amplifier ofinflammationin atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol，2008. 28(3):p. 433-40.   \n20. Sanchez， M.C.，G.A. Chiabrando，and M.A. Vides， Pregnancy zone protein-tissue-type plasminogen activator complexes bind to low-density lipoprotein receptor-related protein (LRP)．Arch Biochem Biophys，2001．389(2):p. 218-22.   \n21. Navarro， S.，et al.， The endothelial cell protein C receptor: its role in thrombosis. Thromb Res，2011．128(5):p.410-6.   \n22. Lin, M.S.，et al.， Higher glutathione peroxidase expression in thoracic aorta as a protective factor against oxidative stress and atherosclerosis in rabbits. Cardiology, 2007．108(4):p. 381-6.   \n23. Li，W.，et al.，Cathepsin L is significantly associated with apoptosis and plaque destabilization in human atherosclerosis. Atherosclerosis，2009. 202(1):p. 92-102.   \n24. Ohta,T.，et al.，Soluble vascular cell-adhesion molecule-1 and soluble intercellular adhesion molecule-l correlate with lipid and apolipoprotein risk factors for coronary artery disease in children. Eur J Pediatr，1999.158(7):p. 592-8.   \n25. Li， X.，R.F. Li， and S.W. Ding， [Effect of xinhe granule on vascular endothelial damage and endothelial expressed endothelin and intercellular adhesion molecule-lin rats fed with high lipid diet]. Zhongguo Zhong Xi Yi Jie He Za Zhi，2001. 21(8): p. 602-4.   \n26. Fortin， C.F.，et al.，Aging and neutrophils: there is still much to do. Rejuvenation Res，2008.11(5):p. 873-82.   \n27. Li， Y.B.， et al.， Oxidized low-density lipoprotein attenuated desmoglein 1 and desmocollin 2 expression via LOX-1/Ca(2+)/PKC-beta signal in human umbilical vein endothelial cells. Biochem Biophys Res Commun，2015. 468(1-2):p. 380-6.   \n28. Jiang， K.， et al.， Galectin-3 regulates desmoglein-2 and intestinal epithelial intercellular adhesion. J Biol Chem，2014. 289(15):p. 10510-7.   \n29. Yanai,H.，et al.， The possible contribution of a general glycosphingolipid transporter, GM2 activator protein， to atherosclerosis. J Atheroscler Thromb,2006. 13(6):p. 281- 5.   \n30. Ozkok, A.，et al.， Low serum pancreatic enzyme levels predict mortality and are associated with malnutrition-inflammation-atherosclerosis syndrome in patients with chronic kidney disease. Int Urol Nephrol，2013. 45(2): p. 477-84.   \n31. Kadowaki， T.， et al.， Defective adipose tissue development associated with hepatomegaly in cathepsin E-deficient mice fed a high-fat diet.Biochem Biophys Res Commun，2014.446(1):p.212-7.   \n32. Carroll， W.X.， et al.， Angiotensinogen gene silencing reduces markers of lipid accumulation and inflammation in cultured adipocytes. Front Endocrinol (Lausanne), 2013．4:p.10.   \n33. Celik，S.F. and E. Celik， Subclinical atherosclerosis and impaired cardiac autonomic control in pediatric patients with Vitamin Bl2 deficiency. Niger JClin Pract，2018. 21(8):p. 1012-1016.   \n34. von zur Muhlen，C.，et al.，Urine proteome analysis reflects atherosclerotic disease in an ApoE-/- mouse model and allows the discovery of new candidate biomarkers in mouse and human atherosclerosis. Mol Cell Proteomics，2012. 11(7): p. M1l1 013847.   \n35. K, M.，et al.， Association of serum regenerating islet-derived protein 3-beta and oncostatin-M levels with the risk of acute coronary syndrome in patients with type $\\mathcal { Z }$ diabetes mellitus - A pilot study.Diabetes Metab Syndr，2020.14(5):p. 1087-1092.   \n36. Grolli， S.，et al.， Odorant binding protein has the biochemical properties of a scavenger for 4-hydroxy-2-nonenal in mammalian nasal mucosa. FEBS J， 2006. 273(22): p. 5131-42.   \n37. De Giorgio， M.R.，et al.， Trefoil factor family member 2 (Tff2) KO mice are protected from high-fat diet-induced obesity. Obesity (Silver Spring)，2013. 21(7): p. 1389-95.   \n38. Liu, H.，et al.， CCN4 regulates vascular smooth muscle cell migration and proliferation. Mol Cells，2013.36(2):p. 112-8.   \n39. Muendlein， A.， et al.， Are AHSG polymorphisms directly associated with coronary atherosclerosis? Clin Chim Acta,2012. 413(1-2): p. 287-90.   \n40. de la Cuesta，F.，et al.，Deregulation of smooth muscle cell cytoskeleton within the human atherosclerotic coronary media layer. J Proteomics，2013.82:p. 155-65.   \n41. Ali,H.，et al.，Localization and characterization of a novel secreted protein, SCUBE2, in the development and progression of atherosclerosis. Kobe J Med Sci， 2013. 59(4): p.E122-31.   \n42. Langlois， M.R. and J.R. Delanghe, Biological and clinical significance of haptoglobin polymorphism in humans.Clin Chem，1996.42(10):p． 1589-600.   \n43. Wigren,M.，et al.， Lack of Ability to Present Antigens on Major Histocompatibility Complex Class II Molecules Aggravates Atherosclerosis in ApoE(-/-） Mice. Circulation, 2019．139(22): p. 2554-2566.   \n44. Dinarello，C.A.， Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol，2007.27(1): p. 98-114.   \n45. Wu，G.，et al.， LAMP-2 gene expression in peripheral leukocytes is increased in patients with coronary artery disease. Clin Cardiol，2011. 34(4): p. 239-43.   \n46. Fujishima, Y.， et al.， Adiponectin association with T-cadherin protects against neointima proliferation and atherosclerosis. FASEB J，2017. 31(4): p. 1571-1583.   \n47. Stenman, S.，K. von Smitten, and A. Vaheri， Fibronectin and atherosclerosis. Acta Med Scand Suppl，1980.642:p. 165-70.   \n48. Ichiki，T.， Thyroid hormone and atherosclerosis. Vascul Pharmacol， 2010. 52(3-4): p. 151-6.   \n49. Kibel，A.， T. Belovari，and I. Drenjancevic-Peric， The role of transferrin in atherosclerosis. Med Hypotheses， 2008. 70(4): p. 793-7.   \n50. Wagsater，D.，et al.， Serine protease inhibitor A3 in atherosclerosis and aneurysm disease. Int J Mol Med,2012.30(2):p. 288-94.   \n51. Sauro，M.D. and N.E. Zorn， Prolactin induces proliferation of vascular smooth muscle cells through a protein kinase $C$ -dependent mechanism. J Cell Physiol，1991. 148(1): p. 133-8.   \n52. Hartman,J.and W.H. Frishman，Inflammation and atherosclerosis:a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev，2014. 22(3):p. 147-51.   \n53. Tinajero， M.G. and A.I. Gotlieb， Recent Developments in Vascular Adventitial Pathobiology: The Dynamic Adventitia as a Complex Regulator of Vascular Disease.Am J Pathol，2020．190(3)：p. 520-534.   \n54. Natarelli，L. and A. Schober， MicroRNAs and the response to injury in atherosclerosis. Hamostaseologie，2015. 35(2):p. 142-50.   \n55. Wight，T.N.， The extracellular matrix and atherosclerosis. Curr Opin Lipidol，1995.   \n6(5) :p. 326-34.   \n56. Fernandez-Murga, M.L.，et al.， Impact of estrogens on atherosclerosis and bone in the apolipoprotein E-deficient mouse model. Menopause，2015.22(4):p. 428-36.   \n57. Isenovic,E.R.，et al.， Insulin， thrombine,ERKl/2 kinase and vascular smooth muscle cells proliferation. Curr Pharm Des，2010.16(35): p. 3895-902.   \n58. Chi，Z. and A.J. Melendez， Role of cell adhesion molecules and immune-cell migration in the initiation, onset and development of atherosclerosis. Cell Adh Migr， 2007.   \n1(4): p. 171-5.   \n59. Whicher， J.，L. Biasucci，and N. Rifai， Inflammation， the acute phase response and atherosclerosis. Clin Chem Lab Med，1999. 37(5):p. 495-503.   \n60. Calkin,A.C. and P. Tontonoz， Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol，2012. 13(4):p. 213-   \n24.   \n61. Hovland， A.， et al.， The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis. Atherosclerosis，2015. 241(2): p.   \n480-94.   \n62. Tiani， C.， et al.， Apelin signaling modulates splanchnic angiogenesisand portosystemic collateral vessel formation in rats with portal hypertension. J Hepatol,   \n2009.50(2):p. 296-305.   \n63. Krychtiuk， K.A.， etal.， Inflammation and coagulation in atherosclerosis. Hamostaseologie，2013.33(4): p. 269-82.   \n64. Schierwagen，R.，et al.， Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis. Sci Rep，2015.5:p.12931.   \n65. Liu, F.T.，R.Y. Yang，and D.K. Hsu, Galectins in acute and chronic inflammation. Ann N Y Acad Sci，2012. 1253:p. 80-91.   \n66. Bachhawat，A.K. and S. Yadav，The glutathione cycle:Glutathione metabolism beyond the gamma-glutamyl cycle. IUBMB Life, 2018. 70(7): p. 585-592.   \n67. Presnell， C.E.，et al.， Computational insights into the role of glutathione in oxidative stress. Curr Neurovasc Res, 2013. 10(2): p. 185-94.   \n68. Posadas-Sanchez， R. and G. Vargas-Alarcon， Innate Immunity in Coronary Disease. The Role of Interleukin-12 Cytokine Family in Atherosclerosis. Rev Invest Clin， 2018.   \n70(1) : p. 5-17.   \n69. Chistiakov，D.A.，et al.，Mechanisms of foam cell formation in atherosclerosis. J Mol Med (Berl)，2017．95(11):p.1153-1165.   \n70. Malavaki，C.，et al.，Recent advances in the structural study of functional chondroitin sulfate and dermatan sulfate in health and disease. Connect Tissue Res, 2008. 49(3): p. 133-9.   \n71. Gao,W.，et al.， Exosomes derived from mature dendritic cells increase endothelial inflammation and atherosclerosis via membrane TNF-alpha mediated NF-kappaB pathway. J Cell Mol Med,2016.20(12):p. 2318-2327.   \n72. Dvir，H.，et al.， Atomic structure of the autosomal recessive hypercholesterolemia phosphotyrosine-binding domain in complex with the LDL-receptor tail. Proc Natl Acad Sci U S A，2012. 109(18):p. 6916-21.   \n73. Wunderer，F.，et al.， The role of hepcidin and iron homeostasis in atherosclerosis. Pharmacol Res，2020．153:p．104664.   \n74. Okabe,K.，et al.， Implications of altered NAD metabolism in metabolic disorders. J Biomed Sci，2019.26(1):p.34.   \n75. Voloshyna, I.，M.J. Littlefield, and A.B. Reiss, Atherosclerosis and interferon-gamma: new insights and therapeutic targets. Trends Cardiovasc Med, 2014. 24(1): p. 45-51.   \n76. Major，A.S.， S. Joyce，and L. Van Kaer，Lipid metabolism， atherogenesis and CD1- restricted antigen presentation. Trends Mol Med, 2006. 12(6): p. 270-8.   \n77. Kumagai， T.，et al.， Inhibition of plasma coagulation through interaction between oxidized low-density lipoprotein and blood coagulation factor VIII. Biol Pharm Bull, 2005．28(6):p. 952-6.   \n78. Zhao，Y.，et al.，Angiotensin II Receptor Type 1 Antagonists Modulate Vascular Smooth Muscle Cell Proliferation and Migration via AMPK/mTOR. Cardiology，2019. 143(1): p. 1-10.   \n79. Lal,H.，et al.， Integrins and proximal signaling mechanisms in cardiovascular disease. Front Biosci (Landmark Ed)，2009.14:p. 2307-34.   \n80. Szekanecz， Z.，et al.， Common mechanisms and holistic care in atherosclerosis and Osteoporosis. Arthritis Res Ther， 2019. 21(1):p. 15.   \n81. Newton，A.H. and S.H. Benedict， Low density lipoprotein promotes human naive T cell differentiation to Thl cells. Hum Immunol，2014. 75(7):p. 621-8.   \n82. Yang， Y.， et al.， $\\it 5$ -Aminolevulinic Acid-Mediated Sonodynamic Therapy Alleviates Atherosclerosis via Enhancing Efferocytosis and Facilitating a Shift in the Th1/Th2 Balance Toward Th2 Polarization. Cell Physiol Biochem， 2018. 47(1): p. 83-96.   \n83. Keller， C.W.，S. Freigang，and J.D. Lunemann，Reciprocal Crosstalk between Dendritic Cells and Natural Killer T Cells: Mechanisms and Therapeutic Potential. Front Immunol, 2017.8:p. 570.   \n84. Wesseling， M.， etal.， Themorphological andmolecularmechanismsof epithelial/endothelial-to-mesenchymaltransitionand its involvement in atherosclerosis. Vascul Pharmacol，2018. 106:p. 1-8.   \n85. Ridley，A.J.，et al.，Cell migration: integrating signals from front to back. Science, 2003．302(5651):p. 1704-9.   \n86. Zhang， P.Y.， X. Xu, and X.C. Li， Cardiovascular diseases: oxidative damage and antioxidant protection. Eur Rev Med Pharmacol Sci，2014. 18(20):p. 3091-6.   \n87. D' Onofrio， N.，L. Servillo，and M.L. Balestrieri， SIRTl and SIRT6 Signaling Pathways in Cardiovascular Disease Protection. Antioxid Redox Signal，2018. 28(8):p. 711-732.   \n88. Xue,Q.，et al.，CEMIP regulates the proliferation and migration of vascular smooth muscle cells in atherosclerosis through the WNT-beta-catenin signaling pathway. Biochem Cell Biol，2020.98(2):p. 249-257.   \n89. Esser,N.，et al.，Inflammation as a link between obesity， metabolic syndrome and type 2 diabetes.Diabetes Res Clin Pract，2014. 105(2): p. 141-50.   \n90. Dai，F.，et al.，RhoGDI stability is regulated by SUMOylation and ubiquitination via the ATl receptor and participates in Ang II-induced smooth muscle proliferation and   \n91. Kasumov，T.，et al.，Ceramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosis. PLoS One，2015. 10(5): p. e0126910.   \n92. Niccoli，G.， et al.， Eosinophil cationic protein: A new biomarker of coronary atherosclerosis. Atherosclerosis，2010. 211(2): p. 606-11.   \n93. Yang，C.S.，et al.， Proteomic analysis of prognostic plasma biomarkers in peripheral arterial occlusive disease. Mol Biosyst，2017. 13(7):p. 1297-1303.   \n94. Josefs， T.，et al.， Neutrophil extracellular traps promote macrophage inflammation and impair atherosclerosis resolution in diabetic mice. JCI Insight，2020.5(7).   \n95. Posma，J. J.，J.J. Posthuma， and H.M. Spronk， Coagulation and non-coagulation effects of thrombin. J Thromb Haemost，2016．14(10):p. 1908-1916.   \n96. Shin,S.K.，et al.，Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. Mol Nutr Food Res，2011. 55(12):p. 1829-40.   \n97. Krolikoski， M.，J. Monslow，and E. Pure， The CD44-HA axis and inflammationin atherosclerosis: A temporal perspective. Matrix Biol，2019. 78-79: p. 201-218.   \n98. Smeets，E.， S. Meiler， and E. Lutgens， Lymphocytic tumor necrosis factor receptor superfamily co-stimulatory molecules in the pathogenesis of atherosclerosis. Curr Opin Lipidol，2013. 24(6):p. 518-24.   \n99. van der Meer， J.H.，T. van der Poll，and C. van ’t Veer， TAM receptors，Gas6, and protein S:roles in inflammation and hemostasis. Blood,2014. 123(16): p. 2460-9.   \n100. Puerta， A.，et al.， Study of the capillary electrophoresis profile of intact alpha1-acid glycoprotein isoforms as a biomarker of atherothrombosis. Analyst，2011. 136(4): p. 816-22.   \n101. Jiang， F.， et al.， Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. Nat Rev Cardiol，2014. 11(7):p. 413-26.   \n102. Wieland， T. and P.V. Attwood， Alterationsin reversible protein histidine phosphorylation as intracellular signals in cardiovascular disease. Front Pharmacol, 2015.6:p. 173.   \n103. Chen,H.，et al.， Inhibition of VDACl prevents Ca(2)(+)-mediated oxidative stress and apoptosis induced by $\\it 5$ aminolevulinic acid mediated sonodynamic therapy in THP-1 macrophages.Apoptosis，2014. 19(12): p. 1712-26.   \n104. Edfeldt， K.， et al.， Involvement of the antimicrobial peptide LL-37 in human atherosclerosis. Arterioscler Thromb Vasc Biol，2006. 26(7):p. 1551-7.   \n105. Wang，L.， et al.， Inhibition of epidermal growth factor receptor attenuates atherosclerosis via decreasing inflammation and oxidative stress. Sci Rep, 2017. 8: p. 45917.   \n106. Zhao， C.F. and D.M. Herrington， The function of cathepsins B, D， and X in atherosclerosis. Am J Cardiovasc Dis，2016.6(4):p. 163-170.   \n107. Biros，E.，et al.， Upregulation of arylsulfatase B in carotid atherosclerosis is associated with symptoms of cerebral embolization. Sci Rep，2017. 7(1): p. 4338.   \n108. Hernandez-Romero，D.，et al.，CALU A29809G polymorphism in coronary atherothrombosis: Implications for coronary calcification and prognosis. Ann Med, 2010. 42(6): p. 439- 46.   \n109. Asano,T.，et al.，Physiological significance of resistin and resistin-like molecules in the inflammatory process and insulin resistance. Curr Diabetes Rev，2006. 2(4): p. 449-54.   \n110. Haversen，L.，et al.，Vimentin deficiency in macrophages induces increased oxidative stress and vascular inflammation but attenuates atherosclerosis in mice. Sci Rep, 2018. 8(1): p. 16973.   \n111. Oszajca, K.，et al.，Association analysis of genetic polymorphisms of factor V， factor VII and fibrinogen beta chain genes with human abdominal aortic aneurysm. Exp Ther Med，2012.4(3):p. 514-518.   \n112. Li，Y.Q.，et al.，Regulation of endothelial cell survival and death by the MAP kinase/ERK kinase kinase 3- glyceraldehyde-3-phosphate dehydrogenase signaling axis. Cell Signal，2019. 58:p. 20-33.   \n113. Fukai， T.， et al.， Vascular expression of extracellular superoxide dismutase in atherosclerosis. J Clin Invest，1998. 101(10):p. 2101-11.   \n114. Yu， X.H.，et al.， NPCl， intracellular cholesterol trafficking and atherosclerosis. Clin Chim Acta，2014. 429:p. 69-75.   \n115. Sun，J.，Z. Wang， and X. Wang， Suppression of LRRC19 promotes cutaneous wound healing in pressure ulcers in mice. Organogenesis，2018. 14(1): p. 13-24.   \n116. Gouni-Berthold, I.，W. Krone,and H.K. Berthold, Vitamin D and cardiovascular disease. Curr Vasc Pharmacol，2009.7(3):p. 414-22.   \n117. Arenas de Larriva,A.P.，et al.，Circulating ceruloplasmin， ceruloplasmin-associated genes and the incidence of venous thromboembolism in the Atherosclerosis Risk in Communities study.J Thromb Haemost，2019.17(5):p. 818-826.   \n118. Pollard，R.D.，et al.，Procollagen $C$ endopeptidase Enhancer Protein 2 (PCPE2) Reduces Atherosclerosis in Mice by Enhancing Scavenger Receptor Class B1 (SR-BI)-mediated High-density Lipoprotein (HDL)-Cholesteryl Ester Uptake.J Biol Chem，2015.290(25): p. 15496-511.   \n119. Teunissen， P.F.，et al.， MAb therapy against the IFN-alpha/beta receptor subunit 1 stimulates arteriogenesis in a murine hindlimb ischaemia model without enhancing atherosclerotic burden. Cardiovasc Res，2015. 107(2): p. 255-66.   \n120. Ichiki，T.，et al.，Endothelial permeability in vitro and in vivo:protective actions of ANP and omapatrilat in experimental atherosclerosis. Peptides，2013. 48:p. 21-6.   \n121. Inoue， M.， et al.， Endothelial cell-selective adhesion molecule modulates atherosclerosis through plaque angiogenesis and monocyte-endothelial interaction. Microvasc Res，2010. 80(2): p. 179-87.   \n122. Franca， K.C.，et al.，Quiescin/sulfhydryl oxidase 1b (QSoXlb） induces migration and proliferation of vascular smooth muscle cells by distinct redox pathways. Arch Biochem Biophys，2020.679:p.108220.   \n123. Bian，T.，et al.， Human beta-Defensin 3 Reduces TNF-alpha-Induced Inflammation and Monocyte Adhesion in Human Umbilical Vein Endothelial Cells. Mediators Inflamm， 2017. 2017:p. 8529542.   \n124. Couchie,D.，et al.，Human Plasma Thioredoxin-80 Increases With Age and in ApoE(-/-) Mice Induces Inflammation， Angiogenesis， and Atherosclerosis. Circulation， 2017. 136(5):p. 464-475.   \n125. Fu,X.，et al.，7-Ketocholesterol inhibits isocitrate dehydrogenase 2 expression and impairs endothelial function via microRNA-144. Free Radic Biol Med，2014. 71: p. 1- 15.   \n126. Smith,J.D.，Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis. Curr Opin Investig Drugs，2010. 11(9): p. 989-96.   \n127. Hewing，B.，et al.， Immunoproteasome subunit ss5i/LMP7-deficiency in atherosclerosis. Sci Rep，2017.7(1): p. 13342.   \n128. Zhang，Y.，et al.， Association of the KLKl rs5516 G allele and the ACE D allele with aortic aneurysm and atherosclerotic stenosis. Medicine (Baltimore)， 2016. 95(44) : p. e5120.   \n129. Lewis，R.D.，et al.， The membrane attack complex of complement drives the progression of atherosclerosis in apolipoprotein $E$ knockout mice. Mol Immunol，2010. 47(5)：p. 1098-105.   \n130. Karshovska,E.，et al.， Hyperreactivity of junctional adhesion molecule A-deficient platelets accelerates atherosclerosis in hyperlipidemic mice. Circ Res,2015. 116(4): p. 587-99.   \n131. Allawi， A.A.D.， Malnutrition, inflamation and atherosclerosis (MIA syndrome） in patients with end stage renal disease on maintenance hemodialysis (a single centre experience).Diabetes Metab Syndr，2018. 12(2): p. 91-97.   \n132. Segedy，A.K.，et al.， Identification of small proline-rich repeat protein 3 as a novel atheroprotective factor that promotes adaptive Akt signaling in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol，2014. 34(12):p. 2527-36.   \n133. Burke， R.M.， et al.， Small proline-rich protein 2B drives stress-dependent p53 degradation and fibroblast proliferation in heart failure. Proc Natl Acad Sci U S A, 2018．115(15):p. E3436-E3445.   \n134. Madrigal-Matute， J.，et al.， Thioredoxin-1/peroxiredoxin-1 as sensors of oxidative stress mediated by NADPH oxidase activity in atherosclerosis.Free Radic Biol Med, 2015.86:p. 352-61.   \n135. Yuan，L.， et al.， Carbonic Anhydrase 1-Mediated Calcification Is Associated With Atherosclerosis,and Methazolamide Alleviates Its Pathogenesis. Front Pharmacol，2019. 10:p.766.   \n136. Zhang,P.，et al.， Impairing eukaryotic elongation factor 2 kinase activity decreases atherosclerotic plaque formation. Can J Cardiol，2014. 30(12): p. 1684-8.   \n137. Habas，K. and L. Shang，Alterations in intercellular adhesion molecule 1 (ICAM-1） and vascular cell adhesion molecule 1 (VCAM-1） in human endothelial cells. Tissue Cell, 2018.54:p. 139-143.   \n138. Yu，H.，et al.，Angiopoietin-2 attenuates angiotensin II-induced aortic aneurysm and atherosclerosis in apolipoprotein E-deficient mice. Sci Rep,2016. 6: p. 35190.   \n139. Adada， M.，C. Luberto， and D. Canals， Inhibitors of the sphingomyelin cycle: Sphingomyelin synthases and sphingomyelinases. Chem Phys Lipids，2016.197:p. 45-59.   \n140. Kohno，T.，et al.，Novel role of copper transport protein antioxidant-1 in neointimal formation after vascular injury. Arterioscler Thromb Vasc Biol， 2013. 33(4): p. 805- 13.   \n141. Then，C.，et al.，Serum uromodulin and risk for cardiovascular morbidity and mortality in the community-based KUkA F4 study. Atheroscleros1s， 2Uzu. 297: p. 1-7.   \n142. Zhang，J.，et al.，Altered expression of lysosomal hydrolase，acid alpha-glucosidase, gene in coronary artery disease. Coron Artery Dis,2016. 27(2): p. 104-8.   \n143. Tawa,H.，et al.，Role of afadin in vascular endothelial growth factor- and sphingosine 1-phosphate-induced angiogenesis. Circ Res，2010. 106(11):p. 1731-42.   \n144. Kremen， M.，et al.， Plasminogen mediates the atherogenic effects of macrophageexpressed urokinase and accelerates atherosclerosis in apoE-knockout mice. Proc Natl Acad Sci U S A，2008.105(44):p. 17109-14.   \n145. Drapkina,O.M.，B.B. Gegenava，and V.V. Fomin， The role of the mLDL-induced activation of the complement system classical pathway and C3 expression stimulation in atherosclerosis. Ter Arkh，2018. 90(4): p. 100-104.   \n146. Hemdahl，A.L.，et al.， Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol， 2006. 26(1): p. 136-42.   \n147. Amighi，J.，et al.，Beta 2 microglobulin and the risk for cardiovascular events in patients with asymptomatic carotid atherosclerosis. Stroke，201. 42(7): p. 1826-33.   \n148. Ragolia,L.，et al.，Accelerated glucose intolerance,nephropathy，and atherosclerosis in prostaglandin D2 synthase knock-out mice.J Biol Chem，2005. 280(33):p. 29946-55.   \n149. Sena，B.F.， J.L. Figueiredo， and E. Aikawa， Cathepsin $S$ Asan Inhibitor of Cardiovascular Inflammation and Calcification in Chronic Kidney Disease. Front Cardiovasc Med，2017. 4: p. 88.   \n150. Baeyens，N.，et al.， Redundant control of migration and adhesion by ERM proteins in vascular smooth muscle cells. Biochem Biophys Res Commun，2013. 441(3):p. 579-85.   \n151. Nahon，J.E.，M. Hoekstra，and M. Van Eck，Total body proteoglycan 4 (Prg4） deficiency increases atherosclerosis susceptibility in apolipoprotein E knockout and low-density lipoprotein receptor knockout mice. Atherosclerosis， 2018. 278:p. 315-316.   \n152. Libby，P.，et al.，Atherosclerosis. Nat Rev Dis Primers，2019.5(1):p. 56.   \n153. Hansson，G.K.， A.K.Robertson， andC. Soderberg-Naucler，Inflammationand atherosclerosis. Annu Rev Pathol，2006. 1: p. 297-329.   \n154. Sueishi，K.，et al.， Atherosclerosis: coagulation and fibrinolysis. Semin Thromb Hemost，1998.24(3):p. 255-60.   \n155. van Dijk，R.A.，et al.，Systematic Evaluation of the Cellular Innate Immune Response During the Process of Human Atherosclerosis.J Am Heart Assoc，2016.5(6).   \n156. Tedgui， A. and Z. Mallat， Cytokines in atherosclerosis: pathogenic and regulatory pathways.Physiol Rev，2006. 86(2): p. 515-81.   \n157. Garcia-Touchard,A.，et al.，Extracellular proteases in atherosclerosis and restenosis. Arterioscler Thromb Vasc Biol，2005. 25(6):p. 1119-27.   \n158. Linton, M.F.，J. J. Moslehi，and V.R. Babaev， Akt Signaling in Macrophage Polarization, Survival，and Atherosclerosis. Int J Mol Sci，2019. 20(11).   \n159. Ustundag，S.，et al.，Carotid intima media thickness is independently associated with urinary sodium excretion in patients with chronic kidney disease. Ren Fail， 2015. 37(8): p. 1285-92.   \n160. Jomova,K. and M. Valko,Advances in metal-induced oxidative stress and human disease. Toxicology，2011． 283(2-3):p. 65-87. 1997. 37: p. 477-515.   \n162. Williams，J.W.，et al.，B Cell-Mediated Antigen Presentation through MHC Class II Is Dispensable for Atherosclerosis Progression. Immunohorizons，2019.3(1):p. 37-44.   \n163. Qiao，L.，et al.，Deficient Chaperone-Mediated Autophagy Promotes Lipid Accumulation in Macrophage. J Cardiovasc Transl Res， 2020.   \n164. Jaisson, S.，C. Pietrement，and P.Gillery，Carbamylation-derived products:bioactive compounds and potential biomarkers in chronic renal failure and atherosclerosis. Clin Chem，2011．57(11):p. 1499-505.   \n165. Wang，Q.，et al.， Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation. Front Biosci (Landmark Ed)，2015. 20:p.1116-43.   \n166. Pamplona,R.， et al.， Proteins in human brain cortex are modified by oxidation, glycoxidation， and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. J Biol Chem，2005.280(22):p. 21522-30.   \n167. Nehler，M.R.，L.M. Taylor，Jr.，and J.M. Porter，Homocysteinemia as a risk factor for atherosclerosis: a review. Cardiovasc Surg， 1997. 5(6): p. 559-67.   \n168. Chen， S.S.，et al.， Sulfur dioxide acts as a novel endogenous gaseous signaling molecule in the cardiovascular system. Chin Med J (Engl)，2011. 124(12):p. 1901-5.   \n169. Lee,S.E.and Y.S. Park， Korean Red Ginseng water extract inhibits COX-2 expression by suppressing p38 in acrolein-treated human endothelial cells. JGinseng Res，2014. 38(1) : p. 34-9.   \n170. McGrath,C.E.，et al.， Structure-activity analysis of diffusible lipid electrophiles associated with phospholipid peroxidation: 4-hydroxynonenal and 4-oxononenal analogues. Chem Res Toxicol，2011． 24(3):p. 357-70.   \n171. Nagai，R.，et al.， Peroxynitrite induces formation of N( epsilon ）-(carboxymethyl) lysine by the cleavage of Amadori product and generation of glucosone and glyoxal from glucose:novel pathways for protein modification by peroxynitrite. Diabetes，2002. 51(9): p. 2833-9.   \n172. Chuang，W.T.， et al.，Benzyl Isothiocyanate and Phenethyl Isothiocyanate Inhibit Adipogenesis and Hepatosteatosis in Mice with Obesity Induced by a High-Fat Diet. J Agric Food Chem，2019.67(25):p. 7136-7146.   \n173. Soares， E.S.A.K.， et al.， Effect of new thiazolidine derivatives LPSF/GQ-02 and LPSF/GQ-16 on atherosclerotic lesions in LDL receptor-deficient mice (LDLR(-/-)). Cardiovasc Pathol，2013. 22(1):p. 81-90.   \n174. Liu,A.，et al.，Metformin Delays the Development of Atherosclerosis in Type 1 Diabetes Mellitus via the Methylglyoxal Pathway. Diabetes Ther，2020.11(3):p. 633-642.   \n175. Becker，D.J. and J.B. Lowe，Fucose:biosynthesis and biological function in mammals. Glycobiology，2003．13(7):p. 41R-53R.   \n176. Hatch，E.，et al.，Differential effects of alcohol and its metabolite acetaldehyde on vascular smooth muscle cell Notch signaling and growth. Am JPhysiol Heart Circ Physiol, 2018．314(1):p. H131-H137.   \n177. Heier， M.， et al.， The advanced glycation end product methylglyoxal-derived hydroimidazolone-l and early signs of atherosclerosis in childhood diabetes. Diab Vasc Dis Res，2015.12(2):p. 139-45.   \n178. Chen，X.F.，X. Chen，and X. Tang，Short-chain fatty acid,acylation and cardiovascular diseases. Clin Sci (Lond)，2020．134(6):p. 657-676.   \n179. Wang，Z.，et al.，Nepsilon-carboxymethyl-lysine-induced PI3K/Akt signaling inhibition promotes foam cell apoptosis and atherosclerosis progression. Biomed Pharmacother, 2019．115:p. 108880.   \n180. Rodgers，K.J.and R.T. Dean，Metabolism of protein-bound DoPA in mammals. Int JBiochem Cell Biol，2000.32(9):p. 945-55.   \n181. Gomez-Baena,G.，et al.，Molecular complexity of the major urinary protein system of the Norway rat，Rattus norvegicus. Sci Rep，2019. 9(1):p. 10757. ",
        "page_idx": 34
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 35
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 36
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 37
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 38
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 39
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 40
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 41
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 42
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 43
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 44
    },
    {
        "type": "text",
        "text": "作者贡献声明：",
        "text_level": 1,
        "page_idx": 45
    },
    {
        "type": "text",
        "text": "高友鹤，华元瑞：提出研究思路，设计研究方案；  \n华元瑞，孟文书，魏静：进行实验；  \n华元瑞，刘永涛：论文数据分析；  \n华元瑞：论文起草；  \n高友鹤：论文最终版本修订。",
        "page_idx": 45
    },
    {
        "type": "text",
        "text": "附表1尿液样品随机组合筛选结果",
        "text_level": 1,
        "page_idx": 45
    },
    {
        "type": "text",
        "text": "为检验差异蛋白随机产生的可能性对筛选结果的影响，按照文章的筛选思路将每两组样品随机排列组合，按照相同的筛选条件（变化倍数 $\\operatorname { F C } { \\geqslant } 1 . 5$ 或 $\\mathrm { F C } { \\leqslant } 0 . 6 7 , \\mathrm { P } { \\ < } 0 . 0 5 )$ ）计算所有排列组合的平均差异蛋白数目。随机分组产生的平均差异蛋白数与正常分组筛选得到的差异蛋白数差别极大，能够说明差异蛋白确实是由组内样品的不同产生的，较为可靠。",
        "page_idx": 45
    },
    {
        "type": "text",
        "text": "Tab.S1 The screening results of random combination of urine samples   \nIn order to test the influence of the possibility of random generation of different proteins   \non the screening results，every two groups of samples were randomly arranged and combined,   \nand the average number of different proteins in all combinations was calculated according to the same screening conditions（ $\\mathrm { F c } \\ \\geqslant 1 . 5$ or $\\mathrm { F c } ~ \\leqslant 0 . 6 7 , \\mathrm { P } { < 0 } . 0 5 )$ .The average number of differential proteins produced by random grouping was significantly different from the   \nnumber of differential proteins obtained by normal grouping screening，which indicated that the differential proteins were indeed generated by the differences in samples within the group，which was relatively reliable. ",
        "page_idx": 45
    },
    {
        "type": "table",
        "img_path": "images/4101a420ea701fa4249999a9859c798ec2159385f6e5bc0df5e43b66fba13159.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td rowspan=\"2\">Group</td><td>Average numbers of proteins with false</td><td>number of correctly identified</td><td rowspan=\"2\">Percentage</td></tr><tr><td>random combinations</td><td>differential proteins</td></tr><tr><td>EW1-EW0</td><td>8.47</td><td>27</td><td>31.37%</td></tr><tr><td>EM1-EWO</td><td>10.35</td><td>51</td><td>20.29%</td></tr><tr><td>EM2-EW0</td><td>9.99</td><td>69</td><td>14.48%</td></tr><tr><td>EM3-EW0</td><td>9.69</td><td>86</td><td>11. 27%</td></tr><tr><td>EM4-EW0</td><td>8.67</td><td>65</td><td>13.33%</td></tr><tr><td>EM5-EW0</td><td>9.64</td><td>88</td><td>10.95%</td></tr><tr><td>EM1-EW1</td><td>8.96</td><td>14</td><td>64.00%</td></tr><tr><td>EM2-EM1</td><td>9.87</td><td>14</td><td>70.50%</td></tr><tr><td>EM3-EM2</td><td>9. 71</td><td>9</td><td>107.89%</td></tr><tr><td>EM4-EM3</td><td>8.54</td><td>15</td><td>56.93%</td></tr><tr><td>EM5-EM4</td><td>8.13</td><td>37</td><td>21. 97%</td></tr><tr><td>EW0-CW0</td><td>9.66</td><td>54</td><td>17.89%</td></tr><tr><td>EW1-CW1</td><td>9.07</td><td>17</td><td>53.35%</td></tr><tr><td>EM1-CM1</td><td>8.31</td><td>55</td><td>15. 11%</td></tr><tr><td>EM2-CM2</td><td>10.16</td><td>25</td><td>40.64%</td></tr><tr><td></td><td></td><td>58</td><td></td></tr><tr><td>EM3-CM3</td><td>9.24 9.48</td><td>62</td><td>15.93% 15.29%</td></tr><tr><td>EM4-CM4 EM5-CM5</td><td>8.53</td><td>55</td><td>15.51%</td></tr></table></body></html>",
        "page_idx": 45
    },
    {
        "type": "text",
        "text": "附表2对照组W1和W0样品的差异蛋白。",
        "text_level": 1,
        "page_idx": 46
    },
    {
        "type": "text",
        "text": "Tab.S2 Differential proteins between weekl and week O samples in control group. ",
        "page_idx": 46
    },
    {
        "type": "table",
        "img_path": "images/ebf458295d45e340df598e1cbe9a48fdd901bc41bb6be7533c866773ed45f99f.jpg",
        "table_caption": [
            "Fig.S3 Differential proteins between adjacent time points of experimental group. "
        ],
        "table_footnote": [
            "附表3实验组相邻时间点前后对照差异蛋白。"
        ],
        "table_body": "<html><body><table><tr><td>Uniprot ID</td><td>Protein Name</td><td>P-value</td><td>Fold Change</td></tr><tr><td>035887</td><td>Calumenin</td><td>0.0386</td><td>2.52</td></tr><tr><td>Q60932</td><td>Voltage-dependent anion-selective channel protein 1</td><td>0.0382</td><td>1.82</td></tr><tr><td>P01660</td><td>Ig kappa chain V-III region PC 3741/TEPC 111</td><td>0.0458</td><td>1. 64</td></tr><tr><td>Q8K426</td><td>Resistin-like gamma</td><td>0.0119</td><td>1.59</td></tr><tr><td>P01898</td><td>H-2 class I histocompatibility antigen，Q10 alpha chain</td><td>0.0290</td><td>0.67</td></tr><tr><td>P23953</td><td>Carboxylesterase 1C</td><td>0.0333</td><td>0.61</td></tr><tr><td>Q60847</td><td>Collagen alpha-1(XII） chain</td><td>0.0437</td><td>0.56</td></tr><tr><td>Q07456</td><td>Protein AMBP</td><td>0.0068</td><td>0.51</td></tr><tr><td>088322</td><td>Nidogen-2</td><td>0.0063</td><td>0.51</td></tr><tr><td>Q9JJS0</td><td>Signal peptide, CUB and EGF-like domain-containing protein 2</td><td>0.0135</td><td>0.46</td></tr><tr><td>P09036</td><td>Serine protease inhibitor Kazal-type 1</td><td>0. 0443</td><td>0.44</td></tr></table></body></html>",
        "page_idx": 46
    },
    {
        "type": "table",
        "img_path": "images/a33710481eecdf60e355c5259edc500f0488199d8dae3fb38cb1a33c3fe731aa.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td rowspan=\"2\">Group</td><td rowspan=\"2\">Uniprot</td><td rowspan=\"2\">Human Uniprot</td><td rowspan=\"2\">Protein Name</td><td rowspan=\"2\">P-value</td><td>Fold</td></tr><tr><td>Change</td></tr><tr><td rowspan=\"13\">EM2 二 EM1</td><td>P10287</td><td>P22223</td><td>Cadherin-3</td><td>0. 0245</td><td>2.74</td></tr><tr><td>Q07797</td><td>Q08380</td><td>Galectin-3-binding protein</td><td>0.0179</td><td>2.57</td></tr><tr><td>P23780</td><td>P16278</td><td>Beta-galactosidase</td><td>0.0468</td><td>2.05</td></tr><tr><td>Q8K1H9</td><td>Q9NY56</td><td>Odorant-binding protein 2a</td><td>0.0328</td><td>2.04</td></tr><tr><td>Q9WVJ3</td><td>Q9Y646</td><td>Carboxypeptidase Q</td><td>0.0235</td><td>1.88</td></tr><tr><td>Q91X17</td><td>P07911</td><td>Uromodulin</td><td>0. 0074</td><td>1.86</td></tr><tr><td>P55288</td><td>P55287</td><td>Cadherin-11</td><td>0. 0395</td><td>1.80</td></tr><tr><td>Q03404</td><td>Q03403</td><td>Trefoil factor 2</td><td>0.0131</td><td>1. 73</td></tr><tr><td>Q91WR6</td><td>Q9NU53</td><td>Glycoprotein integral membrane protein 1</td><td>0.0126</td><td>1. 63</td></tr><tr><td>Q9ESY9</td><td>P13284</td><td>Gamma-interferon-inducible lysosomal thiol reductase</td><td>0.0112</td><td>1. 58</td></tr><tr><td>P06909</td><td>P08603</td><td>Complement factor H</td><td>0.0192</td><td>0.61</td></tr><tr><td>Q8BND5</td><td>000391</td><td>Sulfhydryl oxidase 1</td><td>0.0176</td><td>0.55</td></tr><tr><td>Q8K0E8</td><td>P02675</td><td>Fibrinogen beta chain</td><td>0.0329</td><td>0.24</td></tr><tr><td rowspan=\"8\">EM3 1 EM2</td><td>Q00993</td><td>P30530</td><td>Tyrosine-protein kinase receptor UFO</td><td>0.0114</td><td>2.05</td></tr><tr><td>Q62267</td><td>No</td><td>Cornifin-B</td><td>0.0153</td><td>1.89</td></tr><tr><td>P70663</td><td>Q14515</td><td>SPARC-like protein 1</td><td>0.0128</td><td>1. 79</td></tr><tr><td>P70699</td><td>P10253</td><td>Lysosomal alpha-glucosidase</td><td>0.0364</td><td>1. 68</td></tr><tr><td>P03953</td><td>P00746</td><td>Complement factor D</td><td>0.0176</td><td>0.64</td></tr><tr><td>Q00898</td><td>P01009</td><td>Alpha-1-antitrypsin 1-5</td><td>0.0487</td><td>0.64</td></tr><tr><td>Q9Z0L8</td><td>Q92820</td><td>Gamma-glutamyl hydrolase</td><td>0.0456</td><td>0.54</td></tr><tr><td>Q60847</td><td>Q99715</td><td>Collagen alpha-1(XII） chain</td><td>0. 0499</td><td>0.51</td></tr><tr><td></td><td>Q9EP95</td><td>Q9BQ08</td><td>Resistin-like alpha</td><td>0.0201</td><td>0.26</td></tr><tr><td rowspan=\"2\">EM4 1</td><td>P25119</td><td>P20333</td><td rowspan=\"2\">Tumor necrosis factor receptor superfamily member 1B Trefoil factor 2</td><td>0. 0491</td><td>3.19</td></tr><tr><td>Q03404</td><td>Q03403</td><td>0.0237</td><td>2.74</td></tr></table></body></html>",
        "page_idx": 46
    },
    {
        "type": "table",
        "img_path": "images/039933859ed2c2fc2685bc821e62e2088b1d5bdf1417cb53f3e52cd680f17118.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td>EM3</td><td>Q9DAU7</td><td></td><td>Q14508</td><td>WAP four-disulfide core domain protein 2</td><td>0.0293</td><td>2.61</td></tr><tr><td rowspan=\"11\"></td><td></td><td></td><td>095633</td><td></td><td>0.0460</td><td>2.58</td></tr><tr><td>Q9EQC7</td><td></td><td>Follistatin-related protein 3</td><td></td><td></td><td></td></tr><tr><td>Q07797</td><td>Q08380</td><td>Galectin-3-binding protein</td><td>0.0410</td><td></td><td>2.57</td></tr><tr><td>Q61581</td><td>Q16270</td><td>Insulin-like growth factor-binding protein 7</td><td>0.0404</td><td></td><td>2.50</td></tr><tr><td>Q01339</td><td>P02749</td><td>Beta-2-glycoprotein 1</td><td>0.0411</td><td></td><td>2.45</td></tr><tr><td>Q6SJQ5</td><td>Q6UXZ3</td><td>CMRF35-like molecule 3</td><td>0.0430</td><td></td><td>2.28</td></tr><tr><td></td><td>P15379</td><td>P16070</td><td>CD44 antigen</td><td>0.0313</td><td>2.18</td></tr><tr><td></td><td>Q91WR8</td><td>P59796</td><td>Glutathione peroxidase 6</td><td>0.0096</td><td>1.99</td></tr><tr><td></td><td>Q9Z0M9</td><td>095998</td><td>Interleukin-18-binding protein</td><td>0.0294</td><td>1.89</td></tr><tr><td></td><td>Q5SSE9</td><td>Q86UQ4</td><td>ATP-binding cassette sub-family A member 13</td><td>0.0279</td><td>1. 69</td></tr><tr><td>P01132</td><td></td><td>P01133 Pro-epidermal growth factor</td><td></td><td>0. 0125</td><td>1.69</td></tr><tr><td></td><td>P01631</td><td>No</td><td>Ig kappa chain V-II region 26-10</td><td>0.0087</td><td>1.56</td></tr><tr><td rowspan=\"11\"></td><td></td><td>P07724</td><td>P02768</td><td>Albumin</td><td>0.0193</td><td>0.57 3.35</td></tr><tr><td>Q9ET22</td><td>P01864</td><td>No</td><td>Ig gamma-2A chain C region secreted form</td><td>0.0121 0.0002</td><td>3.31</td></tr><tr><td></td><td></td><td>Q9UHL4 095497</td><td>Dipeptidyl peptidase 2</td><td></td><td>2.98</td></tr><tr><td>Q9Z0K8</td><td>P04746</td><td>Pantetheinase</td><td></td><td>0.0160</td><td></td></tr><tr><td>P00688</td><td>P00915</td><td>Pancreatic alpha-amylase</td><td></td><td>0.0072</td><td>2.76</td></tr><tr><td>P13634 A2ARV4</td><td></td><td>Carbonic anhydrase 1</td><td></td><td>0.0017</td><td>2.51</td></tr><tr><td></td><td>P51910</td><td>P98164 P05090</td><td>Low-density lipoprotein receptor-related protein 2</td><td>0.0248 0. 0496</td><td>2.11 2.04</td></tr><tr><td></td><td>Q9WUU7</td><td>Q9UBR2</td><td>Apolipoprotein D</td><td>0.0121</td><td>1. 78</td></tr><tr><td></td><td></td><td>P10619</td><td>Cathepsin Z</td><td>0.0190</td><td>1. 77</td></tr><tr><td></td><td>P16675</td><td></td><td>Lysosomal protective protein</td><td>0.0094</td><td>1.68</td></tr><tr><td></td><td>P07724</td><td>P02768 P10909</td><td>Albumin</td><td></td><td></td></tr><tr><td rowspan=\"14\">EM5 1 EM4</td><td>Q06890</td><td></td><td>Clusterin</td><td></td><td>0.0384</td><td>1.52</td></tr><tr><td>Q61147</td><td>P00450</td><td>Ceruloplasmin</td><td></td><td>0.0491</td><td>1.52</td></tr><tr><td>P01631</td><td>No</td><td>Ig kappa chain V-II region 26-10</td><td></td><td>0.0067</td><td>0.67</td></tr><tr><td>P61110</td><td></td><td>P61109</td><td> Kidney androgen-regulated protein</td><td>0.0270</td><td>0.46</td></tr><tr><td>Q61129</td><td></td><td>P05156 Complement factor I</td><td></td><td>0.0213</td><td>0.44</td></tr><tr><td>P04441</td><td>P04233</td><td></td><td>H-2 class II histocompatibility antigen gamma chain</td><td>0.0483</td><td>0.44</td></tr><tr><td>Q01339</td><td>P02749</td><td>Beta-2-glycoprotein 1</td><td></td><td>0.0439</td><td>0.42</td></tr><tr><td>P42567</td><td>P42566</td><td>Epidermal growth factor receptor substrate 15</td><td></td><td>0.0482</td><td>0.41</td></tr><tr><td></td><td>Q03404</td><td>Q03403</td><td>Trefoil factor 2</td><td>0.0317 0.0021</td><td>0.41</td></tr><tr><td></td><td>Q91WR8 Q61271</td><td>P59796 P36896</td><td>Glutathione peroxidase 6</td><td>0.0275</td><td>0.38</td></tr><tr><td></td><td></td><td></td><td>Activin receptor type-1B</td><td>0.0402</td><td>0.35 0.34</td></tr><tr><td></td><td>Q62395</td><td>Q07654</td><td>Trefoil factor 3</td><td></td><td></td></tr><tr><td></td><td>P29699</td><td>P02765</td><td>Alpha-2-HS-glycoprotein</td><td>0.0484</td><td>0.34</td></tr><tr><td></td><td>Q08423</td><td>P04155</td><td>Trefoil factor 1</td><td>0.0447</td><td>0.32</td></tr><tr><td></td><td>P10287</td><td>P22223</td><td>Cadherin-3</td><td>0.0126</td><td>0.31</td></tr><tr><td></td><td>Q9EP95</td><td>Q9BQ08</td><td>Resistin-like alpha</td><td>0.0479</td><td>0.30</td></tr><tr><td></td><td>008997</td><td>000244</td><td> Copper transport protein AT0X1</td><td>0.0378</td><td>0.28</td></tr><tr><td></td><td>P0CG49</td><td>P0CG47</td><td>Polyubiquitin-B</td><td>0.0095</td><td>0.28</td></tr><tr><td></td><td>088322</td><td>Q14112</td><td>Nidogen-2</td><td>0.0196</td><td>0.28</td></tr><tr><td></td><td>Q7TMJ8</td><td>Q96FE7</td><td>Phosphoinositide-3-kinase-interacting protein 1</td><td>0.0360</td><td>0.26</td></tr><tr><td></td><td>009051</td><td>Q16661</td><td>Guanylate cyclase activator 2B</td><td>0.0252</td><td>0.23</td></tr></table></body></html>",
        "page_idx": 47
    },
    {
        "type": "table",
        "img_path": "images/8dcaeec9430860620d6ca7479170db4a4156e1bea9ca0df9566db41d3b16a64d.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td></td><td>P09036</td><td>P00995</td><td>Serine protease inhibitor Kazal-type 1</td><td>0.0200</td><td>0.19</td></tr><tr><td></td><td>Q62267</td><td>No</td><td>Cornifin-B</td><td>0.0500</td><td>0.19</td></tr></table></body></html>",
        "page_idx": 48
    },
    {
        "type": "image",
        "img_path": "images/f34fa0a377c08c7023af57da8d00ac37d180a7aadac8911a477ee52ba8bb6261.jpg",
        "img_caption": [
            "附图1实验组和对照组不同时间点差异蛋白韦恩图。"
        ],
        "img_footnote": [],
        "page_idx": 48
    },
    {
        "type": "text",
        "text": "Fig.S1 Venn diagram of differential proteins in different time points between experimental group and control group. ",
        "page_idx": 48
    },
    {
        "type": "text",
        "text": "附表4两种对比方式开放式搜索得到的差异修饰具体信息。",
        "page_idx": 48
    },
    {
        "type": "text",
        "text": "\\* 在unimod 数据库中未检索到的修饰类型；   \nEW0：EWO 组独有的修饰类型；EM5：EM5 组独有的修饰类型；CM5：CM5 组独有的修饰类型。   \nTab.S4 Details of differential modifications in two comparisons by open search.   \n$*$ Modification type not retrieved in UNIMOD database;   \nEW0: The unique modification type of EWo group;EM5:The unique modification types of EM5 group;CM5:The unique modification types of CM5 group. ",
        "page_idx": 48
    },
    {
        "type": "table",
        "img_path": "images/4b9a847c0e494f15354aca15c8b96c4cc88223ba65e3c7b5e7c37bee95451da4.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td>Group</td><td>Modification Name</td><td>Modification Type</td><td>P-value</td><td>Fold Change</td></tr><tr><td></td><td>Oxidation[P]</td><td>Post-translational</td><td>EW0</td><td>EWO</td></tr><tr><td rowspan=\"18\">EM5 EW0</td><td>4-0NE[H]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>AccQTag[AnyN-term]</td><td></td><td></td><td>EM5</td></tr><tr><td>AEBS[K]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>Cation_K[D]</td><td>Artefact</td><td>EM5</td><td>EM5</td></tr><tr><td>Delta_H(2)C(3)[K]</td><td>Artefact</td><td>EM5</td><td>EM5</td></tr><tr><td>Ethyl+Deamidated[N]</td><td>Other</td><td>EM5</td><td>EM5</td></tr><tr><td>Hep[T]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>NHS-LC-Biotin[AnyN-term]</td><td>O-linked glycosylation Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>NO_SMX_SIMD[C]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>Arg->Ser[R]</td><td>AA substitution</td><td>EM5</td><td>EM5</td></tr><tr><td>CHDH[D]</td><td>Post-translational</td><td>EM5</td><td>EM5</td></tr><tr><td>Diisopropylphosphate[AnyN-term]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>glucosone[R]</td><td>Other</td><td>EM5</td><td></td></tr><tr><td>Gly->His[G]</td><td>AA substitution</td><td>EM5</td><td>EM5</td></tr><tr><td>Hex[K]</td><td>Other glycosylation</td><td>EM5</td><td>EM5 EM5</td></tr><tr><td>ICDID[C]</td><td>Artefact</td><td>EM5</td><td>EM5</td></tr><tr><td>ICPL_2H(4)[AnyN-term]</td><td>Artefact</td><td>EM5</td><td>EM5</td></tr><tr><td>LG-anhydrolactam[AnyN-term]</td><td>Post-translational</td><td>EM5</td><td>EM5</td></tr><tr><td>1 NDA[K]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>Phe->Gly[F]</td><td>AA substitution</td><td>EM5</td><td>EM5</td></tr><tr><td>Phospho[C]</td><td>Post-translational</td><td>EM5 EM5</td><td>EM5</td></tr><tr><td>Phosphoadenosine[T]</td><td>Post-translational</td><td>EM5</td><td>EM5</td></tr><tr><td>SMA[AnyN-term]</td><td>Chemical derivative</td><td></td><td>EM5</td></tr><tr><td>BITC[AnyN-term]</td><td></td><td>EM5</td><td></td></tr><tr><td>Bromo[F]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>Cytopiloyne+water[AnyN-term]</td><td>Post-translational Chemical derivative</td><td>EM5</td><td>EM5 EM5</td></tr><tr><td>DAET[S]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>Delta_Hg(1)[C]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>Didehydro[Y]</td><td>Post-translational</td><td>EM5</td><td></td></tr><tr><td>Dimethylphosphothione[C]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>Glu->Tyr[E]</td><td>AA substitution</td><td>EM5</td><td>EM5 EM5</td></tr><tr><td>Hex(2)[T]</td><td>O-linked glycosylation</td><td>EM5</td><td></td></tr><tr><td>HexNAc (2) Sulf(1)[S]</td><td></td><td>EM5</td><td>EM5</td></tr><tr><td>HNE+Delta_H(2)[K]</td><td>O-linked glycosylation</td><td>EM5</td><td>EM5</td></tr><tr><td>Iminobiotin[AnyN-term]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>Iodoacetanilide_13C(6)[AnyN-term]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td></td><td>Artefact</td><td>EM5</td><td>EM5</td></tr><tr><td>Nitro[F]</td><td>Artefact</td><td>EM5</td><td>EM5</td></tr><tr><td>Oxidation[V]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>Oxidation+NEM[C]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr></table></body></html>",
        "page_idx": 49
    },
    {
        "type": "table",
        "img_path": "images/814718398fd188cb51f46799c90dfc833db467ee305188c9a711584b81c39af0.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td>PhosphoUridine[Y]</td><td>Post-translational</td><td>EM5</td><td>EM5</td></tr><tr><td>Thiophospho[T] Xle->Phe[I]</td><td>Other AA substitution</td><td>EM5 EM5</td><td>EM5 EM5</td></tr><tr><td>Xlink_SMCC[219][C]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>Xlink_SMCC[237][C]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td>NEIAA[C]</td><td>Artefact</td><td>28.64</td><td>0.0378</td></tr><tr><td>ICPL_13C(6)[AnyN-term]</td><td>Artefact</td><td>21.41</td><td>0.0151</td></tr><tr><td>Xle->Trp[I]</td><td>AA substitution</td><td>14.55</td><td>0.0002</td></tr><tr><td>Thiazolidine[W]</td><td>Chemical derivative</td><td>14. 17</td><td>0.0194</td></tr><tr><td>SMA[K]</td><td>Chemical derivative</td><td>13.45</td><td>0.0082</td></tr><tr><td>NEMsulfurWater[C]</td><td>Chemical derivative</td><td>13.24</td><td>0.0000</td></tr><tr><td>Guanidinyl[K]</td><td>Chemical derivative</td><td>13.08</td><td>0.0009</td></tr><tr><td>Phosphopropargyl[S]</td><td>Multiple</td><td>12.72</td><td>0.0348</td></tr><tr><td>Thiophospho[S]</td><td>Other</td><td>12.15</td><td>0.0007</td></tr><tr><td>phenylsulfonylethyl[C] Ub-Br2[C]</td><td>Chemical derivative</td><td>11.97</td><td>0.0013</td></tr><tr><td>Asn->Trp[N]</td><td>Chemical derivative</td><td>10.05</td><td>0.0106</td></tr><tr><td></td><td>AA substitution</td><td>9.40</td><td>0.0035</td></tr><tr><td>NEMsulfur[C]</td><td>Chemical derivative</td><td>8.81</td><td>0.0002</td></tr><tr><td>Carboxyethyl[K]</td><td>Post-translational</td><td>7.43</td><td>0.0086</td></tr><tr><td>Ethanedithiol[T] Met->Glu[M]</td><td>Chemical derivative</td><td>7.42</td><td>0.0247</td></tr><tr><td>DeStreak[C]</td><td>AA substitution</td><td>7.11</td><td>0.0250</td></tr><tr><td>Xlink_EGS[115][K]</td><td>Chemical derivative</td><td>6.62</td><td>0.0200</td></tr><tr><td></td><td>Chemical derivative</td><td>6.39</td><td>0.0015</td></tr><tr><td>Xle->Tyr[L]</td><td>AA substitution</td><td>6.26</td><td>0.0012</td></tr><tr><td>2-succinyl[C] Cys->SecNEM_2H(5)[C]</td><td>Chemical derivative</td><td>6.07</td><td>0.0070</td></tr><tr><td>Phenylisocyanate_2H(5)[AnyN-term]</td><td>Chemical derivative</td><td>5.80</td><td>0.0025</td></tr><tr><td>Asn->His[N]</td><td>Chemical derivative</td><td>5.18</td><td>0.0054</td></tr><tr><td></td><td>AA substitution</td><td>5.13</td><td>0.0316</td></tr><tr><td>SulfurDioxide[C] Piperidine[AnyN-term]</td><td>Post-translational</td><td>4.64</td><td>0.0410</td></tr><tr><td>Tris[N]</td><td>Chemical derivative</td><td>4.58</td><td>0.0379</td></tr><tr><td>Delta_H(-4)0(2)[W]</td><td>Artefact</td><td>4.47</td><td>0.0046</td></tr><tr><td>Asn->Cys[N]</td><td>Chemical derivative</td><td>4.42</td><td>0.0341</td></tr><tr><td>Carboxymethyl[AnyN-term]</td><td>AA substitution</td><td>4.35</td><td>0.0222</td></tr><tr><td>Xle->Tyr[I]</td><td>Artefact</td><td>4.13</td><td>0.0371</td></tr><tr><td>Propionamide[C]</td><td>AA substitution</td><td>4.07</td><td>0.0054</td></tr><tr><td></td><td>Artefact</td><td>3.97</td><td>0.0065</td></tr><tr><td>Xle->Cys[I]</td><td>AA substitution</td><td>3.88</td><td>0.0410</td></tr><tr><td>Carboxymethyl[K]</td><td>Artefact</td><td>3.72</td><td>0.0001</td></tr><tr><td>Isopropylphospho[T]</td><td>Chemical derivative</td><td>3.72</td><td>0.0039</td></tr><tr><td>Cation_Ni[II][D]</td><td>Artefact</td><td>3.63</td><td>0.0468</td></tr><tr><td>Trp->Kynurenin[W]</td><td>Chemical derivative</td><td>3.56</td><td>0.0113</td></tr><tr><td>2-monomethylsuccinyl[C] PET[T]</td><td>Chemical derivative Chemical derivative</td><td>3.55 3.46</td><td>0.0012 0.0499</td></tr></table></body></html>",
        "page_idx": 50
    },
    {
        "type": "table",
        "img_path": "images/ec934e3c029818f5e94df9c0522b03deebb3d2efdc6b4f87c545d763f14fc194.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td>Cysteinyl[C]</td><td>Multiple</td><td></td><td>3.44</td><td>0.0059</td></tr><tr><td>Nmethylmaleimide+water[C]</td><td></td><td>Chemical derivative</td><td>3.43</td><td>0.0001</td></tr><tr><td>MDCC[C]</td><td></td><td>Chemical derivative</td><td>3.40</td><td>0.0094</td></tr><tr><td></td><td>MercaptoEthanol[T]</td><td>Chemical derivative</td><td>3.34</td><td>0.0196</td></tr><tr><td></td><td>Acetyl[AnyN-term]</td><td>Multiple</td><td>3.28</td><td>0.0016</td></tr><tr><td></td><td>Formylasparagine[H]</td><td>Chemical derivative</td><td>3.26</td><td>0.0100</td></tr><tr><td></td><td>Glucuronyl[T]</td><td>0-linked glycosylation</td><td>3.10</td><td>0. 0481</td></tr><tr><td></td><td>O-Methylphosphate[S]</td><td>Chemical derivative</td><td>2.87</td><td>0.0318</td></tr><tr><td></td><td>Trioxidation[C]</td><td>Chemical derivative</td><td>2.86</td><td>0.0036</td></tr><tr><td>Asn->Met[N]</td><td>Propionamide[AnyN-term]</td><td>Chemical derivative</td><td>2.85</td><td>0.0399</td></tr><tr><td></td><td></td><td>AA substitution</td><td>2.81</td><td>0. 0195</td></tr><tr><td></td><td>Carbamyl[AnyN-term]</td><td>Multiple</td><td>2.75</td><td>0.0008</td></tr><tr><td></td><td>Cation_Ni[II][E]</td><td>Artefact</td><td>2.65</td><td>0. 0437</td></tr><tr><td></td><td>Cation_Fe[II][E]</td><td>Artefact</td><td>2.64</td><td>0. 0114</td></tr><tr><td></td><td>Trp->0xolactone[W]</td><td>Chemical derivative</td><td>2.49</td><td>0.0071</td></tr><tr><td>dHex[N]</td><td>Arg[AnyN-term]</td><td>Other</td><td>2.44</td><td>0.0268</td></tr><tr><td></td><td></td><td>N-linked glycosylation</td><td>2.32</td><td>0.0048</td></tr><tr><td>Carboxy[W]</td><td>Amidine[AnyN-term]</td><td>Chemical derivative</td><td>2.24</td><td>0. 0444</td></tr><tr><td></td><td></td><td>Chemical derivative</td><td>2.14</td><td>0.0283</td></tr><tr><td></td><td>Nmethylmaleimide[C]</td><td>Chemical derivative</td><td>2.06</td><td>0.0037</td></tr><tr><td></td><td>Dethiomethyl[M]</td><td>Artefact</td><td>1.96</td><td>0.0295</td></tr><tr><td>Gly->Pro[G]</td><td>Unknown_210[AnyN-term]</td><td>Artefact</td><td>1.84</td><td>0.0000</td></tr><tr><td></td><td></td><td>AA substitution</td><td>1.76</td><td>0.0143</td></tr><tr><td>Xle->Gln[I]</td><td>Formyl[T](Thr->Glu[T])</td><td>Artefact</td><td>1.68</td><td>0.0161</td></tr><tr><td></td><td></td><td>AA substitution</td><td>1.55</td><td>0.0318</td></tr><tr><td></td><td>CarbamidomethylDTT[C]</td><td>Artefact</td><td>0.45</td><td>0.0008</td></tr><tr><td></td><td>Pyro-carbamidomethyl[AnyN-termC]</td><td>Artefact</td><td>0.39</td><td>0.0011</td></tr><tr><td></td><td>Thr->Ala[T]</td><td>AA substitution</td><td>0.39</td><td>0.0087</td></tr><tr><td></td><td>Deoxy[S](Ser->Ala[S]) Gln->pyro-Glu[AnyN-termQ]</td><td>Chemical derivative Artefact</td><td>0.36 0.34</td><td>0.0006 0.0000</td></tr><tr><td>EM5 1 CM5</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=\"13\"></td><td>Arg->Trp[R]</td><td>AA substitution</td><td>CM5</td><td>CM5</td></tr><tr><td>His->Ser[H]</td><td>AA substitution</td><td>CM5</td><td>CM5</td></tr><tr><td>HexNAc (2)[N]</td><td>N-linked glycosylation</td><td>CM5</td><td>CM5</td></tr><tr><td>HN2_mustard[C]</td><td>Post-translational</td><td>CM5</td><td>CM5</td></tr><tr><td>Oxidation[P]</td><td>Post-translational</td><td>CM5</td><td>CM5</td></tr><tr><td>Pro->His[P]</td><td>AA substitution</td><td>CM5</td><td>CM5</td></tr><tr><td>Val->Glu[V]</td><td>AA substitution</td><td>CM5</td><td>CM5</td></tr><tr><td>Xle->Val[I]</td><td>AA substitution</td><td>CM5</td><td>CM5</td></tr><tr><td>Delta_H(2)C(3)[K]</td><td>Other</td><td>EM5</td><td></td></tr><tr><td>DeStreak[C]</td><td>Chemical derivative</td><td>EM5</td><td>EM5 EM5</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td>Dihydroxyimidazolidine[R]</td><td>Multiple</td><td>EM5</td><td>EM5</td></tr><tr><td>Guanidinyl[K]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr></table></body></html>",
        "page_idx": 51
    },
    {
        "type": "table",
        "img_path": "images/79f4ecfd6c6ee75fd0dc720040f84d1d0c603ea397bb6257aa773460bd2e559a.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td>phenylsulfonylethyl[C]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>Cation_Cu[I][E]</td><td>Artefact</td><td>EM5</td><td>EM5</td></tr><tr><td>glucosone[R]</td><td>Other</td><td>EM5</td><td>EM5</td></tr><tr><td>Hex[K]</td><td>Other glycosylation</td><td>EM5</td><td>EM5</td></tr><tr><td>HexNAc(1) dHex(1）[T]</td><td>O-linked glycosylation</td><td>EM5</td><td>EM5</td></tr><tr><td>ICDID[C]</td><td>Artefact</td><td>EM5</td><td>EM5</td></tr><tr><td>ICPL_2H(4)[AnyN-term]</td><td>Artefact</td><td>EM5</td><td>EM5</td></tr><tr><td>LG-anhydrolactam[AnyN-term]</td><td>Post-translational</td><td>EM5</td><td>EM5</td></tr><tr><td>mTRAQ[AnyN-term]</td><td>Artefact</td><td>EM5</td><td>EM5</td></tr><tr><td>NDA[K]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>Phe->Gly[F]</td><td>AA substitution</td><td>EM5</td><td>EM5</td></tr><tr><td>Quinone[W]</td><td>Post-translational</td><td>EM5</td><td>EM5</td></tr><tr><td>Quinone[Y]</td><td>Post-translational</td><td>EM5</td><td>EM5</td></tr><tr><td>SMA[K]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>Thiazolidine[F]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>2-hydroxyisobutyrylation[K]</td><td>Post-translational</td><td>EM5</td><td>EM5</td></tr><tr><td>BITC[K]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>Bromo[F]</td><td>Post-translational</td><td>EM5</td><td>EM5</td></tr><tr><td>Cytopiloyne+water[AnyN-term]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>DAET[S]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>Delta_Hg(1) [C]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>HexNAc (2) Sulf(1) [S]</td><td>O-linked glycosylation</td><td>EM5</td><td>EM5</td></tr><tr><td>HNE+Delta_H(2)[K]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>Malonyl[C]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>MTSL[C]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>Oxidation+NEM[C]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>Phe->Thr[F]</td><td>AA substitution</td><td>EM5</td><td>EM5</td></tr><tr><td>PhosphoUridine[Y]</td><td>Post-translational</td><td>EM5</td><td>EM5</td></tr><tr><td>Ser->Trp[S]</td><td>AA substitution</td><td>EM5</td><td>EM5</td></tr><tr><td>SulfanilicAcid_13C(6)[E]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>Xle->Phe[I]</td><td>AA substitution</td><td>EM5</td><td>EM5</td></tr><tr><td>Xlink_SMCC[219][C]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>Xlink_SMCC[237][C]</td><td>Chemical derivative</td><td>EM5</td><td>EM5</td></tr><tr><td>Thiophospho[S]</td><td>Other</td><td>66.16</td><td>0.0010</td></tr><tr><td> NHS-LC-Biotin[AnyN-term]</td><td>Chemical derivative</td><td>58.75</td><td>0.0142</td></tr><tr><td>Ub-Br2[C]</td><td>Chemical derivative</td><td>19.24</td><td>0.0155</td></tr><tr><td>4-0NE[H]</td><td>Chemical derivative</td><td>17.34</td><td>0.0251</td></tr><tr><td>Lys->Pro[K]</td><td>AA substitution</td><td>12.42</td><td>0.0436</td></tr><tr><td>Xle->Thr[I]</td><td>AA substitution</td><td>12.32</td><td>0.0436</td></tr><tr><td>Acetyl[AnyN-term]</td><td>Multiple</td><td>11.08</td><td>0.0007</td></tr><tr><td>Oxidation[E]</td><td>Chemical derivative</td><td>10.95</td><td>0.0314</td></tr><tr><td>methylsulfonylethyl[C]</td><td>Chemical derivative</td><td>10.75</td><td>0.0233</td></tr><tr><td>O-Methylphosphate[S]</td><td>Chemical derivative</td><td>9.42</td><td>0.0011</td></tr></table></body></html>",
        "page_idx": 52
    },
    {
        "type": "table",
        "img_path": "images/15dc3a6c88a835f2b032851c9180b8b3a7b78c74d2c8ff13fa6a962ae97ba012.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td>SulfurDioxide[C]</td><td>Post-translational</td><td>8.68</td><td>0. 0452</td></tr><tr><td>Phosphoadenosine[T]</td><td>Post-translational</td><td>8.63</td><td>0. 0271</td></tr><tr><td>Carbamyl[AnyN-term]</td><td>Multiple</td><td>8.04</td><td>0.0003</td></tr><tr><td>Gly->His[G]</td><td>AA substitution</td><td>7.96</td><td>0.0316</td></tr><tr><td>Asn->Thr[N]</td><td>AA substitution</td><td>7.95</td><td>0.0069</td></tr><tr><td>Asn->Cys[N]</td><td>AA substitution</td><td>7.37</td><td>0.0155</td></tr><tr><td>Isopropylphospho[T]</td><td>Chemical derivative</td><td>7.15</td><td>0.0018</td></tr><tr><td>AccQTag[AnyN-term]</td><td>Chemical derivative</td><td>7.01</td><td>0.0018</td></tr><tr><td>Cys->SecNEM_2H(5)[C]</td><td>AA substitution</td><td>6.97</td><td>0.0025</td></tr><tr><td>Carboxymethyl[K]</td><td>Chemical derivative</td><td>6.82</td><td>0.0000</td></tr><tr><td>NEMsulfur[C]</td><td>Chemical derivative</td><td>6.67</td><td>0.0012</td></tr><tr><td>Ethyl+Deamidated[Q]</td><td>Chemical derivative</td><td>6.58</td><td>0.0313</td></tr><tr><td>Crotonaldehyde[C]</td><td>Other</td><td>6.17</td><td>0.0019</td></tr><tr><td>Hydroxymethyl[N]</td><td>Post-translational</td><td>5.83</td><td>0.0148</td></tr><tr><td>Gly->Pro[G]</td><td>AA substitution</td><td>5.59</td><td>0.0005</td></tr><tr><td>Acetyl_2H(3)[AnyN-term]</td><td>Artefact</td><td>5.48</td><td>0.0284</td></tr><tr><td>Carboxyethyl[K]</td><td>Post-translational</td><td>5.45</td><td>0.0249</td></tr><tr><td>Oxidation[Y]</td><td>Post-translational</td><td>5.36</td><td>0.0477</td></tr><tr><td>Cyano[c]</td><td>Post-translational</td><td>5.33</td><td>0.0035</td></tr><tr><td>Piperidine[AnyN-term]</td><td>Chemical derivative</td><td>5.32</td><td>0.0481</td></tr><tr><td>Cation_Ni[II][D]</td><td>Artefact</td><td>5.27</td><td>0.0354</td></tr><tr><td>Nmethylmaleimide+water[C]</td><td>Chemical derivative</td><td>5.25</td><td>0.0000</td></tr><tr><td>MercaptoEthanol[T]</td><td>Chemical derivative</td><td>5.20</td><td>0.0103</td></tr><tr><td>Carbonyl[I]</td><td>Chemical derivative</td><td>4.87</td><td>0.0075</td></tr><tr><td>Va1->Trp[V]</td><td>AA substitution</td><td>4.68</td><td>0.0061</td></tr><tr><td>Xle->Trp[I]</td><td>AA substitution</td><td>4.58</td><td>0.0032</td></tr><tr><td>Propionyl[AnyN-term]</td><td>Artefact</td><td>4.14</td><td>0.0040</td></tr><tr><td>Amidine[AnyN-term]</td><td>Chemical derivative</td><td>4. 11</td><td>0.0176</td></tr><tr><td>DNCB_hapten[C]</td><td>Chemical derivative</td><td>4.01</td><td>0.0002</td></tr><tr><td>Phenylisocyanate_2H(5)[AnyN-term]</td><td>Chemical derivative</td><td>3.65</td><td>0.0135</td></tr><tr><td>dHex[N]</td><td>N-linked glycosylation</td><td>3.51</td><td>0.0000</td></tr><tr><td>C+12[AnyN-term]</td><td>*</td><td>3.48</td><td>0.0092</td></tr><tr><td>GIST-Quat_2H(3)[AnyN-term]</td><td>Artefact</td><td>3.47</td><td>0.0118</td></tr><tr><td>Asn->Trp[N]</td><td>AA substitution</td><td>3.46</td><td>0.0347</td></tr><tr><td>Trioxidation[C]</td><td>Chemical derivative</td><td>3.42</td><td>0.0058</td></tr><tr><td>Dioxidation[M]</td><td>Post-translational</td><td>3.20</td><td>0.0198</td></tr><tr><td>Unknown_210[AnyN-term]</td><td>Artefact</td><td>3.18</td><td>0.0000</td></tr><tr><td>MG-H1[R](Delta_H(2)C(3)0(1) [R])</td><td>Other</td><td>3.15</td><td>0.0011</td></tr><tr><td>Tris[N]</td><td>Artefact</td><td>3.08</td><td>0.0275</td></tr><tr><td>Asn->Met[N]</td><td>AA substitution</td><td>3.05</td><td>0.0452</td></tr><tr><td>NEMsulfurWater[C]</td><td>Chemical derivative</td><td>3.05</td><td>0.0007</td></tr><tr><td>CarboxymethylDTT[C]</td><td>Artefact</td><td>3.03</td><td>0.0006</td></tr><tr><td>Cation_Fe[II][D]</td><td>Artefact</td><td>3.02</td><td>0.0075</td></tr><tr><td>Carboxy[W]</td><td>Chemical derivative</td><td>3.01</td><td>0.0245</td></tr></table></body></html>",
        "page_idx": 53
    },
    {
        "type": "table",
        "img_path": "images/a0e92a49b3aa3862c11f126329eecefa0d47b401118591a8c697518a14adcb3f.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td rowspan=\"14\">Gly->Glu[G] Arg[AnyN-term]</td><td>AA substitution Artefact Artefact Artefact</td><td>2.87</td><td>0.0142</td></tr><tr><td>Other</td><td>2.75</td><td>0.0165</td></tr><tr><td>Nmethylmaleimide[C] Chemical derivative</td><td>2.74</td><td>0.0020</td></tr><tr><td>Oxidation[H]</td><td>2.65</td><td>0.0134</td></tr><tr><td>Cation_K[D]</td><td>2.50</td><td>0.0354</td></tr><tr><td>Cation_Fe[II][E]</td><td>2.36</td><td>0. 0403</td></tr><tr><td>Formylasparagine [H]</td><td>Chemical derivative 2.35</td><td>0.0472</td></tr><tr><td>Xle->Gln[I]</td><td>2.35</td><td>0.0084</td></tr><tr><td>Delta_H(2)C(2)[AnyN-term]</td><td>AA substitution Other 2.34</td><td>0.0309</td></tr><tr><td>Cysteinyl[C]</td><td>Multiple 2.30</td><td>0. 0237</td></tr><tr><td>Biotin_Thermo-88317[Y]</td><td>Chemical derivative 1.96</td><td>0. 0178</td></tr><tr><td>Formyl[AnyN-term]</td><td>Artefact 1.77</td><td>0.0105</td></tr><tr><td>Xlink_EGS[115][K]</td><td>Chemical derivative 1.76</td><td>0.0190</td></tr><tr><td>Oxidation[W]</td><td>Artefact 1.73</td><td>0.0164</td></tr><tr><td>Cys->Dha[C]</td><td>AA substitution</td><td>1.65 0.0066</td></tr><tr><td>Gln->pyro-Glu[AnyN-termQ]</td><td>AA substitution 0.34</td><td>0.0401</td></tr><tr><td>dichlorination[Y]</td><td>Artefact 0.29</td><td>0.0223</td></tr><tr><td>azole[C]</td><td>Post-translational</td><td>0.12 0.0037</td></tr></table></body></html>",
        "page_idx": 54
    }
]